

4. Menjadi reviewer Jurnal Internasional Bereputasi

KODE K15

DESKRIPSI	: Mereview manuskrip di jurnal Scopus Q2, Jurnal Human Vaccines & Immunotherapeutics	Halaman
BUKTI	: Permohonan mereview	02
	Bukti mereview ke satu	06
	Kinerja mereview ke satu	07
	Respon author dari review ke satu	33
	Bukti mereview ke dua	93
	Kinerja mereview ke dua	95
	Artikel yang sudah publish	111

KHVI-2022-0554 Request to Review from Human Vaccines & Immunotherapeutics

Ronald Ellis <em@editorialmanager.com>

Mon, Oct 3, 2022 at 12:39 PM

Reply-To: Ronald Ellis <rellis.hvi@gmail.com>

To: Gondo Mastutik <gondomastutik@fk.unair.ac.id>

Ref.: Ms. No. KHVI-2022-0554

Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province, China
Human Vaccines & Immunotherapeutics

Dear Dr. Mastutik:

Human Vaccines & Immunotherapeutics requests your assistance with the peer review process for the recently submitted manuscript entitled "Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province, China" by Haowen Yuan; Rengpeng Li; Jian Lv; Guipeng Yi; Xihong Sun; Na zhao; Fengjun Zhao; Aiqiang Xu; Zengqiang Kou; Hongling Wen. We hope that you can complete the review within 18 days of your acceptance to review in order to maintain a timely turn-around time for a decision to the authors. The Editors and Publisher of Human Vaccines & Immunotherapeutics strive to maintain rapid turn-around time while providing useful and constructive comments to authors. The abstract for this manuscript is shown below.

Please reply to this request within 5 days with your ACCEPT or DECLINE (see link towards the end of this email) to review this manuscript in order to maintain the timeliness of our review process.

In the review we ask you to comment on several aspects of the study in order to justify your recommendation and to provide feedback for authors to improve their work if necessary.

Please click here for more detailed instructions:

http://hv.msubmit.net/cgi-bin/main.plex?form_type=display_rev_instructions

You will also have an opportunity to provide comments to the Editors that will not be shared with the authors, as well as an opportunity to recommend a disposition for the manuscript and to assign a priority score to assist the Editors in making the final decision.

Do not forward the manuscript to others except those directly within your research group who can assist you with its review. Please maintain confidentiality of its contents until publication and ask any associates with whom you might discuss its contents to also keep it strictly confidential.

Please affirm your ability to perform this important service to your colleagues as part of the peer review process. If you have any questions or need more information feel free to correspond with us by e-mail.

Thank you in advance for helping with the Human Vaccines & Immunotherapeutics peer-review process. Both the authors and editors appreciate your critical and constructive comments to improve the quality of manuscripts we publish.

If you would like to review this paper, please click this link: [Agree to Review](#)

If you do not wish to review this paper, please click this link: [Decline to Review](#)

We are collaborating with Publons to give you the recognition you deserve for your peer review contributions. On Publons you can effortlessly track, verify and showcase your review work and expertise without compromising anonymity. [Sign up](#) now for free so when you complete any reviews they can be instantly added to your profile.

Whether you ACCEPT or DECLINE, I would greatly appreciate your also suggesting other potential reviewers (with email addresses if possible) who would be qualified to examine this manuscript or related subject matter.

If you are unable to review this manuscript and DECLINE, I can contact one of your suggested reviewers immediately.

Even if you are able to review this manuscript and ACCEPT, one of your recommendations could be a second reviewer or a future reviewer of related subject matter.

Thank you very much for your suggestions - much appreciated.

The journal is now asking reviewers - when suggesting rejection - to clearly note if the paper is academically or scientifically unsound, or if it is merely unsuitable for this journal. The final decision on acceptance of papers will

continue to rest with the journal's editor.

By reviewing this manuscript, you agree for your review and comments to be seen confidentially by editors of other related Taylor & Francis journals if the manuscript is rejected and subsequently transferred. This supports a system of portable peer review.

Kind regards,

On behalf of

Ronald Ellis PhD MBA
Editor-in-Chief
Human Vaccines & Immunotherapeutics
Jerusalem 9254113 Israel
rellis.hvi@gmail.com

ABSTRACT:

Condyloma acuminatum (CA) is a sexually transmitted disease (STD) caused by human papillomavirus (HPV) infection. It is important to study the prevalence and distribution of HPV genotypes before implementing HPV vaccination program. So, the aim of this study was to evaluate the epidemiological characteristics of CA cases and the distribution of HPV genotypes in Shandong Province, China. One-to-one questionnaire surveys were conducted on all patients diagnosed with CA in sentinel hospitals from Shandong Province, China. HPV genotypes were determined using the polymerase chain reaction (PCR)-reverse dot blot hybridization method. The study enrolled 1185 patients (870 males and 315 females) and found that CA patients are mainly males and sexually active people between the ages of 20 and 40. Recurrence occurred in 411 (34.7%) patients. The overall prevalence of HPV among 880 CA patients undergoing HPV typing was 91.4% (804/880). In these cases, low-risk genotypes predominated, with a prevalence of 91.3% (785/804). High-risk HPV genotypes were found in 430 (53.5%) patients. The most frequent HPV genotypes encountered were HPV 6 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%) and HPV 42 (10.3%). HPV 6 and/or HPV 11 are the main infections in all patients, and more than half of the patients are coinfecting with high-risk HPV. However, unlike other regions, HPV42 has a higher prevalence rate among CA patients in Shandong Province and is a nonvaccine HPV genotype. Therefore, regular HPV typing helps to understand the characteristics of specific genotypes and the choice of the best type for vaccine coverage.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. ([Remove my information/details](#)). Please contact the publication office if you have any questions.

Human Vaccines & Immunotherapeutics - Thank you for agreeing to review KHVI-2022-0554

Human Vaccines & Immunotherapeutics <em@editorialmanager.com>

Sat, Oct 8, 2022 at 1:30 PM

Reply-To: Human Vaccines & Immunotherapeutics <khvi-peerreview@journals.tandf.co.uk>

To: Gondo Mastutik <gondomastutik@fk.unair.ac.id>

Dear Gondo Mastutik,

Thank you for agreeing to review manuscript KHVI-2022-0554 for Human Vaccines & Immunotherapeutics.

You will be able to download the manuscript by logging in as a reviewer at <https://www.editorialmanager.com/hv/>, or clicking the following link: <https://www.editorialmanager.com/hv/l.asp?i=200041&l=U0TYPMX0>

I would appreciate receiving your review by 26 Oct 2022. As you approach this due date, please let me know if you anticipate submitting your review late.

You may submit your comments online at <https://www.editorialmanager.com/hv/>. The following deep link will take you directly to the review form:

<https://www.editorialmanager.com/hv/l.asp?i=200042&l=IB4BSNIE>

There you will find spaces for confidential comments to the editor, comments for the author and a report form to be completed.

Kind regards,

Ronald Ellis, PhD MBA
Editor-in-Chief
Human Vaccines & Immunotherapeutics

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/hv/login.asp?a=r>). Please contact the publication office if you have any questions.

 **Review_Due.ics**
1K

Thank you for the review of KHVI-2022-0554

Ronald Ellis <em@editorialmanager.com>
Reply-To: Ronald Ellis <rellis.hvi@gmail.com>
To: Gondo Mastutik <gondomastutik@fk.unair.ac.id>

Sat, Oct 22, 2022 at 11:03 PM

Ref.: Ms. No. KHVI-2022-0554
Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province, China
Human Vaccines & Immunotherapeutics

Dear Gondo Mastutik,

Thank you for your review of this manuscript.

You can access your review comments by logging onto the Editorial Manager site at <https://www.editorialmanager.com/hv/>.

Once again, thank you for your contribution to Human Vaccines & Immunotherapeutics.

We are collaborating with Publons to give you the recognition you deserve for your peer review contributions. If you haven't already added a record of this review to your Publons profile, simply forward this thank you email to reviews@publons.com to ensure your hard work doesn't go unnoticed. Publons helps you effortlessly track, verify and showcase your review work and expertise without compromising anonymity.

We would be interested to hear your experience of reviewing for us today, please click the following link to complete a short survey: <https://survey.alchemer.eu/s3/90329429/Taylor-Francis-peer-review-survey?ac=KHVI>

Kind regards,

Ronald Ellis PhD MBA
Editor-in-Chief
Human Vaccines & Immunotherapeutics
Jerusalem 9254113 Israel
rellis.hvi@gmail.com

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/hv/login.asp?a=r>). Please contact the publication office if you have any questions.

Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province, China

Original Submission
Gondo Mastutik **Reviewer 2**

[Back](#)
[Edit Review](#)
[Print](#)
[Submit Review to Editorial Office](#)

Recommendation: Accept with minor revision**Custom Review Question(s):**

As a thank you and to acknowledge the contribution of our reviewers, the journal may publish a list of the names of those who have reviewed at the end of the year. This will not be linked to any specific paper and will only be done if the list of reviewers is long enough to protect the anonymity of the review process for individual papers. If you would prefer for your name **not to be included** in a published list of reviewers, please indicate this below.

If anyone else was involved in writing this report, for example a student or a colleague, and they agree to be recognised for this work please provide their name and email address in the free text box below.

Do you want to get recognition for this review on [Publons](#)?

Don't let your reviewing work go unnoticed! Researchers the world over use Publons to effortlessly track their valuable peer review contributions for any journal. If you opt in, your Publons profile will automatically be updated to show a verified record of this review in full compliance with the journal's review policy. If you don't have a Publons profile, you will be prompted to create a free account. [\[Learn more\]](#)

Would you be willing to review a revision of this manuscript?

Do you have any conflict of interest to declare?

Response

Include my name

Yes

No

No

Reviewer Comments to Author

In general, the manuscript is very well written. The method used to obtain the data is appropriate. Data is displayed correctly. There are only a few corrections in the writing that I wrote in the pdf file.

1. Avoid using abbreviations or numbers at the beginning of sentences.
2. It would be better if you don't mention the number of patients in the table title.
3. How many female who participated in this study? 336 or 315?
4. Please explain why the sample size is different from that in the sub-chapter on sample characteristics and HPV prevalence. 1185 vs 880?

5. Avoid using abbreviations or numbers at the beginning of sentences. It would be better if you change the sentence to something like this: There were 374 (46.5%) patients infected with LR-HPV. Please correct all similar sentences.

6. Please explain why the prevalence of HPV is 91.36%. I think this is not the true prevalence. From the 76 patients whose HPV DNA was negative, was a repeat specimen taken and continued with an HPV genotype examination? I think the negative result in 76 patients is due to insufficient exfoliated cells, so if the number of cells is more or the cell sampling is repeated, the result may be positive. Therefore, in this case, it is better not to mention the prevalence of HPV but the overall HPV DNA is.....

Reviewer Confidential Comments to Editor:

In general, the manuscript is very well written. The method used to obtain the data is appropriate. Data is displayed correctly. Therefore, I suggest accepting this article with a minor correction. So that the author can improve the article properly, please send a pdf file to the author.

Attachments:

Action	Description	File Name	Size	Last Modified
Download	Comment in pdf file	KHVI-2022-0554 edit GM.pdf	1.1 MB	14 Oct 2022

[Back](#)
[Edit Review](#)
[Print](#)
[Submit Review to Editorial Office](#)

Human Vaccines & Immunotherapeutics

Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province , China --Manuscript Draft--

Manuscript Number:	KHVI-2022-0554
Full Title:	Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province , China
Article Type:	Research Article
Order of Authors:	Haowen Yuan Renpeng Li Jian Lv Guipeng Yi Xihong Sun Na zhao Fengjun Zhao Aiqiang Xu Zengqiang Kou Hongling Wen
Keywords:	condyloma acuminatum; human papillomavirus; epidemiology; HPV genotypes
Manuscript Classifications:	115 HPV; 125 Infectious Disease; 80 Epidemiology
Abstract:	<p>Condyloma acuminatum (CA) is a sexually transmitted disease (STD) caused by human papillomavirus (HPV) infection. It is important to study the prevalence and distribution of HPV genotypes before implementing HPV vaccination program. So, the aim of this study was to evaluate the epidemiological characteristics of CA cases and the distribution of HPV genotypes in Shandong Province, China. One-to-one questionnaire surveys were conducted on all patients diagnosed with CA in sentinel hospitals from Shandong Province, China. HPV genotypes were determined using the polymerase chain reaction (PCR)-reverse dot blot hybridization method. The study enrolled 1185 patients (870 males and 315 females) and found that CA patients are mainly males and sexually active people between the ages of 20 and 40. Recurrence occurred in 411 (34.7%) patients. The overall prevalence of HPV among 880 CA patients undergoing HPV typing was 91.4% (804/880). In these cases, low-risk genotypes predominated, with a prevalence of 91.3% (785/804). High-risk HPV genotypes were found in 430 (53.5%) patients. The most frequent HPV genotypes encountered were HPV 6 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%) and HPV 42 (10.3%). HPV 6 and/or HPV 11 are the main infections in all patients, and more than half of the patients are coinfecting with high-risk HPV. However, unlike other regions, HPV42 has a higher prevalence rate among CA patients in Shandong Province and is a nonvaccine HPV genotype. Therefore, regular HPV typing helps to understand the characteristics of specific genotypes and the choice of the best type for vaccine coverage.</p>

1 **Epidemiology of Human Papillomavirus on Condyloma Acuminatum**
2
3
4 **in Shandong Province , China**

5
6 Yuan Haowen^{a,†}, Li Renpeng^{b,†}, Lv Jian^c, Yi Guipeng^d, Sun Xihong^e, Zhao
7
8 Na^f, Zhao Fengjun^g, Xu Aiqiang^b, Kou Zengqiang^{b,*}, Wen Hongling^{a,*}

9
10 a Department of Microbiological Laboratory Technology, School of
11
12 Public Health, Cheeloo College of Medicine, Shandong University, Key
13
14 laboratory for the prevention and control of infectious diseases (key labor-
15
16 atory of China's "13th Five-Year", Shandong University), Jinan 250012,
17
18 China; yuanhaowen0218@163.com (H.Y.)

19
20 b Shandong Center for Disease Control and Prevention, Shandong
21
22 Provincial Key Laboratory of Infectious Disease Prevention and Control,
23
24 Jinan 250014, China; rpleesd@163.com (R.L.); aqxuepi@163.com (A.X.)

25
26 c Shandong First Medical University & Shandong Academy of Medical
27
28 Sciences, Tai'an 271016, China; sdfmulvjian@163.com

29
30 d Weifang Medical University, Weifang 261053, China;
31
32 2046076711@qq.com

33
34 e Jining City Center for Disease Control and Prevention, Jining 272000,
35
36 China; xihongsun@163.com

37
38 f Shandong Provincial Hospital for Skin Diseases & Shandong
39
40 Provincial Institute of Dermatology and Veneorology, Shandong First
41
42 Medical University & Shandong Academy of Medical Sciences. Jinan
43
44 250000, China; 411657904@qq.com

1 23 g Shandong Oriental Andrology Hospital, Jinan 250000, China;

2
3 24 671830931@qq.com

4
5
6 25 *Correspondence:

7
8
9 26 jack-cou@163.com (Z.K.); wenhongling@sdu.edu.cn (H.W.);

10
11 27 Tel.: +86-0531-82679681 (Z.K.); +86-0531-88382625 (H.W.)

12
13
14 28 † Haowen Yuan and Renpeng Li are Co-first authors.

15
16
17 29

18
19
20 30 **Abstract**

21
22 31 Condyloma acuminatum (CA) is a sexually transmitted disease (STD)

23
24
25 32 caused by human papillomavirus (HPV) infection. It is important to study

26
27
28 33 the prevalence and distribution of HPV genotypes before implementing

29
30
31 34 HPV vaccination program. So, the aim of this study was to evaluate the

32
33
34 35 epidemiological characteristics of CA cases and the distribution of HPV

35
36
37 36 genotypes in Shandong Province, China. One-to-one questionnaire surveys

38
39
40 37 were conducted on all patients diagnosed with CA in sentinel hospitals

41
42
43 38 from Shandong Province, China. HPV genotypes were determined using

44
45
46 39 the polymerase chain reaction (PCR)-reverse dot blot hybridization method.

47
48
49 40 The study enrolled 1185 patients (870 males and 315 females) and found

50
51
52 41 that CA patients are mainly males and sexually active people between the

53
54
55 42 ages of 20 and 40. Recurrence occurred in 411 (34.7%) patients. The

56
57
58 43 overall prevalence of HPV among 880 CA patients undergoing HPV typing

59
60
61 44 was 91.4% (804/880). In these cases, low-risk genotypes predominated,

62
63
64
65

1 45 with a prevalence of 91.3% (785/804). High-risk HPV genotypes were
2
3 46 found in 430 (53.5%) patients. The most frequent HPV genotypes
4
5
6 47 encountered were HPV 6 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%) and
7
8
9 48 HPV 42 (10.3%). HPV 6 and/or HPV 11 are the main infections in all
10
11
12 49 patients, and more than half of the patients are coinfecting with high-risk
13
14
15 50 HPV. However, unlike other regions, HPV42 has a higher prevalence rate
16
17
18 51 among CA patients in Shandong Province and is a nonvaccine HPV
19
20
21 52 genotype. Therefore, regular HPV typing helps to understand the
22
23
24 53 characteristics of specific genotypes and the choice of the best type for
25
26
27 54 vaccine coverage.

28 55

30 56 **Introduction**

31
32
33 57 Condyloma acuminatum (CA), also known as genital wart (GW), is a
34
35
36 58 verrucous hyperplasia of squamous epithelium in the anogenital region
37
38
39 59 caused by human papillomavirus (HPV) infection, and it is one of the most
40
41
42 60 common sexually transmitted diseases (STDs) [1, 2]. CA is the most
43
44
45 61 common benign lesions of the anogenital region, but it can be difficult to
46
47
48 62 treat and easy to recur, which required repeated treatment [3]. Studies have
49
50
51 63 shown that approximately 48.5% of CA patients will experience recurrence
52
53
54 64 [4]. Because the location of CA is relatively private, the treatment process
55
56
57 65 is painful and expensive, which brings serious psychological pressure and
58
59
60 66 economic burden to the patient, and reduces the quality of life of the patient
61
62
63
64
65

1 67 [5-7].

2
3 68 At present, more than 200 HPV genotypes have been identified and
4
5
6 69 classified as high-risk (HR) or low-risk (LR), based on oncogenic risk. At
7
8
9 70 least 40 genotypes are associated with infection in the anogenital region
10
11 71 [8-10]. HPV 6 and 11 are associated with approximately 90% of CA,
12
13
14 72 whereas 70% of cervical cancers are caused by HPV16 and 18[11]. CA
15
16
17 73 patients are often accompanied by HR-HPV infection [12, 13]. HR-HPV
18
19
20 74 persistent infection is the main pathogenic factor of cervical intraepithelial
21
22
23 75 neoplasia and cervical cancer in women [14, 15].
24

25 76 There is reliable evidence that HPV vaccination has a good preventive
26
27
28 77 effect against HPV infection in uninfected individuals, subsequent CA and
29
30
31 78 HPV-attributable cancers, thereby greatly reducing the burden of HPV-
32
33
34 79 related diseases in patients [16, 17]. However, the HPV vaccines-targeted
35
36
37 80 types are limited, and the HPV genotypes varies among different regions
38
39
40 81 and populations [18].
41

42 82 At present, the HPV infection and epidemiological characteristics of CA
43
44
45 83 patients in China are rare and incomplete. Therefore, in this survey, the
46
47
48 84 evaluation of the epidemic characteristics and HPV genotype distribution
49
50
51 85 of CA cases in Shandong Province, China will contribute to the adjustment
52
53
54 86 of CA prevention and control strategies, the research and development of
55
56
57 87 HPV vaccine and the formulation of immunization plan.
58

59 88
60
61
62
63
64
65

1 89 **Materials and methods**

2
3 90 **Study population**

4
5
6 91 Samples were collected from patients diagnosed according to the
7
8
9 92 Diagnosis of Condyloma Acuminatum of China, from Shandong
10
11 93 Provincial Hospital for Skin Diseases, Shandong Oriental Andrology
12
13 94 Hospital, and Jining No.1 People's Hospital from August 2019 to June
14
15 95 2021. All recruited patients had never been vaccinated against HPV. The
16
17 96 selection of sentinel hospitals was based on the number of patients
18
19 97 diagnosed with CA in the past.

20
21
22 98 After accepting a questionnaire administered by trained interviewers, each
23
24 99 patient underwent biopsy for HPV typing. Each individual of the patients
25
26 100 must volunteer to participate in this study and sign the informed consent.
27
28
29 101 Our study was approved by the ethics committee of school of public health,
30
31 102 Shandong University, China (protocol n. 20190320).

32
33 103 **Specimen Collection**

34
35
36 104 All samples were collected by uniformly trained clinicians at each clinic
37
38 105 visit. Exfoliated cell specimen was collected from the surface of each
39
40 106 lesion by using a sampling brush. The brush was rotated 3-5 full turns in
41
42 107 clockwise direction to ensure acquisition of the exfoliated cells. For each
43
44 108 patient, each specimen was independently eluted from the sampling brush
45
46 109 with normal saline and stored in the refrigerator at -80°C before detecting
47
48 110 HPV genotypes.

1 111 **HPV genotyping**

2
3 112 HPV tests were performed with the HPV genotyping panel (polymerase
4
5
6 113 chain reaction (PCR)-reverse dot blot hybridization method; Yaneng
7
8
9 114 Biosciences, Shenzhen, China). This multiplex PCR technique can detect
10
11 115 17 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
12
13 116 59, 66, 68, 73 and 82) and 6 low-risk HPV genotypes (6, 11, 42, 43, 81 and
14
15 117 83). All procedures were carried out following the manufacturer's
16
17
18
19
20 118 instructions.

21
22 119 **Statistical Analysis**

23
24
25 120 Qualitative categorical variables were described as numbers and
26
27
28 121 percentages. Quantitative variables were described using mean and
29
30
31 122 standard deviation or median and interquartile range (P25- P75),
32
33
34 123 depending on the distribution of the variables. T-test was used to compare
35
36
37 124 quantitative variables with a normal distribution, and Mann-Whitney U-
38
39
40 125 test was used to compare quantitative variables without normal distribution.
41
42 126 Chi-square test or Fisher' exact test was conducted to test hypothesis, as
43
44
45 127 appropriate. All hypothesis tests were two-sided, and p-value less than or
46
47
48 128 equal to 0.05 was considered statistically significant. All data were
49
50
51 129 analyzed using SPSS software (version 20.0; IBM Corp.).

52
53 130

54
55
56 131 **Result**

57
58 132 **CA patients' characteristics**

59
60
61
62
63
64
65

1 133 A total of 1185 patients (870 males and 315 females) were included in this
2
3
4 134 study. The ages ranged from 15 to 88, with a mean of 34.85 years (SD =
5
6 135 13.60 years). The mean age varied slightly between males and females
7
8
9 136 (35.90 vs. 31.94 years; $P < 0.01$). Among recruited patients, 63.7% cases
10
11 137 reported more than one sexual partner. The vast majority of patients who
12
13 138 reported their sexual preferences were heterosexual (89.1%), including 745
14
15 139 (70.4%) heterosexual men (men who have sex with women, MSW) and
16
17 140 312 (29.5%) heterosexual women. There were 99 men (11.4% of the male
18
19 141 patients) who had sex with men (MSM), and 2 women were homosexuals.
20
21 142 26 men and 1 woman who had sex with men and women. Compared with
22
23 143 female patients, male patients had more sexual partners ($P < 0.001$). 85.7%
24
25 144 of the patients (86.8% of males and 85.0% of females) claimed that their
26
27 145 sexual partners were not infected with HPV.
28
29 146 Of the 1185 patients with genital warts, 1 or more subsequent genital warts
30
31 147 had been detected in 411 (33.1% of males and 39.0% of females). 32
32
33 148 patients reported other STDs (15 with syphilis, 5 with genital herpes, 6
34
35 149 with HIV/AIDS, 4 with gonorrhea and 2 with chlamydia infection).
36
37 150 The majority of patients stated that only a single body location was infected
38
39 151 with warts (53.5%). 34.26% patients presented warts at two different
40
41 152 locations, 8.8% at three, and 3.4% at four or more different locations. In
42
43 153 females, CA lesions were often located on the urethral orifice / vaginal
44
45 154 introitus (62.86% of cases), labia majora / labia minora (35.87%), and
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

155 perianal region (26.35%), whereas, for males, the corona sulcus (35.98%),
 156 foreskin (26.44%) and perianal region (23.56%) were the most frequent
 157 sites.

158
 159 Table 1. Baseline characteristics of 1185 patients with condyloma acuminatum, by gender

Characteristics	Male (n = 870) n (%)	Female (n= 315) n (%)
Age		
< 18	18 (2.1)	13 (4.1)
18-24	202 (23.2)	99 (31.4)
25-29	120 (13.8)	38 (12.1)
30-39	228 (26.2)	92 (29.2)
40-49	146 (16.8)	38 (12.1)
50-59	93 (10.7)	28 (8.9)
≥60	63 (7.2)	28 (2.2)
Marital status		
Single	319 (36.7)	124 (39.4)
Married	535 (61.1)	182 (57.8)
Widowed/Separated/Divorced	19 (2.2)	9 (2.9)
Education		
Primary/Middle school	225 (25.9)	94 (29.8)
High school	209 (24.0)	49 (15.6)
University/College	419 (48.2)	167 (53.0)
Postgraduate	17 (2.0)	5 (1.6)
Area of residence at diagnosis		
Rural area	263 (30.2)	96 (30.5)
City	607 (69.8)	219 (69.5)
Age of first sexual intercourse		
< 18	76 (8.7)	23 (7.3)
18-21	431 (49.5)	155 (49.2)
≥22	363 (41.7)	137 (43.5)
Type of CA diagnosis		
Recurrent disease	288 (33.1)	123 (39.0)
New diagnosis	582 (75.2)	192 (61.0)
Condom use		
No	108 (12.4)	34 (10.8)
Yes, sometimes/rarely	676 (77.7)	260 (82.5)

Yes, always	86 (9.9)	21 (6.7)
Weekly frequency of sexual		
≤ 1	394 (45.6)	123 (39.0)
$= 2$	314 (36.1)	118 (37.5)
≥ 3	159 (18.3)	74 (23.5)
Wash genitalia before sex		
Yes	543 (62.4)	191 (60.6)
No	327 (37.6)	124 (39.4)
Number of sexual partners		
$= 1$	288 (33.1)	142 (45.1)
≥ 2	582 (66.9)	173 (54.9)

160

161 **HPV prevalence**

162 In total, 880 samples were collected from 659 males and 221 females with
 163 a clinical diagnosis of CA. HPV DNA was detected in 804 of 880 CA cases,
 164 yielding an overall prevalence of 91.4% (90.6% males and 93.7% females).
 165 76 samples (from 62 males and 14 females) were excluded from further
 166 analysis due to PCR inhibition or insufficient DNA.

167 Among the 804 patients, 734 (91.3%) patients had at least one LR-HPV
 168 infection detected, and 430 (53.5%) patients had HR-HPV infection. 374
 169 (46.5%) patients were only infected with LR-HPV, 70 (8.7%) patients were
 170 only infected with HR-HPV, and 360 (44.8%) patients were infected with
 171 LR- HPV and HR-HPV. Compared with male patients, female patients had
 172 a higher rate of HR-HPV infection ($P < 0.001$). Moreover, co-infection of
 173 LR-HPV and HR-HPV was more common in female patients ($P < 0.001$).
 174 In addition, the prevalence of single HPV genotype infections was 44.2%,
 175 while those of multiple HPV genotype coinfections were 55.8%. The total
 176 number of HPV genotypes in patients varied from 1 to 12. The frequency

177 of single and multiple infections varied significantly by gender, with single
 178 infections being more common among males (47.9% males vs. 33.3%
 179 females, $P < 0.001$) and multiple infections more common among females
 180 (52.1% males vs. 66.7% females, $P < 0.001$). (Table 2)

181 Table 2. Distribution of infection types in 804 cases of condyloma acuminatum

	Males (n = 597) ^a	Females (n= 207) ^a	P value
	n (%)	n (%)	
HR-HPV	293(49.1)	137(66.2)	< 0.001
LR-HPV	543(91.0)	191(92.3)	0.563
LR and HR HPV	239 (40.0)	121 (58.5)	< 0.001
Single infection	286 (47.9)	69 (33.3)	< 0.001
Multiple infections	311 (52.1)	138 (66.7)	< 0.001
HPV6 or 11	515 (86.3)	188 (90.8)	0.088
HPV16 or 18	109 (18.3)	49 (23.7)	0.091
Types of 4-valent vaccines ^b	552 (92.5)	196 (94.7)	0.279
Types of 9-valent vaccines ^c	566 (94.8)	200 (96.6)	0.290

182 ^a Patients with unqualified HPV results were excluded from the analysis.

183 ^b The types of 4-valent vaccines conclude HPV 6, 11, 16 or 18.


184 ^c The types of 9-valent vaccines conclude HPV 6, 11, 16, 18, 31, 33, 45, 52 or 58.

186 Distribution of specific HPV genotypes

187 Overall, all 23 different HPV genotypes were identified in males and
 188 females, with a proportion ranging from 1.5% to 57.8% (12/804 to
 189 465/804). The most frequently encountered HPV genotypes were HPV 6
 190 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%), HPV 42 (10.3%) and HPV 52
 191 (8.8%) by decreasing order of frequency (Figure 1).

192 As it was shown, HPV 6 (57.8%), HPV 11 (37.2%) and HPV 42 (10.3%)
 193 were the three most common LR-HPV genotypes in our study population.

194 HPV 6 was the most common HPV genotype detected in both males
 195 (58.1%) and females (57.0%). HPV 6/11 (alone or in coinfection with other
 196 genotypes) were detected in 87.4% patients and there was no significant
 197 difference among males and females. In addition, there was no significant
 198 difference in the distribution of all detective low-risk genotypes between
 199 males and females. The most common HR-HPV genotypes were HPV 16
 200 (13.7%), HPV 52 (8.8%) and HPV 51 (8.1%). HPV 16/18 (alone or in
 201 coinfection with other genotypes) were observed in 19.7% patients. In the
 202 HR-HPV genotypes, the frequency of HPV 45, HPV 56 and HPV 58 were
 203 significantly higher in women than in men ($P < 0.05$). Among the patients
 204 coinfecting with LR-HPV and HR-HPV, the most infection mode is
 205 HPV6+HPV16 (5.6%). Different frequency of other HPV genotypes in
 206 different genders were shown in Table 3.



207
 208 Figure 1 Prevalence of specific human papillomavirus (HPV) infection by decreasing order of
 209 frequency. Patients with unqualified HPV results were excluded from the analysis.

210
 211 Table 3. Prevalence of specific human papillomavirus (HPV) genotypes among 804 cases of

212 condyloma acuminatum, by decreasing order of frequency.

HPV genotypes	Males (n = 597) ^a n (%)	Females (n= 207) ^a n (%)	P value
LR genotypes			
HPV6	347 (58.1)	118 (57.0)	0.779
HPV11	214 (35.8)	85 (41.4)	0.181
HPV42	64 (10.7)	19 (9.2)	0.530
HPV43	37 (6.2)	8 (3.9)	0.208
HPV81	23 (3.9)	12 (5.8)	0.237
HPV83	10 (1.7)	3 (1.4)	0.824
HR genotypes			
HPV16	77 (12.9)	33 (15.9)	0.272
HPV52	51 (8.5)	20 (9.7)	0.625
HPV51	43 (7.2)	22 (10.6)	0.119
HPV18	43 (7.2)	20 (9.7)	0.257
HPV53	44 (7.4)	18 (8.7)	0.538
HPV56	36 (6.0)	24 (11.6)	0.009
HPV59	44 (7.4)	15 (7.2)	0.953
HPV58	34 (5.7)	21 (10.1)	0.029
HPV66	36 (6.0)	17 (8.2)	0.276
HPV68	24 (4.0)	14 (6.8)	0.109
HPV33	20 (3.4)	13 (6.3)	0.067
HPV73	23 (3.9)	3 (1.4)	0.092
HPV39	17 (2.8)	7 (3.4)	0.697
HPV31	16 (2.7)	5 (2.4)	0.837
HPV82	12 (2.0)	5 (2.4)	0.727
HPV35	8 (1.3)	6 (2.9)	0.140
HPV45	5 (0.8)	7 (3.4)	0.009

213 ^a Patients with unqualified HPV results were excluded from the analysis.

214

215 Discussion

216 As we all know, CA is one of the most common sexually transmitted
 217 infections (STIs) caused by HPV infection, and most sexually active
 218 persons are usually exposed to HPV during their lifetime [19]. In this study
 219 based on surveys in sentinel hospitals, we reported the prevalent
 220 characteristics of CA and distribution of HPV genotypes in patients with
 221 CA in Shandong Province, China. In our study, a total of 1185 CA patients

1 222 were recruited. The recruited patients were mainly males. This may be due
2
3 223 to the differences in the anatomical structure of males and females.
4
5
6 224 Compared with males, females need to undergo a professional
7
8
9 225 gynecological examination in the hospital to find out whether they have
10
11 226 CA. The average age of CA patients recruited in this study was 34.85 years.
12
13
14 227 Compared with men, women were younger. These results are consistent
15
16
17 228 with a previous Chinese multi-center study of genital wart conducted in
18
19
20 229 2013 including 1,005 cases from eighteen hospitals in seven geographical
21
22
23 230 regions of China [20]. In this study, most patients were in the sexually
24
25
26 231 active stage aged 20 to 40. These patients had risky sexual behaviors such
27
28
29 232 as multiple sexual partners and irregular condom use. Among them, 32
30
31 233 cases also suffered from other sexually transmitted diseases. These are all
32
33
34 234 risk factors that increase HPV infection [21, 22]. In addition, 34.7% of the
35
36
37 235 patients in this study were recurrences.

38
39 236 Among the 880 patients who underwent HPV testing, the overall HPV
40
41 237 prevalence rate was 91.36%, which shows that HPV is the pathogen that
42
43 238 causes CA. 8.6% of the patients could not be included in the analysis due
44
45
46
47 239 to insufficient cellular DNA content. Some studies have found that 16~26%
48
49
50 240 of the samples will be negative regardless of the type of cell brush sampling
51
52
53 241 [23, 24]. Compared with other studies, the lower negative rate of our study
54
55
56 242 reflects the higher quality of sample collection after unified training. In the
57
58
59 243 analysis of specific HPV types, it was shown that the most common
60
61
62
63
64
65

1 244 genotypes in Shandong Province, China were HPV6, HPV11, HPV16 and
2
3 245 HPV42. Compared with other regions in China, HPV42 had a higher
4
5 246 prevalence in Shandong province and had become one of the common
6
7 247 genotypes of HPV in CA patients. Previous studies have found that the
8
9 248 distribution of HPV genotypes varies from region to region. Although the
10
11 249 risk of diseases related to nonvaccine HPV genotypes is theoretically still
12
13 250 low, the actual situation still needs to be monitored to deal with the disease
14
15 251 burden caused by high prevalence of nonvaccine HPV genotypes.
16
17 252 Furthermore, the distribution of HPV6, HPV11 and HPV16 were
18
19 253 consistent with the results of studies in other regions of China [20, 25, 26].
20
21 254 In this study, males were mainly infected with low-risk HPV, while females
22
23 255 were mainly multiple infected with high-risk and low-risk HPV. Most
24
25 256 patients, both male and female, were infected with more than one different
26
27 257 HPV genotype. According to our results, HPV6 and 11 (alone or in
28
29 258 coinfection with other genotypes) were detected in 87.4% of patients, but
30
31 259 most of these patients also had high-risk HPV infection. In this study, 53.5%
32
33 260 of patients with CA were infected with high-risk HPV. 49.1% of male
34
35 261 patients were infected with at least one high-risk type of HPV. Some studies
36
37 262 have shown that male penile cancer and anal cancer are associated with
38
39 263 high-risk HPV infection [27]. Compared with male patients, female
40
41 264 patients had a higher infection rate of high-risk HPV (66.2% vs. 49.1%),
42
43 265 indicating that women had a higher burden of high-risk HPV infection.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 266 Persistent high-risk HPV infection can lead to precancerous lesions and
2
3 267 cancers of the cervix, vulva, vagina, and anus in women, so it is very
4
5
6 268 important to prevent the occurrence of these lesions [28]. Some studies find
7
8
9 269 that high HPV vaccination coverage significantly reduced the prevalence
10
11
12 270 of CA, HPV infection and cervical intraepithelial neoplasia grade 2+
13
14 271 (CIN2+) [29, 30]. In addition, when formulating policies to prevent HPV
15
16
17 272 infection in women, it should be considered that men also have a higher
18
19
20 273 infection rate of high-risk HPV. Some studies have found that men HPV
21
22
23 274 multiple infection is very common, and the high-risk HPV infection rate is
24
25
26 275 the same as that of women [31-33]. There is a higher risk of cross-infection
27
28
29 276 between men and women [34, 35]. HPV vaccination to men can effectively
30
31
32 277 reduce related HPV infection rates and HPV-related cancer incidence [36,
33
34 278 37].

35
36 279 Nowadays, four prophylactic HPV vaccines are available in China,
37
38
39 280 including the HPV bivalent vaccine (Cervarix[®]; Cecolin[®]) to protect
40
41
42 281 against HPV16 and 18; the HPV quadrivalent vaccine (Gardasil[®]) to
43
44
45 282 protect against HPV 6, 11, 16 and 18; the HPV nonavalent vaccine
46
47
48 283 (Gardasil[®]9) to protect against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 [38,
49
50
51 284 39]. At present, there is no HPV vaccination programs implemented in
52
53
54 285 China, which may be related to the insufficient data of HPV
55
56
57 286 epidemiological survey. However, the distribution of HPV genotypes
58
59
60 287 varies from region to region [40]. Although vaccines can provide
61
62
63
64
65

1 288 protection for people, it is important to study the prevalence and
2
3 289 distribution of HPV genotypes in different regions before implementing
4
5
6 290 the HPV vaccination plan, because understanding the distribution of HPV
7
8
9 291 genotypes will help to choose the best vaccine for HPV protection in each
10
11
12 292 region. In this study, HPV6 and HPV11 were the causes of CA in the
13
14
15 293 majority of patients (87.4%), and they were included in both the
16
17
18 294 quadrivalent and nonavalent vaccines. Considering the economic benefits
19
20
21 295 and the insufficient supply of 9-valent HPV vaccine in China, the 4-valent
22
23
24 296 HPV vaccine may be more suitable for the prevention of CA in Shandong
25
26
27 297 Province, China. Furthermore ,HPV42, as one of the genotypes with higher
28
29
30 298 prevalence in this study, has not been included in any licensed HPV
31
32
33 299 vaccines. Previous studies have found that among people vaccinated with
34
35
36 300 the quadrivalent HPV vaccine, the infection rate of nonvaccine HPV
37
38
39 301 genotypes is remaining flat or higher [41]. Therefore, it is necessary to
40
41
42 302 develop a broader spectrum of HPV vaccines to reduce the disease burden
43
44
45 303 caused by HPV infection [42].

46 304 In conclusion, CA cases are mainly infected with low-risk HPV, but there
47
48
49 305 are more high-risk HPV infections in both males and females, which is a
50
51
52 306 problem that cannot be ignored in clinical treatment. It is necessary to
53
54
55 307 monitor the HPV genotype of CA patients, because high-risk HPV
56
57
58 308 infection is the main risk factor for cancer. For the general public, HPV
59
60
61 309 typing and HPV vaccination will help to prevent CA or HPV-related cancer
62
63
64
65

1 310 and reduce the risk of disease. Additionally, nonvaccine HPV genotypes
2
3 311 also need to be monitored for their prevalence by regular HPV typing. The
4
5
6 312 results of our study provide a contribution to the epidemiology of HPV in
7
8
9 313 Chinese CA patients with improving the understanding of existing HPV
10
11
12 314 genotypes. Furthermore, these will have a positive impact on the
13
14
15 315 adjustment of CA prevention and treatment strategies, the research and
16
17
18 316 development of HPV vaccines and the formulation of immunization
19
20 317 programs.

21
22
23 318

24 25 319 **Acknowledgments**

26
27
28 320 We are grateful to the patients who joined the study. This work has been
29
30
31 321 funded by a research grant from Merck Sharpe & Dohme (MISP
32
33
34 322 IIS#57766). The funders had no role in study design, data collection and
35
36
37 323 analysis, decision to publish, or preparation of the manuscript.

38
39 324

40 41 42 325 **Disclosure of potential conflicts of interest**

43
44
45 326 No potential conflicts of interest were disclosed.

46
47 327

48 49 50 328 **Funding**

51
52
53 329 This work has been funded by a research grant from Merck Sharpe &
54
55
56 330 Dohme (MISP IIS#57766).

57
58 331
59
60
61
62
63
64
65

1 332 **Ethics and dissemination**

2
3 333 Our study was approved by the ethics committee of School of Public
4
5
6 334 Health, Shandong University, China (protocol n. 20190320). Individuals
7
8
9 335 must voluntarily agree to participate and must sign the free and informed
10
11
12 336 consent form.

13
14 337

15
16
17 338

18
19
20 339 **References** 

21
22 340

- 23 341 1. Steben M, Garland SM. Genital warts. Best Practice & Research Clinical
24 342 Obstetrics & Gynaecology. 2014;28(7):1063-73.
- 25 343 2. Dunne EF, Markowitz LE. Genital Human Papillomavirus Infection. Clinical
26 344 Infectious Diseases. 2006;43(5):624-9.
- 27 345 3. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, et al.
28 346 Genital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United
29 347 States. The Journal of Infectious Diseases. 2018;219(5):703-10.
- 30 348 4. Thomas R, Steben M, Greenwald Z, Stutz M, Rodier C, DeAngelis F, et al.
31 349 Recurrence of Human Papillomavirus External Genital Wart Infection Among
32 350 High-Risk Adults in Montréal, Canada. Sexually Transmitted Diseases.
33 351 2017;44(11):700-6.
- 34 352 5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et
35 353 al. Global Burden of Human Papillomavirus and Related Diseases. Vaccine.
36 354 2012;30:F12-F23.
- 37 355 6. Wang S-M, Shi J-F, Kang D-J, Song P, Qiao Y-L. Impact of Human
38 356 Papillomavirus-Related Lesions on Quality of Life: A Multicenter Hospital-Based
39 357 Study of Women in Mainland China. International Journal of Gynecologic Cancer.
40 358 2011;21(1):182-8.
- 41 359 7. McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden
42 360 of human papillomavirus infection in the Netherlands, 1989–2014: the gap
43 361 between females and males is diminishing. Cancer Causes & Control.
44 362 2017;28(3):203-14.
- 45 363 8. Kocjan BJ, Sterbenc A, Hosnjak L, Chouhy D, Bolatti E, Giri AA, et al. Genome
46 364 announcement: complete genome sequence of a novel Mupapillomavirus,
47 365 HPV204. Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(2):21-3.
- 48 366 9. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, Hausen Hz, de Villiers E-M.
49 367 Classification of papillomaviruses (PVs) based on 189 PV types and proposal of
- 50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 368 taxonomic amendments. *Virology*. 2010;401(1):70-9.
- 1 369 10. Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, et al. Global
2 370 estimates of expected and preventable cervical cancers among girls born between
3 371 2005 and 2014: a birth cohort analysis. *The Lancet Public Health*. 2021;6(7):e510-
4 372 e21.
- 5 373 11. Cubie HA. Diseases associated with human papillomavirus infection. *Virology*.
6 374 2013;445(1):21-34.
- 7 375 12. Al-Awadhi R, Al-Mutairi N, Albatineh AN, Chehadeh W. Association of HPV
8 376 genotypes with external anogenital warts: a cross sectional study. *BMC Infectious*
9 377 *Diseases*. 2019;19(1):375.
- 10 378 13. Ma L, Lu S, Jiang Y, Li M, Cong X, Cao Y. Distribution of human papillomavirus
11 379 genotypes (2014–2016) in women with genital warts at a sexually transmitted
12 380 disease clinic in Beijing, China. *Future Virology*. 2018;13(2):111-7.
- 13 381 14. de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
14 382 et al. Human papillomavirus genotype attribution in invasive cervical cancer: a
15 383 retrospective cross-sectional worldwide study. *The Lancet Oncology*.
16 384 2010;11(11):1048-56.
- 17 385 15. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al.
18 386 Persistent Human Papillomavirus Infection as a Predictor of Cervical
19 387 Intraepithelial Neoplasia. *JAMA*. 2001;286(24):3106-14.
- 20 388 16. Hall MT, Simms KT, Lew J-B, Smith MA, Brotherton JML, Saville M, et al. The
21 389 projected timeframe until cervical cancer elimination in Australia: a modelling
22 390 study. *The Lancet Public Health*. 2019;4(1):e19-e27.
- 23 391 17. Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, et al.
24 392 Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts
25 393 Among Female Health-Plan Enrollees, United States. *American Journal of*
26 394 *Epidemiology*. 2017;187(2):298-305.
- 27 395 18. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical
28 396 Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million
29 397 Women with Normal Cytological Findings. *The Journal of Infectious Diseases*.
30 398 2010;202(12):1789-99.
- 31 399 19. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A
32 400 Review of the Evidence for the 2015 Centers for Disease Control and Prevention
33 401 Sexually Transmitted Diseases Treatment Guidelines. *Clinical Infectious Diseases*.
34 402 2015;61(suppl_8):S849-S55.
- 35 403 20. Chang L, Ci P, Shi J, Zhai K, Feng X, Colombara D, et al. Distribution of genital
36 404 wart human papillomavirus genotypes in China: A multi-center study. *Journal of*
37 405 *Medical Virology*. 2013;85(10):1765-74.
- 38 406 21. Mueller SM, Menzi S, Kind AB, Blaich A, Bayer M, Navarini A, et al. Sexually
39 407 transmitted coinfections in patients with anogenital warts – a retrospective analysis
40 408 of 196 patients. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*.
41 409 2020;18(4):325-32.
- 42 410 22. Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR.
43 411 Consistent Condom Use Is Associated with Lower Prevalence of Human

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 412 Papillomavirus Infection in Men. *The Journal of Infectious Diseases*.
413 2010;202(3):445-51.
- 414 23. Aubin F, Prétet J-L, Jacquard A-C, Saunier M, Carcopino X, Jaroud F, et al.
415 Human Papillomavirus Genotype Distribution in External Acuminata
416 Condylomata: A Large French National Study (EDiTH IV). *Clinical Infectious
417 Diseases*. 2008;47(5):610-5.
- 418 24. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. *The
419 Lancet Infectious Diseases*. 2006;6(1):21-31.
- 420 25. The Prevalence and Genotype of Human Papillomavirus from patients with
421 Genital Warts in Eastern Guangdong Province. *Asian Pacific Journal of Cancer
422 Prevention*. 2015;16(14):5675-9.
- 423 26. Zhu C, Wang Y, Mao W, Zhang H, Ma J. Prevalence and distribution of HPV types
424 in genital warts in Xi'an, China: a prospective study. *BMJ Open*.
425 2019;9(5):e023897.
- 426 27. Sudenga SL, Ingles DJ, Pierce Campbell CM, Lin H-Y, Fulp WJ, Messina JL, et
427 al. Genital Human Papillomavirus Infection Progression to External Genital
428 Lesions: The HIM Study. *European Urology*. 2016;69(1):166-73.
- 429 28. Chaturvedi AK. Beyond Cervical Cancer: Burden of Other HPV-Related Cancers
430 Among Men and Women. *Journal of Adolescent Health*. 2010;46(4,
431 Supplement):S20-S6.
- 432 29. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, et al. Population-level
433 impact and herd effects following the introduction of human papillomavirus
434 vaccination programmes: updated systematic review and meta-analysis. *The
435 Lancet*. 2019;394(10197):497-509.
- 436 30. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M,
437 et al. Four year efficacy of prophylactic human papillomavirus quadrivalent
438 vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia
439 and anogenital warts: randomised controlled trial. *BRITISH MEDICAL
440 JOURNAL*. 2010;341.
- 441 31. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi L-F, et al. Genital
442 Human Papillomavirus Infection in Men: Incidence and Risk Factors in a Cohort
443 of University Students. *The Journal of Infectious Diseases*. 2007;196(8):1128-36.
- 444 32. Ingles DJ, Pierce Campbell CM, Messina JA, Stoler MH, Lin H-Y, Fulp WJ, et al.
445 Human Papillomavirus Virus (HPV) Genotype- and Age-Specific Analyses of
446 External Genital Lesions Among Men in the HPV Infection in Men (HIM) Study.
447 *The Journal of Infectious Diseases*. 2014;211(7):1060-7.
- 448 33. Chan PKS, Luk ACS, Luk TNM, Lee K-F, Cheung JLK, Ho K-M, et al.
449 Distribution of human papillomavirus types in anogenital warts of men. *Journal of
450 Clinical Virology*. 2009;44(2):111-4.
- 451 34. Nyitray AG, Menezes L, Lu B, Lin H-Y, Smith De, Abrahamsen M, et al. Genital
452 Human Papillomavirus (HPV) Concordance in Heterosexual Couples. *The Journal
453 of Infectious Diseases*. 2012;206(2):202-11.
- 454 35. Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, de Sanjosé S, et al.
455 Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer

456 in Female Partners. *New England Journal of Medicine*. 2002;346(15):1105-12.

1 457 36. Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Garland SM, et al.
2 458 Prevalence of human papillomavirus in young men who have sex with men after
3 459 the implementation of gender-neutral HPV vaccination: a repeated cross-sectional
4 460 study. *The Lancet Infectious Diseases*. 2021;21(10):1448-57.

5 461 37. Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al.
6 462 Ongoing decline in genital warts among young heterosexuals 7 years after the
7 463 Australian human papillomavirus (HPV) vaccination programme. *Sexually*
8 464 *Transmitted Infections*. 2015;91(3):214-9.

9 465 38. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review.
10 466 *Vaccines*. 2020;8(3):391.

11 467 39. Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, et al. Domestic HPV
12 468 vaccine price and economic returns for cervical cancer prevention in China: a cost-
13 469 effectiveness analysis. *The Lancet Global Health*. 2020;8(10):e1335-e44.

14 470 40. Zhu B, Liu Y, Zuo T, Cui X, Li M, Zhang J, et al. The prevalence, trends, and
15 471 geographical distribution of human papillomavirus infection in China: The pooled
16 472 analysis of 1.7 million women. *Cancer Medicine*. 2019;8(11):5373-85.

17 473 41. Schlecht NF, Diaz A, Nucci-Sack A, Shyhalla K, Shankar V, Guillot M, et al.
18 474 Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and
19 475 Young Women Immunized With the Human Papillomavirus Vaccine. *JAMA*
20 476 *Network Open*. 2021;4(8):e2121893-e.

21 477 42. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future.
22 478 *Epidemiology and Infection*. 2016;144(3):449-68.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




Table 1. Baseline characteristics of 1185 patients with condyloma acuminatum, by gender

Characteristics	Male (n = 870)	Female (n= 315)
	n (%)	n (%)
Age		
< 18	18 (2.1)	13 (4.1)
18-24	202 (23.2)	99 (31.4)
25-29	120 (13.8)	38 (12.1)
30-39	228 (26.2)	92 (29.2)
40-49	146 (16.8)	38 (12.1)
50-59	93 (10.7)	28 (8.9)
≥60	63 (7.2)	28 (2.2)
Marital status		
Single	319 (36.7)	124 (39.4)
Married	535 (61.1)	182 (57.8)
Widowed/Separated/Divorced	19 (2.2)	9 (2.9)
Education		
Primary/Middle school	225 (25.9)	94 (29.8)
High school	209 (24.0)	49 (15.6)
University/College	419 (48.2)	167 (53.0)
Postgraduate	17 (2.0)	5 (1.6)
Area of residence at diagnosis		
Rural area	263 (30.2)	96 (30.5)
City	607 (69.8)	219 (69.5)
Age of first sexual intercourse		
< 18	76 (8.7)	23 (7.3)
18-21	431 (49.5)	155 (49.2)
≥22	363 (41.7)	137 (43.5)
Type of CA diagnosis		
Recurrent disease	288 (33.1)	123 (39.0)
New diagnosis	582 (75.2)	192 (61.0)
Condom use		
No	108 (12.4)	34 (10.8)
Yes, sometimes/rarely	676 (77.7)	260 (82.5)
Yes, always	86 (9.9)	21 (6.7)
Weekly frequency of sexual		
≤1	394 (45.6)	123 (39.0)
=2	314 (36.1)	118 (37.5)
≥3	159 (18.3)	74 (23.5)
Wash genitalia before sex		

Yes	543 (62.4)	191 (60.6)
No	327 (37.6)	124 (39.4)
Number of sexual partners		
=1	288 (33.1)	142 (45.1)
≥2	582 (66.9)	173 (54.9)

Table 2. Distribution of infection types in 804 cases of condyloma acuminatum

	Males (n = 597) ^a	Females (n= 207) ^a	<i>P</i> value
	n (%)	n (%)	
HR-HPV	293(49.1)	137(66.2)	< 0.001
LR-HPV	543(91.0)	191(92.3)	0.563
LR and HR HPV	239 (40.0)	121 (58.5)	< 0.001
Single infection	286 (47.9)	69 (33.3)	< 0.001
Multiple infections	311 (52.1)	138 (66.7)	< 0.001
HPV6 or 11	515 (86.3)	188 (90.8)	0.088
HPV16 or 18	109 (18.3)	49 (23.7)	0.091
Types of 4-valent vaccines ^b	552 (92.5)	196 (94.7)	0.279
Types of 9-valent vaccines ^c	566 (94.8)	200 (96.6)	0.290

^a Patients with unqualified HPV results were excluded from the analysis.

^b The types of 4-valent vaccines conclude HPV 6, 11, 16 or 18.

^c The types of 9-valent vaccines conclude HPV 6, 11, 16, 18, 31, 33, 45, 52 or 58.

Table 3. Prevalence of specific human papillomavirus (HPV) genotypes among 804 cases of condyloma acuminatum, by decreasing order of frequency.

HPV genotypes	Males (n = 597) ^a	Females (n= 207) ^a	<i>P</i> value
	n (%)	n (%)	
LR genotypes			
HPV6	347 (58.1)	118 (57.0)	0.779
HPV11	214 (35.8)	85 (41.4)	0.181
HPV42	64 (10.7)	19 (9.2)	0.530
HPV43	37 (6.2)	8 (3.9)	0.208
HPV81	23 (3.9)	12 (5.8)	0.237
HPV83	10 (1.7)	3 (1.4)	0.824
HR genotypes			

HPV16	77 (12.9)	33 (15.9)	0.272
HPV52	51 (8.5)	20 (9.7)	0.625
HPV51	43 (7.2)	22 (10.6)	0.119
HPV18	43 (7.2)	20 (9.7)	0.257
HPV53	44 (7.4)	18 (8.7)	0.538
HPV56	36 (6.0)	24 (11.6)	0.009
HPV59	44 (7.4)	15 (7.2)	0.953
HPV58	34 (5.7)	21 (10.1)	0.029
HPV66	36 (6.0)	17 (8.2)	0.276
HPV68	24 (4.0)	14 (6.8)	0.109
HPV33	20 (3.4)	13 (6.3)	0.067
HPV73	23 (3.9)	3 (1.4)	0.092
HPV39	17 (2.8)	7 (3.4)	0.697
HPV31	16 (2.7)	5 (2.4)	0.837
HPV82	12 (2.0)	5 (2.4)	0.727
HPV35	8 (1.3)	6 (2.9)	0.140
HPV45	5 (0.8)	7 (3.4)	0.009

^a Patients with unqualified HPV results were excluded from the analysis.

Human Vaccines & Immunotherapeutics

Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province , China --Manuscript Draft--

Manuscript Number:	KHVI-2022-0554R1
Full Title:	Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province , China
Article Type:	Research Article
Order of Authors:	Haowen Yuan Renpeng Li Jian Lv Guipeng Yi Xihong Sun Na zhao Fengjun Zhao Aiqiang Xu Zengqiang Kou Hongling Wen
Keywords:	condyloma acuminatum; human papillomavirus; epidemiology; HPV genotypes
Manuscript Classifications:	115 HPV; 125 Infectious Disease; 80 Epidemiology
Abstract:	<p>Condyloma acuminatum (CA) is a sexually transmitted disease (STD) caused by human papillomavirus (HPV) infection. It is important to study the prevalence and distribution of HPV genotypes before implementing HPV vaccination program. Therefore, the aim of this study was to evaluate the epidemiological characteristics of CA cases and the distribution of HPV genotypes in Shandong Province, China. One-to-one questionnaire surveys were conducted on all patients diagnosed with CA in sentinel hospitals from Shandong Province, China. HPV genotypes were determined using the polymerase chain reaction (PCR)-reverse dot blot hybridization method. The study enrolled 1185 patients (870 males and 315 females) and found that CA patients are mainly males and sexually active people between the ages of 20 and 40. Recurrence occurred in 34.7% patients. Among the 880 CA patients who underwent HPV typing, the HPV test positivity rate was 91.4%. In these cases, low-risk HPV infection was predominant, with an infection rate of 91.3%, while high-risk HPV genotypes were found in 53.5% patients. The most frequent HPV genotypes encountered were HPV 6 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%) and HPV 42 (10.3%). HPV 6 and/or HPV 11 are the main infections in all patients, and more than half of the patients are coinfecting with high-risk HPV. However, unlike other regions, HPV42 has a higher prevalence rate among CA patients in Shandong Province and is a nonvaccine HPV genotype. Therefore, regular HPV typing helps to understand the characteristics of specific genotypes and the choice of the best type for vaccine coverage.</p>
Response to Reviewers:	

Ronald Ellis PhD MBA
Editor-in-Chief
Human Vaccines & Immunotherapeutics

2022.12.16

Dear Prof Ellis,

Re: Manuscript reference No. KHVI-2022-0554
220855034

Please find attached a revised version of our manuscript “**Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province, China**”, which we would like to resubmit for publication as a research article in Human Vaccines & Immunotherapeutics.

Your comments and those of the reviewers were highly insightful and enabled us to greatly improve the quality of our manuscript. In the following pages are our point-by-point responses to each of the comments of the reviewers as well as your own comments. The reviewer’s comments and questions are shown in bold.

We have edited and revised the manuscript using the “Track Changes” tool in Microsoft Word. We have also quoted the articles recommended by you and reviewers. We hope that the revisions in the manuscript and our accompanying responses will be sufficient to make our manuscript suitable for publication in Human Vaccines & Immunotherapeutics.

We shall look forward to hearing from you at your earliest convenience.

Yours sincerely,

Haowen Yuan

Email: yuanhaowen0218@163.com

Hongling Wen, M.D. Ph.D

Email: wenhongling1114@163.com

Department of Microbiological Laboratory Technology

School of Public Health, Shandong University, Jinan, China, 250012

Reviewers' comments and questions:

Editorial Comments

1. Remove the Tables from the manuscript DOC and upload as a separate DOC file.

Response: Thanks for your careful reading and checks. We have removed the Tables from the manuscript DOC and uploaded it as a separate Tables DOC file.

2. Remove the Figures from the manuscript DOC file.

Response: Thanks for your careful reading. We have removed the Figures from the manuscript DOC and uploaded it as a separate Figures DOC file.

3. Avoid using abbreviations or numbers at the beginning of sentences.

Response: Thank you very much for your careful reading. We have fixed these errors.

4. Do not mention the number of patients in the Table title.

Response: We thanks the reviewer for pointing this out. We have removed the number of patients from the Table title. Please review the separate Tables DOC file.

5. Round all numbers to the nearest 0.1 not 0.01.

Response: We appreciate your careful reading. We have corrected these errors.

Major Comments

1. Materials and Methods

a. The part of HPV DNA testing is written too simply. Add specific PCR amplification steps.

Response: Thanks a lot for the reviewer kind suggestion. Under your guidance, we added the specific PCR amplification steps in the part of HPV DNA testing. Please see page 6-7 of the revised manuscript, lines 127–143.

All HPV DNA extraction, amplification and genotype identification were performed with the HPV genotyping panel (polymerase chain reaction (PCR)-reverse dot blot hybridization method; Yaneng Biosciences, Shenzhen, China). The HPV genotyping panel can detect 17 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82) and 6 low-risk HPV genotypes (6, 11, 42, 43, 81 and 83). Genomic DNA was extracted from specimens following manufacturer's protocols. The PCR cycling conditions were as follows: initial denaturation at 95°C for 5 min, then 40 cycles at 94°C for 30 s, 42°C for 90 s, 72°C for 30 s, and a final extension at 72°C for 5 min. The HPV type-specific probes are immobilized on nylon membranes for reverse-blot hybridization, which can detect 23 types of HPV genotypes in a single test. Hybridization was performed and visualized by assessing the protocol according to the manufacturer's instructions. The quality and integrity of the extracted DNA is

monitored by the β -actin gene assay. The specimens with known HPV genotypes were used as positive controls and enzyme-free water was used as a negative control.

b. Describe in detail the examination and specific sampling sites of men and women, such as whether the men or women who received anal sex had anal canal examined and specimen collection. Did women receive the vagina and cervix exam? Was the oral cavity examined for people who had active oral sex? Conduct statistical analysis on the difference of HPV infection in different specimen collection sites.

Response: Thanks for your professional comments. Anal and oral specimens were not collected from all patients with acromegaly in this study, only the site where the CA lesions were located in the patient was examined and samples were collected. Some of these patients had CA lesions located in the anal area. We describe the process of collecting specimens in more detail in Sample Collection. Please see page 6 of the revised manuscript, lines 115–119. We also found that few studies have reported in detail on anal and oral HPV infection in patients with condyloma acuminatum. Your valuable comments will provide us with valuable ideas to improve our next studies.

c. Explain why 1185 patients were enrolled at the beginning of the study, but only 880 patients were tested for HPV typing, why were the remaining 305 patients not tested for HPV typing ?

Response: Thank you very much for your careful reading and your professional comments. A total of 1185 patients in this study consented to the questionnaire. Of these, 880 consented to the sample collection while the remaining 305 patients did not consent to the sample collection and they only consented to the questionnaire.

d. There are three times as many male as female subjects. Does this have any impact on the distribution difference of HPV types between men and women in subsequent analysis?

Response: We appreciate your careful reading and critical comments. The aim of this study was to explore the prevalence characteristics and HPV genotypes distribution of CA cases in Shandong Province, China. We believe that the sample size included in this study is large enough to reflect the current true prevalence of condyloma acuminatum in Shandong Province, China. In addition, previous studies have found that the sex ratio of male to female patients with condyloma acuminatum in China has been increasing year by year, with more male patients than female patients. The patient profile included in this study is consistent with the epidemiological characteristics of patients with condyloma acuminatum in China, and is in line with the findings of relevant studies in China and abroad. Therefore, we do not believe that there will be an impact on the differences in the distribution of HPV types between males and females in the subsequent analysis.

References:

1. Yue X, Gong X, Li J, et al. Epidemiological features of condyloma acuminatum

in national sexually transmitted disease surveillance sites in China from 2008 to 2016 [J]. Chinese Journal of Dermatology,2017,50(05):321-325.

2. Zhu C, Wang Y, Mao W, et al. Prevalence and distribution of HPV types in genital warts in Xi'an, China: a prospective study[J]. BMJ Open,2019,9(5):e23897.

3. Azevedo J, Pista A, Lisboa C, et al. Epidemiology of human papillomavirus on anogenital warts in Portugal - The HERCOLES study[J]. Journal of the European Academy of Dermatology and Venereology,2017,31(8):1342-1348.

2. Results

a. Explain why the prevalence of HPV is 91.4%, which appears incorrect. From the 76 patients whose HPV DNA was negative, was a repeat specimen taken and continued with an HPV genotype examination? The negative result in 76 patients may be due to insufficient exfoliated cells, so if the number of cells is more or the cell sampling is repeated, the result may be positive. Thus in this case, it is better not to mention the prevalence of HPV but the overall HPV DNA is

Response: Thank you very much for your careful reading and valuable comments. Samples that tested negative in this study were retested for confirmation. Insufficient cellular DNA was not included in the analysis mainly due to the cases were β -globin negative. In a review of genital HPV infection in men, the authors reported that, regardless of the type of cytobrush used, the proportion of β -globin-negative samples ranged from 16% to 26%, and our results were lower than in their study (8.6%).

We have changed “HPV DNA was detected in 804 of 880 CA cases, yielding an overall prevalence of 91.4% (90.6% males and 93.7% females)” to “The HPV DNA was detected in 804 of the 880 CA cases, with a positive rate of 91.4% (90.6% males and 93.7% females)”. Please see page 10 of the revised manuscript, lines 204–206.

References:

1. Partridge J M, Koutsky L A. Genital human papillomavirus infection in men[J]. The Lancet Infectious Diseases,2006,6(1):21-31.

b. Table1, marital status, education, urban or rural areas, and the time of the first sexual act, etc., should be further analyzed.

Response: Thanks a lot for the reviewer kind suggestion. The aim of this study was to evaluate the prevalence characteristics and HPV genotype distribution of CA cases in Shandong Province, China. CA cases from sentinel hospitals between August 2019 and June 2021 were collected to illustrate the epidemiological characteristics of condyloma acuminatum in Shandong Province, China. Thank you very much for your suggestion and we will take these factors you suggested into account in a follow-up study to further explore the impact of factors such as marital status, education, urban or rural area, and the time of first sexual intercourse on the prevalence characteristics of CA.

c. Table 2 has a similar number of people between 4v and 9v vaccines. Can it be shown that the protection rate of the quadrivalent vaccine is similar to that of the nine-valent vaccine? In the absence of an expensive nine-valent vaccine, the cost performance of quadrivalent vaccine is higher for individual and group

prevention and control.

Response: We appreciate the reviewer's insightful question. All of the subjects in our study were patients with condyloma acuminatum and the predominant types of infection were HPV6 and HPV11. Because both the quadrivalent and nine-valent vaccines cover HPV6 and HPV11, the number of people infected with the HPV genotypes covered by the quadrivalent and nine-valent vaccines is similar. Both quadrivalent and nine-valent vaccines reduce the prevalence of CA, but it cannot be inferred from the similar number of infections that they have similar protection rates; this requires further clinical trials to obtain the protection rates for both vaccines.

d. In "HPV prevalence", line 7 mentions that 374 cases were only infected with LR-HPV and 70 cases were only infected with HR-HPV, which was slightly reflected in Table 2. Clarify this discrepancy.

Response: We appreciate your careful reading and critical comments. Only infected with LR-HPV means that only low-risk HPV tests are positive and all high-risk HPV tests are negative. Similarly, only infected with HR-HPV means that only the high-risk HPV types tested positive and all the low-risk HPV types tested negative. We have added this section to Table 2 in the separate Tables DOC file.

e. 34.7% of the patients had relapse. Is relapse related to HPV typing? Correlation analysis should be done.

Response: Thanks for your professional comments. There were 215 relapsed patients and 589 non-relapsed patients who received HPV testing. A correlation analysis was performed between recurrence and HPV type, but the results found no correlation between recurrence and HPV type, so the results were not added to the manuscript. The results are as follows:

Schedule 1 Correlation of CA recurrence with HPV genotypes

HPV genotypes	Recurrence (n = 215)	No recurrence (n= 589)	P value
	N (%)	N (%)	
LR genotypes			
HPV6	125 (58.1)	340 (57.7)	0.916
HPV11	76 (35.3)	223 (37.9)	0.514
HPV42	21 (9.8)	62 (10.5)	0.754
HPV43	10 (4.7)	35 (5.9)	0.481
HPV81	5 (2.3)	30 (5.1)	0.089
HPV83	6 (2.8)	7 (1.2)	0.111
HR genotypes			
HPV16	29 (13.5)	81 (13.8)	0.923
HPV52	21 (9.8)	50 (8.5)	0.572
HPV51	13 (6.0)	52 (8.8)	0.200
HPV18	12 (5.6)	51 (8.7)	0.151
HPV53	15 (7.0)	47 (8.0)	0.637
HPV56	14 (6.5)	46 (7.8)	0.535
HPV59	17 (7.9)	42 (7.1)	0.709

HPV58	18 (8.4)	37 (6.3)	0.299
HPV66	20 (9.3)	33 (5.6)	0.061
HPV68	8 (3.7)	30 (5.1)	0.417
HPV33	7 (3.3)	26 (4.4)	0.464
HPV73	6 (2.8)	20 (3.4)	0.668
HPV39	8 (3.7)	16 (2.7)	0.459
HPV31	7 (3.3)	14 (2.4)	0.489
HPV82	5 (2.3)	12 (2.0)	0.801
HPV35	2 (0.9)	12 (2.0)	0.288
HPV45	3 (1.4)	9 (1.5)	0.891

f. State how informed consent was obtained for minors under the age of 18?

Response: Thanks for your nice question. We first obtain the consent of the guardian of a minor under the age of 18 and then the consent of the patient, and only then do we carry out the investigation. Please see page 5-6 of the revised manuscript, lines 109–111.

g. Confirm that the subjects underwent biopsy for HPV typing.

Response: Thanks for the reviewer good suggestion. We think although the cytobrush was probably not the best tool for cell collection, it was surely the most appropriate, because it was noninvasive and represented an easy and acceptable sampling method for patients.

h. "85.7% of the patients (86.8% of males and 85.0% of females) claimed that their sexual partners were not infected with HPV". This part of the data is inconsistent with the clinical data. Are the data obtained by the patient's oral description or confirmed by laboratory testing?

Response: We appreciate your careful reading and critical comments. This part of the data was obtained through face-to-face interviews with the patients. As the patient had more than one number of sexual partners, there were some difficulties in performing laboratory tests on the patient's sexual partners, which made it difficult to obtain consent from the patient and his/her sexual partners. However, this study did require knowledge of the HPV status of the patient's sexual partners, so it was only possible to find out from the patient the infection status of his or her regular sexual partners. Please see page 9 of the revised manuscript, lines 180–182.

i. "32 patients reported other STDs". This part of the data is inconsistent with the clinical data. How did you get these data ?

Response: Thanks for your question. In this study, each patient was examined not only for condyloma acuminatum, but also for other sexually transmitted diseases. This data is obtained by further laboratory tests on the patient.

j. Explain what "a single body location" means.

Response: Thanks for your careful reading. "a single body location" means that only one body site has the condyloma acuminatum lesions. We have modified "The majority of patients stated that only a single body location was infected with warts (53.5%). 34.26% patients presented warts at two different locations, 8.8% at three, and 3.4% at four or more different locations" to "The majority of patients presented warts lesions at one body site (53.5%), 34.3% patients presented warts at two different sites, 8.8% at three, and 3.4% at four or more different sites". Please see page 9 of the revised manuscript, lines 188–192.

3. Discussion

a. The article mentions that compared with other areas of China, Shandong Province HPV42 in patients with condyloma acuminatum prevalence is higher. Do you have data on the prevalence of HPV42 in other regions?

Also, explain whether additional HPV42 vaccine is necessary in the context of virulence and other relevant data.

Response: Thanks for your nice comments. The prevalence of HPV42 in other regions of China was obtained from previously published studies. Currently, the prevalence of HPV42 is not high throughout mainland China, and is only relatively high in Shandong Province. It may not be economically appropriate to develop an additional HPV42 vaccine. If an additional HPV42 vaccine is needed, this may require more epidemiological data as a supporting basis, as well as the need for regular surveillance of the prevalence of non-vaccine covered HPV genotypes.

References:

1. Zhu C, Wang Y, Mao W, et al. Prevalence and distribution of HPV types in genital warts in Xi'an, China: a prospective study[J]. *BMJ Open*,2019,9(5):e23897.
2. Luo Z, Chen Q, Yang H, et al. The Prevalence and Genotype of Human Papillomavirus from Patients with Genital Warts in Eastern Guangdong Province[J]. *Asian Pacific Journal of Cancer Prevention*,2015,16(14):5675-5679.
3. Wang H, Qiao Y L. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis[J]. *International Journal of STD & AIDS*,2008,19(10):680-684.

b. "8.6% of the patients could not be included in the analysis due to insufficient cellular DNA content": Have you considered other reasons?

Response: Thanks for your good question. "8.6% of patients could not be included in the analysis due to insufficient cellular DNA content" was mainly due to a negative result for β -globin during the test. In a review of genital HPV infection in men, the authors reported that, regardless of the type of cytobrush used, the proportion of β -globin-negative samples ranged from 16% to 26%, and our results were lower than in their study (8.6%).

References:

1. Partridge J M, Koutsky L A. Genital human papillomavirus infection in men[J]. *The Lancet Infectious Diseases*,2006,6(1):21-31.

Minor Comments

1. Clarify how many females participated in this study? 336 or 315?

Response: We apologize for our error and thanks for your careful reading. There were 315 women who participated in this study. We have corrected the error in Table 1 in the separate Tables DOC file.

2. Line 34 paragraph 1. Change "So" to "Therefore".

Response: Thanks for your good suggestion. We have changed "So" to "Therefore". Please see page 2 of the revised manuscript, lines 34.

3. Line 57, paragraph 1. Change "genital wart" to "genital warts".

Response: We thanks the reviewer for pointing this out. We have corrected the typo. Please see page 3 of the revised manuscript, lines 63.

4. Lines 64-6. Correct the grammar in "Because the location of CA is relatively private, the treatment economic burden to the patient, and reduces the quality of life of the patient". A sentence should not be composed of two clauses, in other words, a sentence should have a body sentence. Furthermore, better to write the sentence more concrete. For instance, you could write "the treatment process is painful and the treatment fee is expensive."

Response: We appreciate your careful reading and critical comments. We have changed "Because the location of CA is relatively private, the treatment economic burden to the patient, and reduces the quality of life of the patient" to "The occurrence of CA reduces the quality of life of patients. On the one hand, the affected area of CA is private and the treatment process is painful, which brings serious psychological pressure to patients. On the other hand, the treatment fee is expensive, which brings heavy financial burden to patients and their families.". Please see page 4 of the revised manuscript, lines 70–74.

5. Lines 91-2, diagnosed according to ... - Attach the year of the guideline, and cite the guideline in reference.

Response: Thanks for your careful reading. We have attached the year of the guideline, and cited the guideline in reference. Please see page 5 of the revised manuscript, lines 103–104.

References:

1. Chinese Society of Dermatology and Venereology, China Dermatologist Association, Chinese Association of Rehabilitation Dermatology and Venereology. Guideline for the Clinical Management of Anogenital Warts in China (2014) [J]. Chinese Journal of Dermatology, 2014,47(08):598-599.

6. Line 100, Revise "must volunteer to". "Must" means that you have to do something while volunteer means you want to do something without other people's

intention or supervision.

Response: We apologize for our error and thanks the reviewer for pointing this out. We have changed “Each individual of the patients must volunteer to participate in this study and sign the informed consent.” to “All patients volunteered to participate in this study and signed the informed consent (Minors under the age of 18 have the consent of their guardians)”. Please see page 6 of the revised manuscript, lines 113–115.

7. Line 98. Filling in a questionnaire is more idiomatic than "accepting a questionnaire".

Response: According to your valuable comments, we have changed "accepting a questionnaire" to “filling in a questionnaire”. Please see page 5 of the revised manuscript, lines 110.

8. Line 103. Report how many samples were collected from each hospital.

Response: Thanks for your professional comments. Shandong Dermatology Hospital collected 407 samples, while Jining No.1 People’s Hospital and Shandong Oriental Anorectal Hospital collected 321 and 152 samples, respectively. The number of samples collected from each hospital has been described in the Results section. Please see page 11 of the revised manuscript, lines 206–208.

9. Line 137, Among recruited patients, 63.7% cases reported having more than one sexual partner.

Add "having" to make the sentence complete.

Response: Thanks for your careful reading and checks. We have revised our manuscript according to your suggestions. Please see page 8 of the revised manuscript, lines 175.

10. Line 142. From US CDC 2021 STIs Guideline, the term "MSM" often is used clinically to refer to sexual behavior alone, regardless of sexual orientation (e.g., a person might identify as heterosexual but still be classified as MSM). In your study, you reported that 26 men and 1 woman had sex with men and women.

Classify the 26 men as MSM for their sexual behavior.

Response: Thanks for your professional comments. This study needed to know the detailed sexual behavior of each patient, not just the sexual orientation. Therefore, the bisexual group was further delineated. The 26 males and 1 female should be classified as bisexual because they had sex with both males and females. We have changed “There were 99 men (11.4% of the male patients) who had sex with men (MSM), and 2 women were homosexuals. 26 men and 1 woman who had sex with men and women” to “There were 101 patients who were homosexual, including 99 males (men who had sex with men, MSM) and 2 females. In addition, 26 males and 1 female were bisexual who had sex with both males and females”. Please see page 9 of the revised manuscript, lines 178-181.

11. Lines 151-2. In "CA patients' characteristics", the retention of the decimal point is inconsistent.

Response: We appreciate your careful reading. We have corrected these errors. Please see page 9-10 of the revised manuscript, lines 193-200.

12. Line 216, CA is one of the most common STDs. For the term "sexually transmitted infection" (STI) refers to a pathogen that causes infection through sexual contact, whereas the term "sexually transmitted disease" (STD) refers to a recognizable disease state that has developed from an infection.

Response: According to your valuable comments, we have changed “sexually transmitted infection” to “sexually transmitted disease”. Please see page 14 of the revised manuscript, lines 267.

13. Line 276, Is it feasible for men to be vaccinated with HPV vaccine in case of vaccine shortage?

Response: We think that HPV vaccination for men is feasible in the face of vaccine shortages. Previous studies have found that HPV vaccination in men significantly reduces the prevalence of anal cancer, condyloma acuminata, and other diseases. In addition, there is a good immunization effect with only one dose.

References:

1. Chow E P F, Tabrizi S N, Fairley C K, et al. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study[J]. The Lancet Infectious Diseases,2021.
2. Goldstone S E, Giuliano A R, Palefsky J M, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial[J]. The Lancet Infectious Diseases,2021.
3. Basu P, Malvi S G, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study[J]. The Lancet Oncology,2021,22(11):1518-1529.

14. Line 312. "make" a contribution. "make" is more idiomatic than "provide".

Response: We thanks the reviewer for pointing this out. We have corrected these errors. Please see page 19 of the revised manuscript, lines 363.

15. Table 1

a. variable "weekly frequency of sexually" seems like an uncompleted expression.

b. male vertical column, $394+314+159=867$. Please explain why it is not 870.

c. variable "type of CA diagnosis", male vertical column, $33.1\%+75.2\%=108.3\%$. Explain why it is not 100%.

Response: We apologize for our errors and thanks for your careful reading. We have corrected these errors in Table 1 in the separate Tables DOC file.

1 **Epidemiology of Human Papillomavirus on Condyloma Acuminatum**
2
3
4 **in Shandong Province , China**

5
6 Yuan Haowen^{a,†}, Li Renpeng^{b,†}, Lv Jian^c, Yi Guipeng^d, Sun Xihong^e, Zhao
7
8 Na^f, Zhao Fengjun^g, Xu Aiqiang^b, Kou Zengqiang^{b,*}, Wen Hongling^{a,*}

9
10 a Department of Microbiological Laboratory Technology, School of
11
12 Public Health, Cheeloo College of Medicine, Shandong University, Key
13
14 laboratory for the prevention and control of infectious diseases (key labor-
15
16 atory of China's "13th Five-Year", Shandong University), Jinan 250012,
17
18 China; yuanhaowen0218@163.com (H.Y.)

19
20 b Shandong Center for Disease Control and Prevention, Shandong
21
22 Provincial Key Laboratory of Infectious Disease Prevention and Control,
23
24 Jinan 250014, China; rpleesd@163.com (R.L.); aqxuepi@163.com (A.X.)

25
26 c Shandong First Medical University & Shandong Academy of Medical
27
28 Sciences, Tai'an 271016, China; sdfmulvjian@163.com

29
30 d Weifang Medical University, Weifang 261053, China;
31
32 2046076711@qq.com

33
34 e Jining City Center for Disease Control and Prevention, Jining 272000,
35
36 China; xihongsun@163.com

37
38 f Shandong Provincial Hospital for Skin Diseases & Shandong
39
40 Provincial Institute of Dermatology and Veneorology, Shandong First
41
42 Medical University & Shandong Academy of Medical Sciences. Jinan
43
44 250000, China; 411657904@qq.com

1 23 g Shandong Oriental Andrology Hospital, Jinan 250000, China;

2
3 24 671830931@qq.com

4
5
6 25 *Correspondence:

7
8
9 26 jack-cou@163.com (Z.K.); wenhongling@sdu.edu.cn (H.W.);

10
11 27 Tel.: +86-0531-82679681 (Z.K.); +86-0531-88382625 (H.W.)

12
13
14 28 † Haowen Yuan and Renpeng Li are Co-first authors.

15
16
17 29

18
19
20 30 **Abstract**

21
22 31 Condyloma acuminatum (CA) is a sexually transmitted disease (STD)

23
24 32 caused by human papillomavirus (HPV) infection. It is important to study

25
26 33 the prevalence and distribution of HPV genotypes before implementing

27
28 34 HPV vaccination program. Therefore, the aim of this study was to evaluate

29
30 35 the epidemiological characteristics of CA cases and the distribution of HPV

31
32 36 genotypes in Shandong Province, China. One-to-one questionnaire surveys

33
34 37 were conducted on all patients diagnosed with CA in sentinel hospitals

35
36 38 from Shandong Province, China. HPV genotypes were determined using

37
38 39 the polymerase chain reaction (PCR)-reverse dot blot hybridization method.

39
40 40 The study enrolled 1185 patients (870 males and 315 females) and found

41
42 41 that CA patients are mainly males and sexually active people between the

43
44 42 ages of 20 and 40. Recurrence occurred in 34.7% patients. Among the 880

45
46 43 CA patients who underwent HPV typing, the HPV test positivity rate was

47
48 44 91.4%. In these cases, low-risk HPV genotypes infection was predominant,

49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 45 with an infection rate of 91.3%, while high-risk HPV genotypes were found
2
3
4 46 in 53.5% patients. The most frequent HPV genotypes encountered were
5
6 47 HPV 6 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%) and HPV 42 (10.3%).
7
8
9 48 HPV 6 and/or HPV 11 are the main infections in all patients, and more than
10
11
12 49 half of the patients are coinfecting with high-risk HPV. However, unlike
13
14
15 50 other regions, HPV42 has a higher prevalence rate among CA patients in
16
17
18 51 Shandong Province and is a nonvaccine HPV genotype. Therefore, regular
19
20
21 52 HPV typing helps to understand the characteristics of specific genotypes
22
23
24 53 and the choice of the best type for vaccine coverage.

25 54 **Keywords:** condyloma acuminatum; human papillomavirus;
26
27
28 55 epidemiology; HPV genotypes
29
30

31 56

32 57 **Introduction**

33
34
35
36 58 Condyloma acuminatum (CA), also known as genital warts (GW), is a
37
38
39 59 verrucous hyperplasia of squamous epithelium in the anogenital region
40
41
42 60 caused by human papillomavirus (HPV) infection, and it is one of the most
43
44
45 61 common sexually transmitted diseases (STDs) [1, 2]. The CA is the most
46
47
48 62 common benign lesions of the anogenital region, but it can be difficult to
49
50
51 63 treat and easy to recur, which required repeated treatment [3]. Studies have
52
53
54 64 shown that approximately 48.5% of CA patients will experience recurrence
55
56
57 65 [4]. The occurrence of CA reduces the quality of life of patients. On the
58
59
60 66 one hand, the affected area of CA is private and the treatment process is

1 67 painful, which brings serious psychological pressure to patients. On the
2
3 68 other hand, the treatment fee is expensive, which brings heavy financial
4
5
6 69 burden to patients and their families. [5-7].
7

8
9 70 At present, more than 200 HPV genotypes have been identified and
10
11 71 classified as high-risk (HR) or low-risk (LR), based on oncogenic risk. At
12
13
14 72 least 40 genotypes are associated with infection in the anogenital region
15
16
17 73 [8-10]. HPV 6 and 11 are associated with approximately 90% of CA,
18
19
20 74 whereas 70% of cervical cancers are caused by HPV16 and 18[11]. Patients
21
22 75 with CA are often accompanied by HR-HPV infection [12-15]. Persistent
23
24
25 76 HR-HPV infection is the main pathogenic factor of cervical intraepithelial
26
27
28 77 neoplasia and cervical cancer in women [16,17].
29

30
31 78 There is reliable evidence that HPV vaccination has a good preventive
32
33
34 79 effect against HPV infection in uninfected individuals, subsequent CA and
35
36
37 80 HPV-attributable cancers, thereby greatly reducing the burden of HPV-
38
39
40 81 related diseases in patients [18, 19]. However, the HPV vaccines-targeted
41
42
43 82 types are limited, and the HPV genotypes varies among different regions
44
45
46 83 and populations [20].
47

48
49 84 At present, the HPV infection and epidemiological characteristics of CA
50
51
52 85 patients in China are rare and incomplete. Therefore, in this survey, the
53
54
55 86 evaluation of the epidemic characteristics and HPV genotype distribution
56
57
58 87 of CA cases in Shandong Province, China will contribute to the adjustment
59
60
61 88 of CA prevention and control strategies, the research and development of
62
63
64
65

1 89 HPV vaccine and the formulation of immunization plan.
2
3

4 90
5

6 91 **Materials and methods** 7

8 92 **Study population** 9

10 93 Participants were recruited from patients diagnosed according to the
11

12 94 Guideline for the Clinical Management of Anogenital Warts in China
13

14 95 (2014) [21], from Shandong Provincial Hospital for Skin Diseases,
15

16 96 Shandong Oriental Andrology Hospital, and Jining No.1 People's Hospital
17

18 97 from August 2019 to June 2021. All recruited patients had never been
19

20 98 vaccinated against HPV. The selection of sentinel hospitals was based on
21

22 99 the number of patients diagnosed with CA in the past.
23

24 100 After filling in a questionnaire administered by trained interviewers, each
25

26 101 patient underwent sample collection for HPV typing. All patients
27

28 102 volunteered to participate in this study and signed the informed consent
29

30 103 (Minors under the age of 18 had the consent of their guardians). Our study
31

32 104 was approved by the ethics committee of school of public health, Shandong
33

34 105 University, China (protocol n. 20190320).
35

36 106 **Specimen Collection** 37

38 107 All patients undergo a clinical examination by a trained clinician at each
39

40 108 visit to determine whether there are CA lesions in the cervical, vaginal,
41

42 109 vulva, anal and perianal areas in women or in the external genital, anal and
43

44 110 perianal sites in men. If the CA lesion is found, the sample will be collected
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 111 from the site by clinician. Exfoliated cell specimen was collected from the
2
3 112 surface of each CA lesion by using a sampling brush. The brush was rotated
4
5
6 113 3-5 full turns in clockwise direction to ensure acquisition of the exfoliated
7
8
9 114 cells. For each patient, each specimen was independently eluted from the
10
11 115 sampling brush with normal saline and stored in the refrigerator at -80°C
12
13
14 116 before detecting HPV genotypes.
15

16 117 **HPV genotyping**

17
18 118 All HPV DNA extraction, amplification and genotype identification were
19
20
21 119 performed with the HPV genotyping panel (polymerase chain reaction
22
23 120 (PCR)-reverse dot blot hybridization method; Yaneng Biosciences,
24
25
26 121 Shenzhen, China). The HPV genotyping panel can detect 17 high-risk HPV
27
28
29 122 genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and
30
31
32 123 82) and 6 low-risk HPV genotypes (6, 11, 42, 43, 81 and 83). Genomic
33
34
35 124 DNA was extracted from specimens following manufacturer's protocols.
36
37
38 125 The PCR cycling conditions were as follows: initial denaturation at 95°C
39
40
41 126 for 5 min, then 40 cycles at 94°C for 30 s, 42°C for 90 s, 72°C for 30 s, and
42
43
44 127 a final extension at 72°C for 5 min. The HPV type-specific probes are
45
46
47 128 immobilized on nylon membranes for reverse-blot hybridization on, which
48
49
50 129 can detect 23 types of HPV genotypes in a single test. Hybridization was
51
52
53 130 performed and visualized by assessing the protocol according to the
54
55
56 131 manufacturer's instructions. The quality and integrity of the extracted DNA
57
58
59 132 is monitored by the β -actin gene assay. The specimens with known HPV
60
61
62
63
64
65

1 133 genotypes were used as positive controls and enzyme-free water was used
2
3 134 as a negative control.
4
5

6 135 **Statistical Analysis**

7
8
9 136 Qualitative categorical variables were described as numbers and
10
11 137 percentages. Quantitative variables were described using mean and
12
13 138 standard deviation or median and interquartile range (P25- P75),
14
15 139 depending on the distribution of the variables. *T*-test was used to compare
16
17 140 quantitative variables with a normal distribution, and Mann-Whitney *U*-
18
19 141 test was used to compare quantitative variables without normal distribution.
20
21 142 Chi-square test or Fisher' exact test was conducted to test hypothesis, as
22
23 143 appropriate. All hypothesis tests were two-sided, and *P*-value less than or
24
25 144 equal to 0.05 was considered statistically significant. All data were
26
27 145 analyzed using SPSS software (version 20.0; IBM Corp.).
28
29
30
31
32
33
34
35
36
37
38

39 147 **Result**

40 148 **CA patients' characteristics**

41
42 149 A total of 1185 patients (870 males and 315 females) were included in this
43
44 150 study. Shandong Provincial Hospital for Skin Diseases contributed 52.8%
45
46 151 of the total participants, whilst 34.4% and 12.8% were from Jining No.1
47
48 152 People's Hospital and Shandong Oriental Andrology Hospital, respectively.
49
50 153 The ages ranged from 15 to 88, with a mean of 34.85 years (SD = 13.60
51
52 154 years). The mean age varied slightly between males and females (35.90 vs.
53
54
55
56
57
58
59
60
61
62
63
64
65

1 155 31.94 years; $P < 0.01$). Among recruited patients, 63.7% cases reported
2
3 156 having more than one sexual partner. The vast majority of patients who
4
5
6 157 reported their sexual preferences were heterosexual (89.1%), including 745
7
8
9 158 (70.4%) heterosexual men (men who have sex with women, MSW) and
10
11
12 159 312 (29.5%) heterosexual women. There were 101 patients who were
13
14 160 homosexual, including 99 males (men who had sex with men, MSM) and
15
16
17 161 2 females. In addition, 26 males and 1 female were bisexual who had sex
18
19
20 162 with both males and females. Compared with female patients, male patients
21
22
23 163 had more sexual partners ($P < 0.001$). In this study, 85.7% of the patients
24
25 164 (86.8% of males and 85.0% of females) themselves claimed that their
26
27
28 165 sexual partners were not infected with HPV.

29
30
31 166 Of the 1185 patients with genital warts, one or more subsequent genital
32
33
34 167 warts had been detected in 411 patients (33.1% of males and 39.0% of
35
36 168 females). In addition, there have 32 patients reported other STDs (Fifteen
37
38
39 169 with syphilis, five with genital herpes, six with HIV/AIDS, four with
40
41
42 170 gonorrhea and two with chlamydia infection).

43
44
45 171 The majority of patients presented warts lesions at one location (53.5%),
46
47
48 172 34.3% patients presented warts at two different locations, 8.8% at three,
49
50
51 173 and 3.4% at four or more different locations. In females, the CA lesions
52
53 174 were often located on the urethral orifice / vaginal introitus (62.9% of
54
55
56 175 cases), labia majora / labia minora (35.9%), and perianal region (26.4%),
57
58
59 176 whereas, for males, the corona sulcus (36.0%), foreskin (26.4%) and
60
61
62
63
64
65

1 177 perianal region (23.6%) were the most frequent sites.
2
3

4 178

5
6 179 **HPV prevalence**
7

8
9 180 A total of 880 samples were collected from 659 males and 221 females
10
11 181 with a clinical diagnosis of CA. Shandong Dermatology Hospital collected
12
13 182 407 samples, while Jining No.1 People's Hospital and Shandong Oriental
14
15 183 Anorectal Hospital collected 321 and 152 samples, respectively. The HPV
16
17 184 DNA was detected in 804 of the 880 CA cases, with a positive rate of 91.4%
18
19 185 (90.6% males and 93.7% females). Seventy-six samples (from 62 males
20
21 186 and 14 females) were excluded from further analysis due to PCR inhibition
22
23 187 or insufficient DNA.
24
25
26
27
28
29

30
31 188 Among the 804 patients, 734 (91.3%) patients had at least one LR-HPV
32
33 189 infection detected, and 430 (53.5%) patients had HR-HPV infection. In
34
35 190 addition, there were 374 (46.5%) patients only infected with LR-HPV, 70
36
37 191 (8.7%) patients were only infected with HR-HPV, and 360 (44.8%) patients
38
39 192 were infected with both LR- HPV and HR-HPV. Compared with male
40
41 193 patients, female patients had a higher rate of HR-HPV infection ($P < 0.001$).
42
43 194 Moreover, co-infection of LR-HPV and HR-HPV was more common in
44
45 195 female patients ($P < 0.001$). In addition, the prevalence of single HPV
46
47 196 genotype infections was 44.2%, while those of multiple HPV genotype
48
49 197 coinfections were 55.8%. The total number of HPV genotypes in patients
50
51 198 varied from 1 to 12. The frequency of single and multiple infections varied
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 199 significantly by gender, with single infections being more common among
2
3
4 200 males (47.9% males vs. 33.3% females, $P < 0.001$) and multiple infections
5
6 201 more common among females (52.1% males vs. 66.7% females, $P < 0.001$).
7
8
9 202 (Table 2)

10
11 203

14 204 **Distribution of specific HPV genotypes**

15
16
17 205 Overall, all 23 different HPV genotypes were identified in males and
18
19
20 206 females, with a proportion ranging from 1.5% to 57.8% (12/804 to
21
22 207 465/804). The most frequently encountered HPV genotypes were HPV 6
23
24
25 208 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%), HPV 42 (10.3%) and HPV 52
26
27
28 209 (8.8%) by decreasing order of frequency. (Figure 1)

29
30
31 210 As it was shown, HPV 6 was the most common HPV genotype detected in
32
33
34 211 both males (58.1%) and females (57.0%). HPV 6/11 (alone or in
35
36 212 coinfection with other genotypes) were detected in 87.4% patients and
37
38
39 213 there was no significant difference among males and females. In addition,
40
41
42 214 there was no significant difference in the distribution of all detective low-
43
44
45 215 risk genotypes between males and females. The most common HR-HPV
46
47
48 216 genotypes were HPV 16 (13.7%), HPV 52 (8.8%) and HPV 51 (8.1%).
49
50
51 217 HPV 16/18 (alone or in coinfection with other genotypes) were observed
52
53 218 in 19.7% patients. In the HR-HPV genotypes, the frequency of HPV 45,
54
55
56 219 HPV 56 and HPV 58 were significantly higher in women than in men (P
57
58
59 220 < 0.05). Among the patients coinfecting with LR-HPV and HR-HPV, the

1 221 most infection mode is HPV6+HPV16 (5.6%). Different frequency of
2
3 222 other HPV genotypes in different genders were shown in Table 3.
4
5

6 223
7

8 224 **Discussion**

9
10 225 As we all know, CA is one of the most common sexually transmitted
11
12 226 diseases (STDs) caused by HPV infection, and most sexually active
13
14 227 persons are usually exposed to HPV during their lifetime [22]. In this study
15
16 228 based on surveys in sentinel hospitals, we reported the prevalent
17
18 229 characteristics of CA and distribution of HPV genotypes in patients with
19
20 230 CA in Shandong Province, China. In our study, a total of 1185 CA patients
21
22 231 were recruited. The recruited patients were mainly males. This may be due
23
24 232 to the differences in the anatomical structure of males and females.
25
26 233 Compared with males, females need to undergo a professional
27
28 234 gynecological examination in the hospital to find out whether they have
29
30 235 CA. The average age of CA patients recruited in this study was 34.85 years.
31
32 236 Compared with men, women were younger. These results are consistent
33
34 237 with a previous Chinese multi-center study of genital wart conducted in
35
36 238 2013 including 1,005 cases from eighteen hospitals in seven geographical
37
38 239 regions of China [23]. In this study, most patients were in the sexually
39
40 240 active stage aged 20 to 40. These patients had risky sexual behaviors such
41
42 241 as multiple sexual partners and irregular condom use. Among them, 32
43
44 242 cases also suffered from other sexually transmitted diseases. These are all
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 243 risk factors that increase HPV infection [24, 25]. In addition, 34.7% of the
2
3 244 patients in this study were recurrences.
4

5
6 245 Among the 880 patients who underwent HPV testing, the overall HPV test
7
8 246 positivity rate was 91.4%, which shows that HPV is the pathogen that
9
10 247 causes CA. There were 8.6% of the patients could not be included in the
11
12 248 analysis due to insufficient cellular DNA content. Previous studies have
13
14 249 found that 16~26% of the samples will be negative regardless of the type
15
16 250 of cell brush sampling [26, 27]. Compared with other studies, the lower
17
18 251 negative rate of our study reflects the higher quality of sample collection
19
20 252 after unified training. In the analysis of specific HPV types, it was shown
21
22 253 that the most common genotypes in Shandong Province, China were HPV6,
23
24 254 HPV11, HPV16 and HPV42. Compared with other regions in China,
25
26 255 HPV42 had a higher prevalence in Shandong province and had become one
27
28 256 of the common genotypes of HPV in CA patients. Previous studies have
29
30 257 found that the distribution of HPV genotypes varies from region to region.
31
32 258 Although the risk of diseases related to nonvaccine HPV genotypes is
33
34 259 theoretically still low, the actual situation still needs to be monitored to deal
35
36 260 with the disease burden caused by high prevalence of nonvaccine HPV
37
38 261 genotypes. Furthermore, the distribution of HPV6, HPV11 and HPV16
39
40 262 were consistent with the results of studies in other regions of China [23, 28,
41
42 263 29].
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 264 In this study, males were mainly infected with low-risk HPV, while females
59
60
61
62
63
64
65

1 265 were mainly multiple infected with high-risk and low-risk HPV. Most
2
3
4 266 patients, both male and female, were infected with more than one different
5
6 267 HPV genotype. According to our results, HPV6 and 11 (alone or
7
8
9 268 coinfection with other genotypes) were detected in 87.4% of patients, but
10
11 269 most of these patients also had high-risk HPV infection. In this study, 53.5%
12
13
14 270 of patients with CA were infected with high-risk HPV. Among male
15
16
17 271 patients, 49.1% were infected with at least one high-risk type of HPV.
18
19
20 272 Some studies have shown that male penile cancer and anal cancer are
21
22
23 273 associated with high-risk HPV infection [30]. Compared with male patients,
24
25
26 274 female patients had a higher infection rate of high-risk HPV (66.2% vs.
27
28
29 275 49.1%), indicating that women had a higher burden of high-risk HPV
30
31
32 276 infection. Persistent high-risk HPV infection can lead to precancerous
33
34
35 277 lesions and cancers of the cervix, vulva, vagina, and anus in women, so it
36
37
38 278 is very important to prevent the occurrence of these lesions [31]. Some
39
40
41 279 studies find that high HPV vaccination coverage significantly reduced the
42
43
44 280 prevalence of CA, HPV infection and cervical intraepithelial neoplasia
45
46
47 281 grade 2+ (CIN2+) [32, 33]. In addition, when formulating policies to
48
49
50 282 prevent HPV infection in women, it should be considered that men also
51
52
53 283 have a higher infection rate of high-risk HPV. Some studies have found that
54
55
56 284 men HPV multiple infection is very common, and the high-risk HPV
57
58
59 285 infection rate is the same as that of women [34-36]. There is a higher risk
60
61
62 286 of cross-infection between men and women [37, 38]. HPV vaccination to
63
64
65

1 287 men can effectively reduce related HPV infection rates and HPV-related
2
3
4 288 cancer incidence [39, 40].
5
6 289 Nowadays, four prophylactic HPV vaccines are available in China,
7
8
9 290 including the HPV bivalent vaccine (Cervarix[®]; Cecolin[®]) to protect
10
11 291 against HPV16 and 18; the HPV quadrivalent vaccine (Gardasil[®]) to
12
13
14 292 protect against HPV 6, 11, 16 and 18; the HPV nonavalent vaccine
15
16
17 293 (Gardasil[®]9) to protect against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 [41,
18
19
20 294 42]. At present, there is no HPV vaccination programs implemented in
21
22
23 295 China, which may be related to the insufficient data of HPV
24
25
26 296 epidemiological survey. However, the distribution of HPV genotypes
27
28
29 297 varies from region to region [43]. Although vaccines can provide
30
31 298 protection for people, it is important to study the prevalence and
32
33
34 299 distribution of HPV genotypes in different regions before implementing
35
36
37 300 the HPV vaccination plan, because understanding the distribution of HPV
38
39
40 301 genotypes will help to choose the best vaccine for HPV protection in each
41
42
43 302 region [44]. In this study, HPV6 and HPV11 were the causes of CA in the
44
45
46 303 majority of patients (87.4%), and they were included in both the
47
48
49 304 quadrivalent and nonavalent vaccines. Considering the economic benefits
50
51
52 305 and the insufficient supply of 9-valent HPV vaccine in China, the 4-valent
53
54
55 306 HPV vaccine may be more suitable for the prevention of CA in Shandong
56
57
58 307 Province, China. Furthermore ,HPV42, as one of the genotypes with higher
59
60
61 308 prevalence in this study, has not been included in any licensed HPV
62
63
64
65

1 309 vaccines. Previous studies have found that among people vaccinated with
2
3 310 the quadrivalent HPV vaccine, the infection rate of nonvaccine HPV
4
5 311 genotypes is remaining flat or higher [45]. Therefore, it is necessary to
6
7 312 develop a broader spectrum of HPV vaccines to reduce the disease burden
8
9 313 caused by HPV infection [46].
10

11
12
13 314 In conclusion, CA cases are mainly infected with low-risk HPV, but there
14
15 315 are more high-risk HPV infections in both males and females, which is a
16
17 316 problem that cannot be ignored in clinical treatment. It is necessary to
18
19 317 monitor the HPV genotype of CA patients, because high-risk HPV
20
21 318 infection is the main risk factor for cancer. For the general public, HPV
22
23 319 typing and HPV vaccination will help to prevent CA or HPV-related cancer
24
25 320 and reduce the risk of disease. Additionally, nonvaccine HPV genotypes
26
27 321 also need to be monitored for their prevalence by regular HPV typing. The
28
29 322 results of our study make a contribution to the epidemiology of HPV in
30
31 323 Chinese CA patients with improving the understanding of existing HPV
32
33 324 genotypes. Furthermore, these will have a positive impact on the
34
35 325 adjustment of CA prevention and treatment strategies, the research and
36
37 326 development of HPV vaccines and the formulation of immunization
38
39 327 programs.
40
41
42
43
44
45
46
47
48
49
50
51
52

53 328

54 55 329 **Acknowledgments**

56
57
58 330 We are grateful to the patients who joined the study. This work has been
59
60
61
62
63
64
65

1 331 funded by a research grant from Merck Sharpe & Dohme (MISP
2
3 332 IIS#57766). The funders had no role in study design, data collection and
4
5
6 333 analysis, decision to publish, or preparation of the manuscript.
7
8

9 334

10 11 335 **Disclosure of potential conflicts of interest**

12
13
14 336 No potential conflicts of interest were disclosed.
15
16

17 337

18 19 20 338 **Funding**

21
22 339 This work has been funded by a research grant from Merck Sharpe &
23
24
25 340 Dohme (MISP IIS#57766).
26

27
28 341

29 30 31 342 **Ethics and dissemination**

32
33
34 343 Our study was approved by the ethics committee of School of Public
35
36 344 Health, Shandong University, China (protocol n. 20190320). All patients
37
38
39 345 volunteered to participate in this study and signed the informed consent
40
41
42 346 (Minors under the age of 18 had the consent of their guardians).
43

44
45 347

46 47 348 **References**

- 48
49 349 1. Steben M, Garland SM. Genital warts. Best Practice & Research Clinical
50 350 Obstetrics & Gynaecology. 2014;28(7):1063-73.
51 351 2. Dunne EF, Markowitz LE. Genital Human Papillomavirus Infection. Clinical
52 352 Infectious Diseases. 2006;43(5):624-9.
53
54 353 3. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, et al.
55 354 Genital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United
56 355 States. The Journal of Infectious Diseases. 2018;219(5):703-10.
57
58
59 356 4. Thomas R, Steben M, Greenwald Z, Stutz M, Rodier C, DeAngelis F, et al.

60
61
62
63
64
65

1 357 Recurrence of Human Papillomavirus External Genital Wart Infection Among
2 358 High-Risk Adults in Montréal, Canada. *Sexually Transmitted Diseases*.
3 359 2017;44(11):700-6.

4 360 5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et
5 361 al. Global Burden of Human Papillomavirus and Related Diseases. *Vaccine*.
6 362 2012;30:F12-F23.

7 363 6. Wang S-M, Shi J-F, Kang D-J, Song P, Qiao Y-L. Impact of Human
8 364 Papillomavirus-Related Lesions on Quality of Life: A Multicenter Hospital-Based
9 365 Study of Women in Mainland China. *International Journal of Gynecologic Cancer*.
10 366 2011;21(1):182-8.

11 367 7. McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden
12 368 of human papillomavirus infection in the Netherlands, 1989–2014: the gap
13 369 between females and males is diminishing. *Cancer Causes & Control*.
14 370 2017;28(3):203-14.

15 371 8. Kocjan BJ, Sterbenc A, Hosnjak L, Chouhy D, Bolatti E, Giri AA, et al. Genome
16 372 announcement: complete genome sequence of a novel Mupapillomavirus,
17 373 HPV204. *Acta Dermatovenerol Alp Pannonica Adriat*. 2015;24(2):21-3.

18 374 9. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, Hausen Hz, de Villiers E-M.
19 375 Classification of papillomaviruses (PVs) based on 189 PV types and proposal of
20 376 taxonomic amendments. *Virology*. 2010;401(1):70-9.

21 377 10. Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, et al. Global
22 378 estimates of expected and preventable cervical cancers among girls born between
23 379 2005 and 2014: a birth cohort analysis. *The Lancet Public Health*. 2021;6(7):e510-
24 380 e21.

25 381 11. Cubie HA. Diseases associated with human papillomavirus infection. *Virology*.
26 382 2013;445(1):21-34.

27 383 12. Al-Awadhi R, Al-Mutairi N, Albatineh AN, Chehadeh W. Association of HPV
28 384 genotypes with external anogenital warts: a cross sectional study. *BMC Infectious*
29 385 *Diseases*. 2019;19(1):375.

30 386 13. Ma L, Lu S, Jiang Y, Li M, Cong X, Cao Y. Distribution of human papillomavirus
31 387 genotypes (2014–2016) in women with genital warts at a sexually transmitted
32 388 disease clinic in Beijing, China. *Future Virology*. 2018;13(2):111-7.

33 389 14. Mastutik G, Rahniayu A, Murtiastutik D, et al. Distribution Genotype High Risk
34 390 (HR) And Low Risk (LR) Human Papillomavirus (HPV) at Condyloma
35 391 Acuminata[J]. *Biomolecular and Health Science Journal*,2021,4(1):10-14.

36 392 15. Mastutik G, Rahniayu A, Arista A, et al. p16INK4A Expression in Condyloma
37 393 Acuminata Lesions Associated with High-Risk Human Papillomavirus
38 394 Infection[J]. *Asian Pacific Journal of Cancer Prevention*,2021,22(10):3219-3225.

39 395 16. de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
40 396 et al. Human papillomavirus genotype attribution in invasive cervical cancer: a
41 397 retrospective cross-sectional worldwide study. *The Lancet Oncology*.
42 398 2010;11(11):1048-56.

43 399 17. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al.
44 400 Persistent Human Papillomavirus Infection as a Predictor of Cervical

- 401 Intraepithelial Neoplasia. *JAMA*. 2001;286(24):3106-14.
- 402 18. Hall MT, Simms KT, Lew J-B, Smith MA, Brotherton JML, Saville M, et al. The
403 projected timeframe until cervical cancer elimination in Australia: a modelling
404 study. *The Lancet Public Health*. 2019;4(1):e19-e27.
- 405 19. Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, et al.
406 Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts
407 Among Female Health-Plan Enrollees, United States. *American Journal of
408 Epidemiology*. 2017;187(2):298-305.
- 409 20. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical
410 Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million
411 Women with Normal Cytological Findings. *The Journal of Infectious Diseases*.
412 2010;202(12):1789-99.
- 413 21. Chinese Society of Dermatology and Venereology, China Dermatologist
414 Association, Chinese Association of Rehabilitation Dermatology and Venereology.
415 Guideline for the Clinical Management of Anogenital Warts in China (2014) [J].
416 *Chinese Journal of Dermatology*, 2014,47(08):598-599.
- 417 22. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A
418 Review of the Evidence for the 2015 Centers for Disease Control and Prevention
419 Sexually Transmitted Diseases Treatment Guidelines. *Clinical Infectious Diseases*.
420 2015;61(suppl_8):S849-S55.
- 421 23. Chang L, Ci P, Shi J, Zhai K, Feng X, Colombara D, et al. Distribution of genital
422 wart human papillomavirus genotypes in China: A multi-center study. *Journal of
423 Medical Virology*. 2013;85(10):1765-74.
- 424 24. Mueller SM, Menzi S, Kind AB, Blaich A, Bayer M, Navarini A, et al. Sexually
425 transmitted coinfections in patients with anogenital warts – a retrospective analysis
426 of 196 patients. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*.
427 2020;18(4):325-32.
- 428 25. Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR.
429 Consistent Condom Use Is Associated with Lower Prevalence of Human
430 Papillomavirus Infection in Men. *The Journal of Infectious Diseases*.
431 2010;202(3):445-51.
- 432 26. Aubin F, Prétet J-L, Jacquard A-C, Saunier M, Carcopino X, Jaroud F, et al.
433 Human Papillomavirus Genotype Distribution in External Acuminata
434 Condylomata: A Large French National Study (EDiTH IV). *Clinical Infectious
435 Diseases*. 2008;47(5):610-5.
- 436 27. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. *The
437 Lancet Infectious Diseases*. 2006;6(1):21-31.
- 438 28. The Prevalence and Genotype of Human Papillomavirus from patients with
439 Genital Warts in Eastern Guangdong Province. *Asian Pacific Journal of Cancer
440 Prevention*. 2015;16(14):5675-9.
- 441 29. Zhu C, Wang Y, Mao W, Zhang H, Ma J. Prevalence and distribution of HPV types
442 in genital warts in Xi'an, China: a prospective study. *BMJ Open*.
443 2019;9(5):e023897.
- 444 30. Sudenga SL, Ingles DJ, Pierce Campbell CM, Lin H-Y, Fulp WJ, Messina JL, et

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 445 al. Genital Human Papillomavirus Infection Progression to External Genital
446 Lesions: The HIM Study. *European Urology*. 2016;69(1):166-73.
- 447 31. Chaturvedi AK. Beyond Cervical Cancer: Burden of Other HPV-Related Cancers
448 Among Men and Women. *Journal of Adolescent Health*. 2010;46(4,
449 Supplement):S20-S6.
- 450 32. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, et al. Population-level
451 impact and herd effects following the introduction of human papillomavirus
452 vaccination programmes: updated systematic review and meta-analysis. *The
453 Lancet*. 2019;394(10197):497-509.
- 454 33. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M,
455 et al. Four year efficacy of prophylactic human papillomavirus quadrivalent
456 vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia
457 and anogenital warts: randomised controlled trial. *BRITISH MEDICAL
458 JOURNAL*. 2010;341.
- 459 34. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi L-F, et al. Genital
460 Human Papillomavirus Infection in Men: Incidence and Risk Factors in a Cohort
461 of University Students. *The Journal of Infectious Diseases*. 2007;196(8):1128-36.
- 462 35. Ingles DJ, Pierce Campbell CM, Messina JA, Stoler MH, Lin H-Y, Fulp WJ, et al.
463 Human Papillomavirus Virus (HPV) Genotype- and Age-Specific Analyses of
464 External Genital Lesions Among Men in the HPV Infection in Men (HIM) Study.
465 *The Journal of Infectious Diseases*. 2014;211(7):1060-7.
- 466 36. Chan PKS, Luk ACS, Luk TNM, Lee K-F, Cheung JLK, Ho K-M, et al.
467 Distribution of human papillomavirus types in anogenital warts of men. *Journal of
468 Clinical Virology*. 2009;44(2):111-4.
- 469 37. Nyitray AG, Menezes L, Lu B, Lin H-Y, Smith De, Abrahamsen M, et al. Genital
470 Human Papillomavirus (HPV) Concordance in Heterosexual Couples. *The Journal
471 of Infectious Diseases*. 2012;206(2):202-11.
- 472 38. Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, de Sanjosé S, et al.
473 Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer
474 in Female Partners. *New England Journal of Medicine*. 2002;346(15):1105-12.
- 475 39. Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Garland SM, et al.
476 Prevalence of human papillomavirus in young men who have sex with men after
477 the implementation of gender-neutral HPV vaccination: a repeated cross-sectional
478 study. *The Lancet Infectious Diseases*. 2021;21(10):1448-57.
- 479 40. Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al.
480 Ongoing decline in genital warts among young heterosexuals 7 years after the
481 Australian human papillomavirus (HPV) vaccination programme. *Sexually
482 Transmitted Infections*. 2015;91(3):214-9.
- 483 41. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review.
484 *Vaccines*. 2020;8(3):391.
- 485 42. Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, et al. Domestic HPV
486 vaccine price and economic returns for cervical cancer prevention in China: a cost-
487 effectiveness analysis. *The Lancet Global Health*. 2020;8(10):e1335-e44.
- 488 43. Zhu B, Liu Y, Zuo T, Cui X, Li M, Zhang J, et al. The prevalence, trends, and

1 489 geographical distribution of human papillomavirus infection in China: The pooled
2 490 analysis of 1.7 million women. *Cancer Medicine*. 2019;8(11):5373-85.
3 491 44. Mastutik G, Alia R, Rahniayu A, et al. GENOTYPING OF HUMAN
4 492 PAPPILOMAVIRUS IN CERVICAL PRECANCEROUS LESION AND
5 493 SQUAMOUS CELL CARCINOMA AT DR. SOETOMO HOSPITAL,
6 494 SURABAYA, INDONESIA[J]. *African journal of infectious diseases*,2018,12(1
7 495 Suppl):7-12.
8 496 45. Schlecht NF, Diaz A, Nucci-Sack A, Shyhalla K, Shankar V, Guillot M, et al.
9 497 Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and
10 498 Young Women Immunized With the Human Papillomavirus Vaccine. *JAMA*
11 499 *Network Open*. 2021;4(8):e2121893-e.
12 500 46. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future.
13 501 *Epidemiology and Infection*. 2016;144(3):449-68.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Epidemiology of Human Papillomavirus on Condyloma Acuminatum**
2
3
4 **in Shandong Province , China**

5
6 Yuan Haowen^{a,†}, Li Renpeng^{b,†}, Lv Jian^c, Yi Guipeng^d, Sun Xihong^e, Zhao
7
8 Na^f, Zhao Fengjun^g, Xu Aiqiang^b, Kou Zengqiang^{b,*}, Wen Hongling^{a,*}

9
10 a Department of Microbiological Laboratory Technology, School of
11
12 Public Health, Cheeloo College of Medicine, Shandong University, Key
13
14 laboratory for the prevention and control of infectious diseases (key labor-
15
16 atory of China's "13th Five-Year", Shandong University), Jinan 250012,
17
18 China; yuanhaowen0218@163.com (H.Y.)

19
20 b Shandong Center for Disease Control and Prevention, Shandong
21
22 Provincial Key Laboratory of Infectious Disease Prevention and Control,
23
24 Jinan 250014, China; rpleesd@163.com (R.L.); aqxuepi@163.com (A.X.)

25
26 c Shandong First Medical University & Shandong Academy of Medical
27
28 Sciences, Tai'an 271016, China; sdfmulvjian@163.com

29
30 d Weifang Medical University, Weifang 261053, China;
31
32 2046076711@qq.com

33
34 e Jining City Center for Disease Control and Prevention, Jining 272000,
35
36 China; xihongsun@163.com

37
38 f Shandong Provincial Hospital for Skin Diseases & Shandong
39
40 Provincial Institute of Dermatology and Veneorology, Shandong First
41
42 Medical University & Shandong Academy of Medical Sciences. Jinan
43
44 250000, China; 411657904@qq.com

1 23 g Shandong Oriental Andrology Hospital, Jinan 250000, China;

2
3 24 671830931@qq.com

4
5
6 25 *Correspondence:

7
8
9 26 jack-cou@163.com (Z.K.); wenhongling@sdu.edu.cn (H.W.);

10
11
12 27 Tel.: +86-0531-82679681 (Z.K.); +86-0531-88382625 (H.W.)

13
14 † Haowen Yuan and Renpeng Li are Co-first authors.

15
16
17 29

18
19
20 30 **Abstract**

21
22 31 Condyloma acuminatum (CA) is a sexually transmitted disease (STD)

23
24
25 32 caused by human papillomavirus (HPV) infection. It is important to study

26
27
28 33 the prevalence and distribution of HPV genotypes before implementing

29
30
31 34 HPV vaccination program. ~~So~~Therefore, the aim of this study was to

32
33
34 35 evaluate the epidemiological characteristics of CA cases and the

35
36
37 36 distribution of HPV genotypes in Shandong Province, China. One-to-one

38
39
40 37 questionnaire surveys were conducted on all patients diagnosed with CA

41
42
43 38 in sentinel hospitals from Shandong Province, China. HPV genotypes were

44
45
46 39 determined using the polymerase chain reaction (PCR)-reverse dot blot

47
48
49 40 hybridization method. The study enrolled 1185 patients (870 males and 315

50
51
52 41 females) and found that CA patients are mainly males and sexually active

53
54
55 42 people between the ages of 20 and 40. Recurrence occurred in ~~411~~(34.7%)

56
57
58 43 patients. Among the 880 CA patients who underwent HPV typing, the HPV

59
60
61 44 test positivity rate was 91.4%.The overall prevalence of HPV among 880

62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 ~~CA patients undergoing HPV typing was 91.4% (804/880). In these cases,~~
46 ~~low-risk HPV infection was predominant, with an infection rate of 91.3%,~~
47 ~~while high-risk HPV genotypes were found in 53.5% patients. In these~~
48 ~~cases, low risk genotypes predominated, with a prevalence of 91.3%~~
49 ~~(785/804). High risk HPV genotypes were found in 430 (53.5%) patients.~~

50 The most frequent HPV genotypes encountered were HPV 6 (57.8%), HPV
51 11 (37.2%), HPV 16 (13.7%) and HPV 42 (10.3%). HPV 6 and/or HPV 11
52 are the main infections in all patients, and more than half of the patients
53 are coinfecting with high-risk HPV. However, unlike other regions, HPV42
54 has a higher prevalence rate among CA patients in Shandong Province and
55 is a nonvaccine HPV genotype. Therefore, regular HPV typing helps to
56 understand the characteristics of specific genotypes and the choice of the
57 best type for vaccine coverage.

58 **Keywords:** condyloma acuminatum; human papillomavirus;
59 epidemiology; HPV genotypes

60 61 **Introduction**

62 Condyloma acuminatum (CA), also known as ~~genital wart~~genital warts
63 (GW), is a verrucous hyperplasia of squamous epithelium in the anogenital
64 region caused by human papillomavirus (HPV) infection, and it is one of
65 the most common sexually transmitted diseases (STDs) [1, 2]. The CA is
66 the most common benign lesions of the anogenital region, but it can be

1 67 difficult to treat and easy to recur, which required repeated treatment [3].
2
3 68 Studies have shown that approximately 48.5% of CA patients will
4
5
6 69 experience recurrence [4]. The occurrence of CA reduces the quality of life
7
8
9 70 of patients. On the one hand, the affected area of CA is private and the
10
11
12 71 treatment process is painful, which brings serious psychological pressure
13
14
15 72 to patients. On the other hand, the treatment fee is expensive, which brings
16
17
18 73 heavy financial burden to patients and their families.~~Because the location~~
19
20 74 ~~of CA is relatively private, the treatment process is painful and expensive,~~
21
22
23 75 ~~which brings serious psychological pressure and economic burden to the~~
24
25
26 76 ~~patient, and reduces the quality of life of the patient~~ [5-7].

27
28 77 At present, more than 200 HPV genotypes have been identified and
29
30
31 78 classified as high-risk (HR) or low-risk (LR), based on oncogenic risk. At
32
33
34 79 least 40 genotypes are associated with infection in the anogenital region
35
36
37 80 [8-10]. HPV 6 and 11 are associated with approximately 90% of CA,
38
39
40 81 whereas 70% of cervical cancers are caused by HPV16 and 18[11]. Patients
41
42 82 with CACA patients are often accompanied by HR-HPV infection [12-15;
43
44
45 83 13]. Persistent HR-HPV ~~persistent~~ infection is the main pathogenic factor
46
47
48 84 of cervical intraepithelial neoplasia and cervical cancer in women [1416,
49
50
51 85 1517].

52
53 86 There is reliable evidence that HPV vaccination has a good preventive
54
55
56 87 effect against HPV infection in uninfected individuals, subsequent CA and
57
58
59 88 HPV-attributable cancers, thereby greatly reducing the burden of HPV-

1 89 related diseases in patients [~~1618~~, ~~1719~~]. However, the HPV vaccines-
2
3 90 targeted types are limited, and the HPV genotypes varies among different
4
5
6 91 regions and populations [~~1820~~].
7

8
9 92 At present, the HPV infection and epidemiological characteristics of CA
10
11 93 patients in China are rare and incomplete. Therefore, in this survey, the
12
13 94 evaluation of the epidemic characteristics and HPV genotype distribution
14
15 95 of CA cases in Shandong Province, China will contribute to the adjustment
16
17 96 of CA prevention and control strategies, the research and development of
18
19 97 HPV vaccine and the formulation of immunization plan.
20
21
22
23
24
25
26
27

28 99 **Materials and methods**

30 100 **Study population**

31
32
33 101 ~~Samples~~Participants were ~~collected~~recruited from patients diagnosed
34
35 102 according to the Guideline for the Clinical Management of Anogenital
36
37 103 Warts in China (2014) [21]~~Diagnosis of Condyloma Acuminatum of China,~~
38
39 104 from Shandong Provincial Hospital for Skin Diseases, Shandong Oriental
40
41 105 Andrology Hospital, and Jining No.1 People's Hospital from August 2019
42
43 106 to June 2021. All recruited patients had never been vaccinated against HPV.
44
45 107 The selection of sentinel hospitals was based on the number of patients
46
47 108 diagnosed with CA in the past.
48
49
50
51
52
53
54

55
56 109 After filling in ~~accepting~~ a questionnaire administered by trained
57
58 110 interviewers, each patient underwent biopsysample collection for HPV
59
60
61
62
63
64
65

1 111 typing. ~~Each individual of the patients must volunteer to participate in this~~
2
3 112 ~~study and sign the informed consent. All patients volunteered to participate~~
4
5 113 ~~in this study and signed the informed consent (Minors under the age of 18~~
6
7 114 ~~had the consent of their guardians).~~ Our study was approved by the ethics
8
9 115 committee of school of public health, Shandong University, China
10
11 116 (protocol n. 20190320).

117 **Specimen Collection**

118 ~~All patients undergo a clinical examination by a trained clinician at each~~
119 ~~visit to determine whether there are CA lesions in the cervical, vaginal,~~
120 ~~vulva, anal and perianal areas in women or in the external genital, anal and~~
121 ~~perianal sites in men. If the CA lesion is found, the sample will be collected~~
122 ~~from the site by clinician. All samples were collected by uniformly trained~~
123 ~~clinicians at each clinic visit.~~ Exfoliated cell specimen was collected from
124 the surface of each CA lesion by using a sampling brush. The brush was
125 rotated 3-5 full turns in clockwise direction to ensure acquisition of the
126 exfoliated cells. For each patient, each specimen was independently eluted
127 from the sampling brush with normal saline and stored in the refrigerator
128 at -80°C before detecting HPV genotypes.

129 **HPV genotyping**

130 ~~All HPV DNA extraction, amplification and genotype identification were~~
131 ~~performed with the HPV genotyping panel (polymerase chain reaction~~
132 ~~(PCR)-reverse dot blot hybridization method; Yaneng Biosciences,~~

1 133 Shenzhen, China). The HPV genotyping panel can detect 17 high-risk HPV
2
3 134 genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and
4
5
6 135 82) and 6 low-risk HPV genotypes (6, 11, 42, 43, 81 and 83). Genomic
7
8 136 DNA was extracted from specimens following manufacturer's protocols.
9
10 137 The PCR cycling conditions were as follows: initial denaturation at 95°C
11
12 138 for 5 min, then 40 cycles at 94°C for 30 s, 42°C for 90 s, 72°C for 30 s, and
13
14 139 a final extension at 72°C for 5 min. The HPV type-specific probes are
15
16 140 immobilized on nylon membranes for reverse-blot hybridization on, which
17
18 141 can detect 23 types of HPV genotypes in a single test. Hybridization was
19
20 142 performed and visualized by assessing the protocol according to the
21
22 143 manufacturer's instructions. The quality and integrity of the extracted DNA
23
24 144 is monitored by the β -actin gene assay. The specimens with known HPV
25
26 145 genotypes were used as positive controls and enzyme-free water was used
27
28 146 as a negative control.~~HPV tests were performed with the HPV genotyping~~
29
30 147 ~~panel (polymerase chain reaction (PCR) reverse dot blot hybridization~~
31
32 148 ~~method; Yaneng Biosciences, Shenzhen, China). This multiplex PCR~~
33
34 149 ~~technique can detect 17 high-risk HPV genotypes (16, 18, 31, 33, 35, 39,~~
35
36 150 ~~45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82) and 6 low-risk HPV genotypes~~
37
38 151 ~~(6, 11, 42, 43, 81 and 83). All procedures were carried out following the~~
39
40 152 ~~manufacturer's instructions.~~

153 **Statistical Analysis**

154 Qualitative categorical variables were described as numbers and

1 155 percentages. Quantitative variables were described using mean and
2
3
4 156 standard deviation or median and interquartile range (P25- P75),
5
6 157 depending on the distribution of the variables. *T*-test was used to compare
7
8
9 158 quantitative variables with a normal distribution, and Mann-Whitney *U*-
10
11
12 159 test was used to compare quantitative variables without normal distribution.
13
14 160 Chi-square test or Fisher' exact test was conducted to test hypothesis, as
15
16
17 161 appropriate. All hypothesis tests were two-sided, and *P*-value less than or
18
19
20 162 equal to 0.05 was considered statistically significant. All data were
21
22
23 163 analyzed using SPSS software (version 20.0; IBM Corp.).
24
25
26 164

27 28 165 **Result**

29 30 166 **CA patients' characteristics**

31
32
33 167 A total of 1185 patients (870 males and 315 females) were included in this
34
35
36 168 study. Shandong Provincial Hospital for Skin Diseases contributed 52.8%
37
38
39 169 of the total participants, whilst 34.4% and 12.8% were from Jining No.1
40
41
42 170 People's Hospital and Shandong Oriental Andrology Hospital, respectively.
43
44
45 171 The ages ranged from 15 to 88, with a mean of 34.85 years (SD = 13.60
46
47
48 172 years). The mean age varied slightly between males and females (35.90 vs.
49
50
51 173 31.94 years; *P* < 0.01). Among recruited patients, 63.7% cases reported
52
53 174 having more than one sexual partner. The vast majority of patients who
54
55
56 175 reported their sexual preferences were heterosexual (89.1%), including 745
57
58
59 176 (70.4%) heterosexual men (men who have sex with women, MSW) and
60
61
62
63
64
65

177 312 (29.5%) heterosexual women. There were 101 patients who were
178 homosexual, including 99 males (men who had sex with men, MSM) and
179 2 females. In addition, 26 males and 1 female were bisexual who had sex
180 with both males and females.~~There were 99 men (11.4% of the male~~
181 ~~patients) who had sex with men (MSM), and 2 women were homosexuals.~~
182 ~~26 men and 1 woman who had sex with men and women.~~ Compared with
183 female patients, male patients had more sexual partners ($P < 0.001$). In this
184 study, 85.7% of the patients (86.8% of males and 85.0% of females)
185 themselves claimed that their sexual partners were not infected with HPV.
186 Of the 1185 patients with genital warts, one or more subsequent genital
187 warts had been detected in 411 patients (33.1% of males and 39.0% of
188 females). In addition, there have 32 patients reported other STDs
189 (~~Fifteen~~15 with syphilis, ~~5~~five with genital herpes, ~~6~~six with HIV/AIDS,
190 ~~4~~four with gonorrhea and ~~2~~two with chlamydia infection).
191 The majority of patients presented warts lesions at one location (53.5%),
192 ~~34.3%~~The majority of patients stated that only a single body location was
193 ~~infected with warts (53.5%).~~ ~~34.26%~~ patients presented warts at two
194 different locations, 8.8% at three, and 3.4% at four or more different
195 locations. In females, the CA lesions were often located on the urethral
196 orifice / vaginal introitus (~~62.86~~62.9% of cases), labia majora / labia
197 minora (~~35.87~~35.9%), and perianal region (~~26.35~~26.4%), whereas, for
198 males, the corona sulcus (~~35.98~~36.0%), foreskin (~~26.44~~26.4%) and

perianal region (23.5623.6%) were the most frequent sites.

Table 1. Baseline characteristics of 1185 patients with condyloma acuminatum, by gender

Characteristics	Male (n = 870) n (%)	Female (n= 315) n (%)
Age		
— < 18	18 (2.1)	13 (4.1)
— 18-24	202 (23.2)	99 (31.4)
— 25-29	120 (13.8)	38 (12.1)
— 30-39	228 (26.2)	92 (29.2)
— 40-49	146 (16.8)	38 (12.1)
— 50-59	93 (10.7)	28 (8.9)
— ≥ 60	63 (7.2)	28 (2.2)
Marital status		
— Single	319 (36.7)	124 (39.4)
— Married	535 (61.1)	182 (57.8)
— Widowed/Separated/Divorced	19 (2.2)	9 (2.9)
Education		
— Primary/Middle school	225 (25.9)	94 (29.8)
— High school	209 (24.0)	49 (15.6)
— University/College	419 (48.2)	167 (53.0)
— Postgraduate	17 (2.0)	5 (1.6)
Area of residence at diagnosis		
— Rural area	263 (30.2)	96 (30.5)
— City	607 (69.8)	219 (69.5)
Age of first sexual intercourse		
— < 18	76 (8.7)	23 (7.3)
— 18-21	431 (49.5)	155 (49.2)
— ≥ 22	363 (41.7)	137 (43.5)
Type of CA diagnosis		
— Recurrent disease	288 (33.1)	123 (39.0)
— New diagnosis	582 (75.2)	192 (61.0)
Condom use		
— No	108 (12.4)	34 (10.8)
— Yes, sometimes/rarely	676 (77.7)	260 (82.5)
— Yes, always	86 (9.9)	21 (6.7)
Weekly frequency of sexual		
— ≤ 1	394 (45.6)	123 (39.0)
— = 2	314 (36.1)	118 (37.5)

≥3	159 (18.3)	74 (23.5)
Wash genitalia before sex		
Yes	543 (62.4)	191 (60.6)
No	327 (37.6)	124 (39.4)
Number of sexual partners		
=1	288 (33.1)	142 (45.1)
≥2	582 (66.9)	173 (54.9)

202

203 HPV prevalence

204 A total of 880 samples were collected from 659 males and 221 females
 205 with a clinical diagnosis of CA. Shandong Dermatology Hospital collected
 206 407 samples, while Jining No.1 People's Hospital and Shandong Oriental
 207 Anorectal Hospital collected 321 and 152 samples, respectively. The HPV
 208 DNA was detected in 804 of the 880 CA cases, with a positive rate of 91.4%
 209 (90.6% males and 93.7% females).~~In total, 880 samples were collected~~
 210 ~~from 659 males and 221 females with a clinical diagnosis of CA. HPV~~
 211 ~~DNA was detected in 804 of 880 CA cases, yielding an overall prevalence~~
 212 ~~of 91.4% (90.6% males and 93.7% females).~~ Seventy-six~~76~~ samples (from
 213 62 males and 14 females) were excluded from further analysis due to PCR
 214 inhibition or insufficient DNA.

215 Among the 804 patients, 734 (91.3%) patients had at least one LR-HPV
 216 infection detected, and 430 (53.5%) patients had HR-HPV infection. In
 217 addition, there were 374 (46.5%) patients ~~were~~ only infected with LR-HPV,
 218 70 (8.7%) patients were only infected with HR-HPV, and 360 (44.8%)
 219 patients were infected with both LR- HPV and HR-HPV. Compared with

220 male patients, female patients had a higher rate of HR-HPV infection ($P <$
 221 0.001). Moreover, co-infection of LR-HPV and HR-HPV was more
 222 common in female patients ($P < 0.001$). In addition, the prevalence of
 223 single HPV genotype infections was 44.2%, while those of multiple HPV
 224 genotype coinfections were 55.8%. The total number of HPV genotypes in
 225 patients varied from 1 to 12. The frequency of single and multiple
 226 infections varied significantly by gender, with single infections being more
 227 common among males (47.9% males vs. 33.3% females, $P < 0.001$) and
 228 multiple infections more common among females (52.1% males vs. 66.7%
 229 females, $P < 0.001$). (Table 2)

230 **Table 2. Distribution of infection types in 804 cases of condyloma acuminatum**

	Males (n=597) ^a	Females (n=207) ^a	P value
	n(%)	n(%)	
HR-HPV	293(49.1)	137(66.2)	<0.001
LR-HPV	543(91.0)	191(92.3)	0.563
LR and HR-HPV	239(40.0)	121(58.5)	<0.001
Single infection	286(47.9)	69(33.3)	<0.001
Multiple infections	311(52.1)	138(66.7)	<0.001
HPV6 or 11	515(86.3)	188(90.8)	0.088
HPV16 or 18	109(18.3)	49(23.7)	0.091
Types of 4-valent vaccines ^b	552(92.5)	196(94.7)	0.279
Types of 9-valent vaccines ^c	566(94.8)	200(96.6)	0.290

231 ^aPatients with unqualified HPV results were excluded from the analysis.

232 ^bThe types of 4-valent vaccines conclude HPV 6, 11, 16 or 18.

233 ^cThe types of 9-valent vaccines conclude HPV 6, 11, 16, 18, 31, 33, 45, 52 or 58.

235 Distribution of specific HPV genotypes


236 Overall, all 23 different HPV genotypes were identified in males and

1 237 females, with a proportion ranging from 1.5% to 57.8% (12/804 to
2
3
4 238 465/804). The most frequently encountered HPV genotypes were HPV 6
5
6 239 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%), HPV 42 (10.3%) and HPV 52
7
8
9 240 (8.8%) by decreasing order of frequency (Figure 1).

10
11
12 241 As it was shown, ~~HPV 6 (57.8%), HPV 11 (37.2%) and HPV 42 (10.3%)~~

13
14
15 242 ~~were the three most common LR-HPV genotypes in our study population.~~

16
17 243 HPV 6 was the most common HPV genotype detected in both males
18
19 244 (58.1%) and females (57.0%). HPV 6/11 (alone or in coinfection with other
20
21 245 genotypes) were detected in 87.4% patients and there was no significant
22
23 246 difference among males and females. In addition, there was no significant
24
25 247 difference in the distribution of all detective low-risk genotypes between
26
27 248 males and females. The most common HR-HPV genotypes were HPV 16
28
29 249 (13.7%), HPV 52 (8.8%) and HPV 51 (8.1%). HPV 16/18 (alone or in
30
31 250 coinfection with other genotypes) were observed in 19.7% patients. In the
32
33 251 HR-HPV genotypes, the frequency of HPV 45, HPV 56 and HPV 58 were
34
35 252 significantly higher in women than in men ($P < 0.05$). Among the patients
36
37 253 coinfecting with LR-HPV and HR-HPV, the most infection mode is
38
39 254 HPV6+HPV16 (5.6%). Different frequency of other HPV genotypes in
40
41 255 different genders were shown in Table 3.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



256
257 ~~Figure 1 Prevalence of specific human papillomavirus (HPV) infection by decreasing order of~~
258 ~~frequency. Patients with unqualified HPV results were excluded from the analysis.~~

259
260 ~~Table 3. Prevalence of specific human papillomavirus (HPV) genotypes among 804 cases of~~
261 ~~condyloma acuminatum, by decreasing order of frequency.~~

HPV genotypes	Males (n = 597) [#]	Females (n= 207) [#]	P value
	n(%)	n(%)	
LR genotypes			
HPV6	347 (58.1)	118 (57.0)	0.779
HPV11	214 (35.8)	85 (41.4)	0.181
HPV42	64 (10.7)	19 (9.2)	0.530
HPV43	37 (6.2)	8 (3.9)	0.208
HPV81	23 (3.9)	12 (5.8)	0.237
HPV83	10 (1.7)	3 (1.4)	0.824
HR genotypes			
HPV16	77 (12.9)	33 (15.9)	0.272
HPV52	51 (8.5)	20 (9.7)	0.625
HPV51	43 (7.2)	22 (10.6)	0.119
HPV18	43 (7.2)	20 (9.7)	0.257
HPV53	44 (7.4)	18 (8.7)	0.538
HPV56	36 (6.0)	24 (11.6)	0.009
HPV59	44 (7.4)	15 (7.2)	0.953
HPV58	34 (5.7)	21 (10.1)	0.029
HPV66	36 (6.0)	17 (8.2)	0.276
HPV68	24 (4.0)	14 (6.8)	0.109
HPV33	20 (3.4)	13 (6.3)	0.067
HPV73	23 (3.9)	3 (1.4)	0.092
HPV39	17 (2.8)	7 (3.4)	0.697
HPV31	16 (2.7)	5 (2.4)	0.837
HPV82	12 (2.0)	5 (2.4)	0.727

HPV35	8 (1.3)	6 (2.9)	0.140
HPV45	5 (0.8)	7 (3.4)	0.009

*Patients with unqualified HPV results were excluded from the analysis.

Discussion

As we all know, CA is one of the most common sexually transmitted infections—diseases (STIsSTDs) caused by HPV infection, and most sexually active persons are usually exposed to HPV during their lifetime [1922]. In this study based on surveys in sentinel hospitals, we reported the prevalent characteristics of CA and distribution of HPV genotypes in patients with CA in Shandong Province, China. In our study, a total of 1185 CA patients were recruited. The recruited patients were mainly males. This may be due to the differences in the anatomical structure of males and females. Compared with males, females need to undergo a professional gynecological examination in the hospital to find out whether they have CA. The average age of CA patients recruited in this study was 34.85 years. Compared with men, women were younger. These results are consistent with a previous Chinese multi-center study of genital wart conducted in 2013 including 1,005 cases from eighteen hospitals in seven geographical regions of China [2023]. In this study, most patients were in the sexually active stage aged 20 to 40. These patients had risky sexual behaviors such as multiple sexual partners and irregular condom use. Among them, 32 cases also suffered from other sexually transmitted diseases. These are all risk factors that increase HPV infection [2124, 2225]. In addition, 34.7%

1 284 of the patients in this study were recurrences.

2
3 285 Among the 880 patients who underwent HPV testing, the overall HPV

4
5
6 286 ~~prevalence~~ test positivity rate was ~~91.36~~91.4%, which shows that HPV is

7
8
9 287 the pathogen that causes CA. There were 8.6% of the patients could not be

10
11 288 included in the analysis due to insufficient cellular DNA content.

12
13
14 289 ~~Previous~~Some studies have found that 16~26% of the samples will be

15
16
17 290 negative regardless of the type of cell brush sampling [2326, 2427].

18
19
20 291 Compared with other studies, the lower negative rate of our study reflects

21
22 292 the higher quality of sample collection after unified training. In the analysis

23
24
25 293 of specific HPV types, it was shown that the most common genotypes in

26
27
28 294 Shandong Province, China were HPV6, HPV11, HPV16 and HPV42.

29
30
31 295 Compared with other regions in China, HPV42 had a higher prevalence in

32
33
34 296 Shandong province and had become one of the common genotypes of HPV

35
36
37 297 in CA patients. Previous studies have found that the distribution of HPV

38
39
40 298 genotypes varies from region to region. Although the risk of diseases

41
42
43 299 related to nonvaccine HPV genotypes is theoretically still low, the actual

44
45
46 300 situation still needs to be monitored to deal with the disease burden caused

47
48
49 301 by high prevalence of nonvaccine HPV genotypes. Furthermore, the

50
51
52 302 distribution of HPV6, HPV11 and HPV16 were consistent with the results

53
54
55 303 of studies in other regions of China [2023, 2528, 2629].

56
57
58 304 In this study, males were mainly infected with low-risk HPV, while females

59
60
61 305 were mainly multiple infected with high-risk and low-risk HPV. Most

62
63
64
65

1 306 patients, both male and female, were infected with more than one different
2
3 307 HPV genotype. According to our results, HPV6 and 11 (alone or
4
5
6 308 coinfection with other genotypes) were detected in 87.4% of patients, but
7
8
9 309 most of these patients also had high-risk HPV infection. In this study, 53.5%
10
11 310 of patients with CA were infected with high-risk HPV. Among male
12
13 311 patients, 49.1% ~~of male patients~~ were infected with at least one high-risk
14
15
16 312 type of HPV. Some studies have shown that male penile cancer and anal
17
18
19 313 cancer are associated with high-risk HPV infection [2730]. Compared with
20
21
22 314 male patients, female patients had a higher infection rate of high-risk HPV
23
24
25 315 (66.2% vs. 49.1%), indicating that women had a higher burden of high-risk
26
27
28 316 HPV infection. Persistent high-risk HPV infection can lead to precancerous
29
30
31 317 lesions and cancers of the cervix, vulva, vagina, and anus in women, so it
32
33
34 318 is very important to prevent the occurrence of these lesions [2831]. Some
35
36
37 319 studies find that high HPV vaccination coverage significantly reduced the
38
39
40 320 prevalence of CA, HPV infection and cervical intraepithelial neoplasia
41
42 321 grade 2+ (CIN2+) [2932, 3033]. In addition, when formulating policies to
43
44
45 322 prevent HPV infection in women, it should be considered that men also
46
47
48 323 have a higher infection rate of high-risk HPV. Some studies have found that
49
50
51 324 men HPV multiple infection is very common, and the high-risk HPV
52
53 325 infection rate is the same as that of women [3134-3336]. There is a higher
54
55
56 326 risk of cross-infection between men and women [3437, 3538]. HPV
57
58
59 327 vaccination to men can effectively reduce related HPV infection rates and
60
61
62
63
64
65

1 328 HPV-related cancer incidence [[3639](#), [3740](#)].
2
3
4 329 Nowadays, four prophylactic HPV vaccines are available in China,
5
6 330 including the HPV bivalent vaccine (Cervarix[®]; Cecolin[®]) to protect
7
8
9 331 against HPV16 and 18; the HPV quadrivalent vaccine (Gardasil[®]) to
10
11 332 protect against HPV 6, 11, 16 and 18; the HPV nonavalent vaccine
12
13 333 (Gardasil[®]9) to protect against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58
14
15
16
17 334 [[3841](#), [3942](#)]. At present, there is no HPV vaccination programs
18
19 335 implemented in China, which may be related to the insufficient data of
20
21
22 336 HPV epidemiological survey. However, the distribution of HPV genotypes
23
24
25 337 varies from region to region [[4043](#)]. Although vaccines can provide
26
27
28 338 protection for people, it is important to study the prevalence and
29
30 339 distribution of HPV genotypes in different regions before implementing
31
32 340 the HPV vaccination plan, because understanding the distribution of HPV
33
34
35 341 genotypes will help to choose the best vaccine for HPV protection in each
36
37
38
39 342 region [[44](#)]. In this study, HPV6 and HPV11 were the causes of CA in the
40
41 343 majority of patients (87.4%), and they were included in both the
42
43
44 344 quadrivalent and nonavalent vaccines. Considering the economic benefits
45
46
47 345 and the insufficient supply of 9-valent HPV vaccine in China, the 4-valent
48
49 346 HPV vaccine may be more suitable for the prevention of CA in Shandong
50
51
52 347 Province, China. Furthermore ,HPV42, as one of the genotypes with higher
53
54
55 348 prevalence in this study, has not been included in any licensed HPV
56
57
58 349 vaccines. Previous studies have found that among people vaccinated with
59
60
61
62
63
64
65

1 350 the quadrivalent HPV vaccine, the infection rate of nonvaccine HPV
2
3 351 genotypes is remaining flat or higher [4145]. Therefore, it is necessary to
4
5
6 352 develop a broader spectrum of HPV vaccines to reduce the disease burden
7
8 353 caused by HPV infection [4246].
9

10
11 354 In conclusion, CA cases are mainly infected with low-risk HPV, but there
12
13 355 are more high-risk HPV infections in both males and females, which is a
14
15 356 problem that cannot be ignored in clinical treatment. It is necessary to
16
17 357 monitor the HPV genotype of CA patients, because high-risk HPV
18
19 358 infection is the main risk factor for cancer. For the general public, HPV
20
21 359 typing and HPV vaccination will help to prevent CA or HPV-related cancer
22
23 360 and reduce the risk of disease. Additionally, nonvaccine HPV genotypes
24
25 361 also need to be monitored for their prevalence by regular HPV typing. The
26
27 362 results of our study ~~providemake~~ a contribution to the epidemiology of
28
29 363 HPV in Chinese CA patients with improving the understanding of existing
30
31 364 HPV genotypes. Furthermore, these will have a positive impact on the
32
33 365 adjustment of CA prevention and treatment strategies, the research and
34
35 366 development of HPV vaccines and the formulation of immunization
36
37 367 programs.
38
39
40
41
42
43
44
45
46
47
48
49

50 368

51 369 **Acknowledgments**

52
53 370 We are grateful to the patients who joined the study. This work has been
54
55
56 371 funded by a research grant from Merck Sharpe & Dohme (MISP
57
58
59
60
61
62
63
64
65

1 372 IIS#57766). The funders had no role in study design, data collection and
2
3 373 analysis, decision to publish, or preparation of the manuscript.
4
5

6 374

7
8
9 375 **Disclosure of potential conflicts of interest**

10
11 376 No potential conflicts of interest were disclosed.
12
13

14 377

15
16
17 378 **Funding**

18
19
20 379 This work has been funded by a research grant from Merck Sharpe &
21
22 380 Dohme (MISP IIS#57766).
23
24

25 381

26
27
28 382 **Ethics and dissemination**

29
30 383 Our study was approved by the ethics committee of School of Public
31
32
33 384 Health, Shandong University, China (protocol n. 20190320). All patients
34
35
36 385 volunteered to participate in this study and signed the informed consent
37
38
39 386 (Minors under the age of 18 had the consent of their guardians).
40
41

42 387

43
44
45 388

46
47 389 **References**

48
49 390

- 50
51 391 1. Steben M, Garland SM. Genital warts. Best Practice & Research Clinical
52 392 Obstetrics & Gynaecology. 2014;28(7):1063-73.
53 393 2. Dunne EF, Markowitz LE. Genital Human Papillomavirus Infection. Clinical
54 394 Infectious Diseases. 2006;43(5):624-9.
55 395 3. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, et al.
56 396 Genital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United
57
58 397 States. The Journal of Infectious Diseases. 2018;219(5):703-10.
59
60
61
62
63
64
65

- 398 4. Thomas R, Steben M, Greenwald Z, Stutz M, Rodier C, DeAngelis F, et al.
399 Recurrence of Human Papillomavirus External Genital Wart Infection Among
400 High-Risk Adults in Montréal, Canada. *Sexually Transmitted Diseases*.
401 2017;44(11):700-6.
- 402 5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et
403 al. Global Burden of Human Papillomavirus and Related Diseases. *Vaccine*.
404 2012;30:F12-F23.
- 405 6. Wang S-M, Shi J-F, Kang D-J, Song P, Qiao Y-L. Impact of Human
406 Papillomavirus-Related Lesions on Quality of Life: A Multicenter Hospital-Based
407 Study of Women in Mainland China. *International Journal of Gynecologic Cancer*.
408 2011;21(1):182-8.
- 409 7. McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden
410 of human papillomavirus infection in the Netherlands, 1989–2014: the gap
411 between females and males is diminishing. *Cancer Causes & Control*.
412 2017;28(3):203-14.
- 413 8. Kocjan BJ, Sterbenc A, Hosnjak L, Chouhy D, Bolatti E, Giri AA, et al. Genome
414 announcement: complete genome sequence of a novel Mupapillomavirus,
415 HPV204. *Acta Dermatovenerol Alp Pannonica Adriat*. 2015;24(2):21-3.
- 416 9. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, Hausen Hz, de Villiers E-M.
417 Classification of papillomaviruses (PVs) based on 189 PV types and proposal of
418 taxonomic amendments. *Virology*. 2010;401(1):70-9.
- 419 10. Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, et al. Global
420 estimates of expected and preventable cervical cancers among girls born between
421 2005 and 2014: a birth cohort analysis. *The Lancet Public Health*. 2021;6(7):e510-
422 e21.
- 423 11. Cubie HA. Diseases associated with human papillomavirus infection. *Virology*.
424 2013;445(1):21-34.
- 425 12. Al-Awadhi R, Al-Mutairi N, Albatineh AN, Chehadeh W. Association of HPV
426 genotypes with external anogenital warts: a cross sectional study. *BMC Infectious*
427 *Diseases*. 2019;19(1):375.
- 428 13. Ma L, Lu S, Jiang Y, Li M, Cong X, Cao Y. Distribution of human papillomavirus
429 genotypes (2014–2016) in women with genital warts at a sexually transmitted
430 disease clinic in Beijing, China. *Future Virology*. 2018;13(2):111-7.
- 431 14. Mastutik G, Rahniayu A, Murtiastutik D, et al. Distribution Genotype High Risk
432 (HR) And Low Risk (LR) Human Papillomavirus (HPV) at Condyloma
433 Acuminata[J]. Biomolecular and Health Science Journal,2021,4(1):10-14.
- 434 15. Mastutik G, Rahniayu A, Arista A, et al. p16INK4A Expression in Condyloma
435 Acuminata Lesions Associated with High-Risk Human Papillomavirus
436 Infection[J]. Asian Pacific Journal of Cancer Prevention,2021,22(10):3219-3225.
- 437 ~~14~~16. de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE,
438 Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical
439 cancer: a retrospective cross-sectional worldwide study. *The Lancet Oncology*.
440 2010;11(11):1048-56.
- 441 ~~15~~17. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et

- al. Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial Neoplasia. JAMA. 2001;286(24):3106-14.
- 444 ~~16~~18. Hall MT, Simms KT, Lew J-B, Smith MA, Brotherton JML, Saville M, et al.
445 The projected timeframe until cervical cancer elimination in Australia: a
446 modelling study. The Lancet Public Health. 2019;4(1):e19-e27.
- 447 ~~17~~19. Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, et al.
448 Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts
449 Among Female Health-Plan Enrollees, United States. American Journal of
450 Epidemiology. 2017;187(2):298-305.
- 451 ~~18~~20. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical
452 Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million
453 Women with Normal Cytological Findings. The Journal of Infectious Diseases.
454 2010;202(12):1789-99.
- 455 21. Chinese Society of Dermatology and Venereology, China Dermatologist
456 Association, Chinese Association of Rehabilitation Dermatology and Venereology.
457 Guideline for the Clinical Management of Anogenital Warts in China (2014) [J].
458 Chinese Journal of Dermatology, 2014,47(08):598-599.
- 459 ~~19~~22. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A
460 Review of the Evidence for the 2015 Centers for Disease Control and Prevention
461 Sexually Transmitted Diseases Treatment Guidelines. Clinical Infectious Diseases.
462 2015;61(suppl_8):S849-S55.
- 463 ~~20~~23. Chang L, Ci P, Shi J, Zhai K, Feng X, Colombara D, et al. Distribution of
464 genital wart human papillomavirus genotypes in China: A multi-center study.
465 Journal of Medical Virology. 2013;85(10):1765-74.
- 466 ~~21~~24. Mueller SM, Menzi S, Kind AB, Blaich A, Bayer M, Navarini A, et al.
467 Sexually transmitted coinfections in patients with anogenital warts – a
468 retrospective analysis of 196 patients. JDDG: Journal der Deutschen
469 Dermatologischen Gesellschaft. 2020;18(4):325-32.
- 470 ~~22~~25. Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR.
471 Consistent Condom Use Is Associated with Lower Prevalence of Human
472 Papillomavirus Infection in Men. The Journal of Infectious Diseases.
473 2010;202(3):445-51.
- 474 ~~23~~26. Aubin F, Prétet J-L, Jacquard A-C, Saunier M, Carcopino X, Jaroud F, et al.
475 Human Papillomavirus Genotype Distribution in External Acuminata
476 Condylomata: A Large French National Study (EDiTH IV). Clinical Infectious
477 Diseases. 2008;47(5):610-5.
- 478 ~~24~~27. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men.
479 The Lancet Infectious Diseases. 2006;6(1):21-31.
- 480 ~~25~~28. The Prevalence and Genotype of Human Papillomavirus from patients with
481 Genital Warts in Eastern Guangdong Province. Asian Pacific Journal of Cancer
482 Prevention. 2015;16(14):5675-9.
- 483 ~~26~~29. Zhu C, Wang Y, Mao W, Zhang H, Ma J. Prevalence and distribution of HPV
484 types in genital warts in Xi'an, China: a prospective study. BMJ Open.
485 2019;9(5):e023897.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 486 [2730](#). Sudenga SL, Ingles DJ, Pierce Campbell CM, Lin H-Y, Fulp WJ, Messina JL,
487 et al. Genital Human Papillomavirus Infection Progression to External Genital
488 Lesions: The HIM Study. *European Urology*. 2016;69(1):166-73.
- 489 [2831](#). Chaturvedi AK. Beyond Cervical Cancer: Burden of Other HPV-Related
490 Cancers Among Men and Women. *Journal of Adolescent Health*. 2010;46(4,
491 Supplement):S20-S6.
- 492 [2932](#). Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, et al. Population-
493 level impact and herd effects following the introduction of human papillomavirus
494 vaccination programmes: updated systematic review and meta-analysis. *The*
495 *Lancet*. 2019;394(10197):497-509.
- 496 [3033](#). Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila
497 M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent
498 vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia
499 and anogenital warts: randomised controlled trial. *BRITISH MEDICAL*
500 *JOURNAL*. 2010;341.
- 501 [3134](#). Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi L-F, et al. Genital
502 Human Papillomavirus Infection in Men: Incidence and Risk Factors in a Cohort
503 of University Students. *The Journal of Infectious Diseases*. 2007;196(8):1128-36.
- 504 [3235](#). Ingles DJ, Pierce Campbell CM, Messina JA, Stoler MH, Lin H-Y, Fulp WJ,
505 et al. Human Papillomavirus Virus (HPV) Genotype- and Age-Specific Analyses
506 of External Genital Lesions Among Men in the HPV Infection in Men (HIM)
507 Study. *The Journal of Infectious Diseases*. 2014;211(7):1060-7.
- 508 [3336](#). Chan PKS, Luk ACS, Luk TNM, Lee K-F, Cheung JLK, Ho K-M, et al.
509 Distribution of human papillomavirus types in anogenital warts of men. *Journal of*
510 *Clinical Virology*. 2009;44(2):111-4.
- 511 [3437](#). Nyitray AG, Menezes L, Lu B, Lin H-Y, Smith De, Abrahamsen M, et al.
512 Genital Human Papillomavirus (HPV) Concordance in Heterosexual Couples. *The*
513 *Journal of Infectious Diseases*. 2012;206(2):202-11.
- 514 [3538](#). Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, de Sanjosé S,
515 et al. Male Circumcision, Penile Human Papillomavirus Infection, and Cervical
516 Cancer in Female Partners. *New England Journal of Medicine*.
517 2002;346(15):1105-12.
- 518 [3639](#). Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Garland SM, et al.
519 Prevalence of human papillomavirus in young men who have sex with men
520 after the implementation of gender-neutral HPV vaccination: a repeated cross-
521 sectional study. *The Lancet Infectious Diseases*. 2021;21(10):1448-57.
- 522 [3740](#). Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al.
523 Ongoing decline in genital warts among young heterosexuals 7 years after the
524 Australian human papillomavirus (HPV) vaccination programme. *Sexually*
525 *Transmitted Infections*. 2015;91(3):214-9.
- 526 [3841](#). Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review.
527 *Vaccines*. 2020;8(3):391.
- 528 [3942](#). Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, et al. Domestic HPV
529 vaccine price and economic returns for cervical cancer prevention in China: a cost-

530 effectiveness analysis. The Lancet Global Health. 2020;8(10):e1335-e44.


531 ~~4043~~. Zhu B, Liu Y, Zuo T, Cui X, Li M, Zhang J, et al. The prevalence, trends, and
532 geographical distribution of human papillomavirus infection in China: The pooled
533 analysis of 1.7 million women. Cancer Medicine. 2019;8(11):5373-85.

534 44. Mastutik G, Alia R, Rahniayu A, et al. GENOTYPING OF HUMAN
535 PAPPILOMAVIRUS IN CERVICAL PRECANCEROUS LESION AND
536 SQUAMOUS CELL CARCINOMA AT DR. SOETOMO HOSPITAL,
537 SURABAYA, INDONESIA[J]. African journal of infectious diseases,2018,12(1
538 Suppl):7-12.

539 ~~4145~~. Schlecht NF, Diaz A, Nucci-Sack A, Shyhalla K, Shankar V, Guillot M, et al.
540 Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and
541 Young Women Immunized With the Human Papillomavirus Vaccine. JAMA
542 Network Open. 2021;4(8):e2121893-e.

543 ~~4246~~. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future.
544 Epidemiology and Infection. 2016;144(3):449-68.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65






Figure 1 Prevalence of specific human papillomavirus (HPV) infection by decreasing order of frequency.

*Patients with unqualified HPV results were excluded from the analysis.

Table 1. Baseline characteristics of with condyloma acuminatum patients, by gender

Characteristics	Male (n = 870)	Female (n= 315)
	n (%)	n (%)
Age		
< 18	18 (2.1)	13 (4.1)
18-24	202 (23.2)	99 (31.4)
25-29	120 (13.8)	38 (12.1)
30-39	228 (26.2)	92 (29.2)
40-49	146 (16.8)	38 (12.1)
50-59	93 (10.7)	28 (8.9)
≥60	63 (7.2)	7 (2.2)
Marital status		
Single	319 (36.7)	124 (39.3)
Married	532 (61.1)	182 (57.8)
Widowed/Separated/Divorced	19 (2.2)	9 (2.9)
Education		
Primary/Middle school	225 (25.9)	94 (29.8)
High school	209 (24.0)	49 (15.6)
University/College	419 (48.2)	167 (53.0)
Postgraduate	17 (1.9)	5 (1.6)
Area of residence at diagnosis		
Rural area	263 (30.2)	96 (30.5)
City	607 (69.8)	219 (69.5)
Age of first sexual intercourse		
< 18	76 (8.7)	23 (7.3)
18-21	431 (49.6)	155 (49.2)
≥22	363 (41.7)	137 (43.5)
Type of CA diagnosis		
Recurrent disease	288 (33.1)	123 (39.0)
New diagnosis	582 (66.9)	192 (61.0)
Condom use		
No	108 (12.4)	34 (10.8)
Yes, sometimes/rarely	676 (77.7)	260 (82.5)
Yes, always	86 (9.9)	21 (6.7)
Weekly frequency of sex		
≤1	397 (45.6)	123 (39.0)
=2	314 (36.1)	118 (37.5)
≥3	159 (18.3)	74 (23.5)
Wash genitalia before sex		

Yes	543 (62.4)	191 (60.6)
No	327 (37.6)	124 (39.4)
Number of sexual partners		
=1	288 (33.1)	142 (45.1)
≥2	582 (66.9)	173 (54.9)

Table 2. Distribution of infection types in condyloma acuminatum patients, by gender

	Males (n = 597) ^a	Females (n= 207) ^a	P value
	n (%)	n (%)	
HR-HPV	293(49.1)	137(66.2)	< 0.001
LR-HPV	543(91.0)	191(92.3)	0.563
Only HR-HPV	54 (9.0)	16 (7.7)	0.563
Only LR-HPV	304 (50.9)	70 (33.8)	< 0.001
LR and HR HPV	239 (40.0)	121 (58.5)	< 0.001
Single infection	286 (47.9)	69 (33.3)	< 0.001
Multiple infections	311 (52.1)	138 (66.7)	< 0.001
HPV6 or 11	515 (86.3)	188 (90.8)	0.088
HPV16 or 18	109 (18.3)	49 (23.7)	0.091
Types of 4-valent vaccines ^b	552 (92.5)	196 (94.7)	0.279
Types of 9-valent vaccines ^c	566 (94.8)	200 (96.6)	0.290

^a Patients with unqualified HPV results were excluded from the analysis.

^b The types of 4-valent vaccines conclude HPV 6, 11, 16 or 18.

^c The types of 9-valent vaccines conclude HPV 6, 11, 16, 18, 31, 33, 45, 52 or 58.

Table 3. Prevalence of specific human papillomavirus (HPV) genotypes in condyloma acuminatum patients, by decreasing order of frequency.

HPV genotypes	Males (n = 597) ^a	Females (n= 207) ^a	<i>P</i> value
	n (%)	n (%)	
LR genotypes			
HPV6	347 (58.1)	118 (57.0)	0.779
HPV11	214 (35.8)	85 (41.4)	0.181
HPV42	64 (10.7)	19 (9.2)	0.530
HPV43	37 (6.2)	8 (3.9)	0.208
HPV81	23 (3.9)	12 (5.8)	0.237
HPV83	10 (1.7)	3 (1.4)	0.824
HR genotypes			
HPV16	77 (12.9)	33 (15.9)	0.272
HPV52	51 (8.5)	20 (9.7)	0.625
HPV51	43 (7.2)	22 (10.6)	0.119
HPV18	43 (7.2)	20 (9.7)	0.257
HPV53	44 (7.4)	18 (8.7)	0.538
HPV56	36 (6.0)	24 (11.6)	0.009
HPV59	44 (7.4)	15 (7.2)	0.953
HPV58	34 (5.7)	21 (10.1)	0.029
HPV66	36 (6.0)	17 (8.2)	0.276
HPV68	24 (4.0)	14 (6.8)	0.109
HPV33	20 (3.4)	13 (6.3)	0.067
HPV73	23 (3.9)	3 (1.4)	0.092
HPV39	17 (2.8)	7 (3.4)	0.697
HPV31	16 (2.7)	5 (2.4)	0.837
HPV82	12 (2.0)	5 (2.4)	0.727
HPV35	8 (1.3)	6 (2.9)	0.140
HPV45	5 (0.8)	7 (3.4)	0.009

^a Patients with unqualified HPV results were excluded from the analysis.

Review II

Close

KHVI-2022-0554R1

"Epidemiology of Human Papillomavirus on Condyloma Acuminatum in Shandong Province, China"

Revision 1

Gondo Mastutik (Reviewer 2)

Reviewer Recommendation Term:	Accept with minor revision
Custom Review Question(s):	Response
As a thank you and to acknowledge the contribution of our reviewers, the journal may publish a list of the names of those who have reviewed at the end of the year. This will not be linked to any specific paper and will only be done if the list of reviewers is long enough to protect the anonymity of the review process for individual papers. If you would prefer for your name not to be included in a published list of reviewers, please indicate this below.	Include my name
If anyone else was involved in writing this report, for example a student or a colleague, and they agree to be recognised for this work please provide their name and email address in the free text box below.	
Do you want to get recognition for this review on Publons ?	Yes
<i>Don't let your reviewing work go unnoticed! Researchers the world over use Publons to effortlessly track their valuable peer review contributions for any journal. If you opt in, your Publons profile will automatically be updated to show a verified record of this review in full compliance with the journal's review policy. If you don't have a Publons profile, you will be prompted to create a free account. [Learn more]</i>	
Would you be willing to review a revision of this manuscript?	No
Do you have any conflict of interest to declare?	No
Comments to Editor:	
Dear Professor Ronald Ellis Ph.D. MBA In general, the authors have edited and revised well. But there are still some minor corrections. I am attaching a manuscript that I have highlighted to give to the author. Thank you very much for the opportunity given to me to review the article. I suggest accepting with a minor correction. Best Regard, Gondo Mastutik	
Comments to Author:	
Dear authors, Thank you very much for revising and editing this manuscript so well. However, it is our duty to review this article. Please find the results of the review in the manuscript that we have given a high light yellow (as attachment). 1. Line 67 & 68. On the other hand, the treatment fee is expensive ("on the other hand" in this sentence, it would be better changed to "in addition"). 2. Please mention Table in the main tex. (Table 1 has not been mentioned in the main text). 3. Line 307. Province, China. Furthermore, HPV42, as one of the genotypes with higher. Please, delete space between Furthermore and ", ". To be "Furthermore," 4. Line 192. were infected with both LR- HPV and HR-HPV. Compared with male. Please delete space between LR- and HPV, it would be "LR-HPV". 5. In all sentences, it should be consistent in writing the HPV genotype. For example HPV space 6 (HPV 6) or HPV6. Please choose one typing type. Please check all sentences. Example line 50, 253, 254, etc.	

6. In the line 71. It was mentioned that "as high-risk (HR) or low-risk (LR)", but in the line 264, 265, 269, etc, it mentioned with "high-risk and low-risk HPV".

Please be consistent to use HR or LR after making abbreviations.

7. Please be consistent in mentioning reference sources. After the "point", then mention the reference source number OR mention the reference source number first, then "point".

Example line 69: burden to patients and their families. [5-7] OR line 72, 73, 74, 75, 76, etc. least 40 genotypes are associated with infection in the anogenital region [8-10].

Thank you very much and good luck.

Attachments:

Action	Description	File Name	Size	Last Modified
Download	KHVI	KHVI-2022-0554_R1 EDIT.pdf	2.3 MB	04 Jan 2023

Close

1 **Epidemiology of Human Papillomavirus on Condyloma Acuminatum**
2
3
4 **in Shandong Province , China**

5
6 Yuan Haowen^{a,†}, Li Renpeng^{b,†}, Lv Jian^c, Yi Guipeng^d, Sun Xihong^e, Zhao
7
8 Na^f, Zhao Fengjun^g, Xu Aiqiang^b, Kou Zengqiang^{b,*}, Wen Hongling^{a,*}

9
10 a Department of Microbiological Laboratory Technology, School of
11
12 Public Health, Cheeloo College of Medicine, Shandong University, Key
13
14 laboratory for the prevention and control of infectious diseases (key labor-
15
16 atory of China's "13th Five-Year", Shandong University), Jinan 250012,
17
18 China; yuanhaowen0218@163.com (H.Y.)

19
20 b Shandong Center for Disease Control and Prevention, Shandong
21
22 Provincial Key Laboratory of Infectious Disease Prevention and Control,
23
24 Jinan 250014, China; rpleesd@163.com (R.L.); aqxuepi@163.com (A.X.)

25
26 c Shandong First Medical University & Shandong Academy of Medical
27
28 Sciences, Tai'an 271016, China; sdfmulvjian@163.com

29
30 d Weifang Medical University, Weifang 261053, China;
31
32 2046076711@qq.com

33
34 e Jining City Center for Disease Control and Prevention, Jining 272000,
35
36 China; xihongsun@163.com

37
38 f Shandong Provincial Hospital for Skin Diseases & Shandong
39
40 Provincial Institute of Dermatology and Veneorology, Shandong First
41
42 Medical University & Shandong Academy of Medical Sciences. Jinan
43
44 250000, China; 411657904@qq.com

1 23 g Shandong Oriental Andrology Hospital, Jinan 250000, China;

2
3 24 671830931@qq.com

4
5
6 25 *Correspondence:

7
8 26 jack-cou@163.com (Z.K.); wenhongling@sdu.edu.cn (H.W.);

9
10 27 Tel.: +86-0531-82679681 (Z.K.); +86-0531-88382625 (H.W.)

11
12 28 † Haowen Yuan and Renpeng Li are Co-first authors.

13
14
15
16
17 29

18
19
20 30 **Abstract**

21
22 31 Condyloma acuminatum (CA) is a sexually transmitted disease (STD)

23
24 32 caused by human papillomavirus (HPV) infection. It is important to study

25
26 33 the prevalence and distribution of HPV genotypes before implementing

27
28 34 HPV vaccination program. Therefore, the aim of this study was to evaluate

29
30 35 the epidemiological characteristics of CA cases and the distribution of HPV

31
32 36 genotypes in Shandong Province, China. One-to-one questionnaire surveys

33
34 37 were conducted on all patients diagnosed with CA in sentinel hospitals

35
36 38 from Shandong Province, China. HPV genotypes were determined using

37
38 39 the polymerase chain reaction (PCR)-reverse dot blot hybridization method.

39
40 40 The study enrolled 1185 patients (870 males and 315 females) and found

41
42 41 that CA patients are mainly males and sexually active people between the

43
44 42 ages of 20 and 40. Recurrence occurred in 34.7% patients. Among the 880

45
46 43 CA patients who underwent HPV typing, the HPV test positivity rate was

47
48 44 91.4%. In these cases, low-risk HPV genotypes infection was predominant,

49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 45 with an infection rate of 91.3%, while high-risk HPV genotypes were found
2
3 46 in 53.5% patients. The most frequent HPV genotypes encountered were
4
5
6 47 HPV 6 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%) and HPV 42 (10.3%).
7
8
9 48 HPV 6 and/or HPV 11 are the main infections in all patients, and more than
10
11
12 49 half of the patients are coinfecting with high-risk HPV. However, unlike
13
14
15 50 other regions, HPV42 has a higher prevalence rate among CA patients in
16
17
18 51 Shandong Province and is a nonvaccine HPV genotype. Therefore, regular
19
20
21 52 HPV typing helps to understand the characteristics of specific genotypes
22
23
24 53 and the choice of the best type for vaccine coverage.

25 54 **Keywords:** condyloma acuminatum; human papillomavirus;
26
27
28 55 epidemiology; HPV genotypes
29
30

31 56

32 33 34 57 **Introduction**

35
36 58 Condyloma acuminatum (CA), also known as genital warts (GW), is a
37
38
39 59 verrucous hyperplasia of squamous epithelium in the anogenital region
40
41
42 60 caused by human papillomavirus (HPV) infection, and it is one of the most
43
44
45 61 common sexually transmitted diseases (STDs) [1, 2]. The CA is the most
46
47
48 62 common benign lesions of the anogenital region, but it can be difficult to
49
50
51 63 treat and easy to recur, which required repeated treatment [3]. Studies have
52
53
54 64 shown that approximately 48.5% of CA patients will experience recurrence
55
56
57 65 [4]. The occurrence of CA reduces the quality of life of patients. On the
58
59
60 66 one hand, the affected area of CA is private and the treatment process is

1 67 painful, which brings serious psychological pressure to patients. On the
2
3 68 other hand, the treatment fee is expensive, which brings heavy financial
4
5
6 69 burden to patients and their families. [5-7].
7

8
9 70 At present, more than 200 HPV genotypes have been identified and
10
11 71 classified as high-risk (HR) or low-risk (LR), based on oncogenic risk. At
12
13
14 72 least 40 genotypes are associated with infection in the anogenital region
15
16
17 73 [8-10]. HPV 6 and 11 are associated with approximately 90% of CA,
18
19
20 74 whereas 70% of cervical cancers are caused by HPV16 and 18[11]. Patients
21
22
23 75 with CA are often accompanied by HR-HPV infection [12-15]. Persistent
24
25
26 76 HR-HPV infection is the main pathogenic factor of cervical intraepithelial
27
28
29 77 neoplasia and cervical cancer in women [16,17].
30

31 78 There is reliable evidence that HPV vaccination has a good preventive
32
33
34 79 effect against HPV infection in uninfected individuals, subsequent CA and
35
36
37 80 HPV-attributable cancers, thereby greatly reducing the burden of HPV-
38
39
40 81 related diseases in patients [18, 19]. However, the HPV vaccines-targeted
41
42
43 82 types are limited, and the HPV genotypes varies among different regions
44
45
46 83 and populations [20].
47

48 84 At present, the HPV infection and epidemiological characteristics of CA
49
50
51 85 patients in China are rare and incomplete. Therefore, in this survey, the
52
53
54 86 evaluation of the epidemic characteristics and HPV genotype distribution
55
56
57 87 of CA cases in Shandong Province, China will contribute to the adjustment
58
59
60 88 of CA prevention and control strategies, the research and development of
61
62
63
64
65

1 89 HPV vaccine and the formulation of immunization plan.
2
3

4 90
5

6 91 **Materials and methods** 7

8 92 **Study population** 9

10 93 Participants were recruited from patients diagnosed according to the
11

12 94 Guideline for the Clinical Management of Anogenital Warts in China
13

14 95 (2014) [21], from Shandong Provincial Hospital for Skin Diseases,
15

16 96 Shandong Oriental Andrology Hospital, and Jining No.1 People's Hospital
17

18 97 from August 2019 to June 2021. All recruited patients had never been
19

20 98 vaccinated against HPV. The selection of sentinel hospitals was based on
21

22 99 the number of patients diagnosed with CA in the past.
23

24 100 After filling in a questionnaire administered by trained interviewers, each
25

26 101 patient underwent sample collection for HPV typing. All patients
27

28 102 volunteered to participate in this study and signed the informed consent
29

30 103 (Minors under the age of 18 had the consent of their guardians). Our study
31

32 104 was approved by the ethics committee of school of public health, Shandong
33

34 105 University, China (protocol n. 20190320).
35

36 106 **Specimen Collection** 37

38 107 All patients undergo a clinical examination by a trained clinician at each
39

40 108 visit to determine whether there are CA lesions in the cervical, vaginal,
41

42 109 vulva, anal and perianal areas in women or in the external genital, anal and
43

44 110 perianal sites in men. If the CA lesion is found, the sample will be collected
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 111 from the site by clinician. Exfoliated cell specimen was collected from the
2
3 112 surface of each CA lesion by using a sampling brush. The brush was rotated
4
5
6 113 3-5 full turns in clockwise direction to ensure acquisition of the exfoliated
7
8
9 114 cells. For each patient, each specimen was independently eluted from the
10
11 115 sampling brush with normal saline and stored in the refrigerator at -80°C
12
13
14 116 before detecting HPV genotypes.
15

16 117 **HPV genotyping**

17
18 118 All HPV DNA extraction, amplification and genotype identification were
19
20
21 119 performed with the HPV genotyping panel (polymerase chain reaction
22
23
24 120 (PCR)-reverse dot blot hybridization method; Yaneng Biosciences,
25
26
27 121 Shenzhen, China). The HPV genotyping panel can detect 17 high-risk HPV
28
29 122 genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and
30
31 123 82) and 6 low-risk HPV genotypes (6, 11, 42, 43, 81 and 83). Genomic
32
33
34 124 DNA was extracted from specimens following manufacturer's protocols.
35
36
37 125 The PCR cycling conditions were as follows: initial denaturation at 95°C
38
39
40 126 for 5 min, then 40 cycles at 94°C for 30 s, 42°C for 90 s, 72°C for 30 s, and
41
42
43 127 a final extension at 72°C for 5 min. The HPV type-specific probes are
44
45
46 128 immobilized on nylon membranes for reverse-blot hybridization on, which
47
48
49 129 can detect 23 types of HPV genotypes in a single test. Hybridization was
50
51
52 130 performed and visualized by assessing the protocol according to the
53
54
55 131 manufacturer's instructions. The quality and integrity of the extracted DNA
56
57
58 132 is monitored by the β -actin gene assay. The specimens with known HPV
59
60
61
62
63
64
65

1 133 genotypes were used as positive controls and enzyme-free water was used
2
3 134 as a negative control.
4

5 135 **Statistical Analysis**

6
7
8
9 136 Qualitative categorical variables were described as numbers and
10
11 137 percentages. Quantitative variables were described using mean and
12
13
14 138 standard deviation or median and interquartile range (P25- P75),
15
16
17 139 depending on the distribution of the variables. *T*-test was used to compare
18
19
20 140 quantitative variables with a normal distribution, and Mann-Whitney *U*-
21
22
23 141 test was used to compare quantitative variables without normal distribution.
24
25
26 142 Chi-square test or Fisher' exact test was conducted to test hypothesis, as
27
28
29 143 appropriate. All hypothesis tests were two-sided, and *P*-value less than or
30
31 144 equal to 0.05 was considered statistically significant. All data were
32
33
34 145 analyzed using SPSS software (version 20.0; IBM Corp.).
35

36 146

37 38 39 147 **Result**

40 41 42 148 **CA patients' characteristics**

43
44
45 149 A total of 1185 patients (870 males and 315 females) were included in this
46
47
48 150 study. Shandong Provincial Hospital for Skin Diseases contributed 52.8%
49
50
51 151 of the total participants, whilst 34.4% and 12.8% were from Jining No.1
52
53 152 People's Hospital and Shandong Oriental Andrology Hospital, respectively.
54
55
56 153 The ages ranged from 15 to 88, with a mean of 34.85 years (SD = 13.60
57
58
59 154 years). The mean age varied slightly between males and females (35.90 vs.

1 155 31.94 years; $P < 0.01$). Among recruited patients, 63.7% cases reported
2
3 156 having more than one sexual partner. The vast majority of patients who
4
5
6 157 reported their sexual preferences were heterosexual (89.1%), including 745
7
8
9 158 (70.4%) heterosexual men (men who have sex with women, MSW) and
10
11 159 312 (29.5%) heterosexual women. There were 101 patients who were
12
13
14 160 homosexual, including 99 males (men who had sex with men, MSM) and
15
16
17 161 2 females. In addition, 26 males and 1 female were bisexual who had sex
18
19
20 162 with both males and females. Compared with female patients, male patients
21
22 163 had more sexual partners ($P < 0.001$). In this study, 85.7% of the patients
23
24
25 164 (86.8% of males and 85.0% of females) themselves claimed that their
26
27
28 165 sexual partners were not infected with HPV.

29
30 166 Of the 1185 patients with genital warts, one or more subsequent genital
31
32
33 167 warts had been detected in 411 patients (33.1% of males and 39.0% of
34
35
36 168 females). In addition, there have 32 patients reported other STDs (Fifteen
37
38
39 169 with syphilis, five with genital herpes, six with HIV/AIDS, four with
40
41
42 170 gonorrhea and two with chlamydia infection).

43
44 171 The majority of patients presented warts lesions at one location (53.5%),
45
46
47 172 34.3% patients presented warts at two different locations, 8.8% at three,
48
49
50 173 and 3.4% at four or more different locations. In females, the CA lesions
51
52
53 174 were often located on the urethral orifice / vaginal introitus (62.9% of
54
55
56 175 cases), labia majora / labia minora (35.9%), and perianal region (26.4%),
57
58
59 176 whereas, for males, the corona sulcus (36.0%), foreskin (26.4%) and
60
61
62
63
64
65

1 177 perianal region (23.6%) were the most frequent sites.
2
3

4 178

5
6 179 **HPV prevalence**
7

8
9 180 A total of 880 samples were collected from 659 males and 221 females
10
11 181 with a clinical diagnosis of CA. Shandong Dermatology Hospital collected
12
13 182 407 samples, while Jining No.1 People's Hospital and Shandong Oriental
14
15 183 Anorectal Hospital collected 321 and 152 samples, respectively. The HPV
16
17 184 DNA was detected in 804 of the 880 CA cases, with a positive rate of 91.4%
18
19 185 (90.6% males and 93.7% females). Seventy-six samples (from 62 males
20
21 186 and 14 females) were excluded from further analysis due to PCR inhibition
22
23 187 or insufficient DNA.
24
25
26
27
28

29 188 Among the 804 patients, 734 (91.3%) patients had at least one LR-HPV
30
31 189 infection detected, and 430 (53.5%) patients had HR-HPV infection. In
32
33 190 addition, there were 374 (46.5%) patients only infected with LR-HPV, 70
34
35 191 (8.7%) patients were only infected with HR-HPV, and 360 (44.8%) patients
36
37 192 were infected with both LR- HPV and HR-HPV. Compared with male
38
39 193 patients, female patients had a higher rate of HR-HPV infection ($P < 0.001$).
40
41 194 Moreover, co-infection of LR-HPV and HR-HPV was more common in
42
43 195 female patients ($P < 0.001$). In addition, the prevalence of single HPV
44
45 196 genotype infections was 44.2%, while those of multiple HPV genotype
46
47 197 coinfections were 55.8%. The total number of HPV genotypes in patients
48
49 198 varied from 1 to 12. The frequency of single and multiple infections varied
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

199 significantly by gender, with single infections being more common among
200 males (47.9% males vs. 33.3% females, $P < 0.001$) and multiple infections
201 more common among females (52.1% males vs. 66.7% females, $P < 0.001$).
202 (Table 2)

203

204 **Distribution of specific HPV genotypes**

205 Overall, all 23 different HPV genotypes were identified in males and
206 females, with a proportion ranging from 1.5% to 57.8% (12/804 to
207 465/804). The most frequently encountered HPV genotypes were HPV 6
208 (57.8%), HPV 11 (37.2%), HPV 16 (13.7%), HPV 42 (10.3%) and HPV 52
209 (8.8%) by decreasing order of frequency. (Figure 1)

210 As it was shown, HPV 6 was the most common HPV genotype detected in
211 both males (58.1%) and females (57.0%). HPV 6/11 (alone or in
212 coinfection with other genotypes) were detected in 87.4% patients and
213 there was no significant difference among males and females. In addition,
214 there was no significant difference in the distribution of all detective low-
215 risk genotypes between males and females. The most common HR-HPV
216 genotypes were HPV 16 (13.7%), HPV 52 (8.8%) and HPV 51 (8.1%).
217 HPV 16/18 (alone or in coinfection with other genotypes) were observed
218 in 19.7% patients. In the HR-HPV genotypes, the frequency of HPV 45,
219 HPV 56 and HPV 58 were significantly higher in women than in men (P
220 < 0.05). Among the patients coinfecting with LR-HPV and HR-HPV, the

1 221 most infection mode is HPV6+HPV16 (5.6%). Different frequency of
2
3 222 other HPV genotypes in different genders were shown in Table 3.
4
5

6 223
7

8 224 **Discussion**

9
10 225 As we all know, CA is one of the most common sexually transmitted
11
12 226 diseases (STDs) caused by HPV infection, and most sexually active
13
14 227 persons are usually exposed to HPV during their lifetime [22]. In this study
15
16 228 based on surveys in sentinel hospitals, we reported the prevalent
17
18 229 characteristics of CA and distribution of HPV genotypes in patients with
19
20 230 CA in Shandong Province, China. In our study, a total of 1185 CA patients
21
22 231 were recruited. The recruited patients were mainly males. This may be due
23
24 232 to the differences in the anatomical structure of males and females.
25
26 233 Compared with males, females need to undergo a professional
27
28 234 gynecological examination in the hospital to find out whether they have
29
30 235 CA. The average age of CA patients recruited in this study was 34.85 years.
31
32 236 Compared with men, women were younger. These results are consistent
33
34 237 with a previous Chinese multi-center study of genital wart conducted in
35
36 238 2013 including 1,005 cases from eighteen hospitals in seven geographical
37
38 239 regions of China [23]. In this study, most patients were in the sexually
39
40 240 active stage aged 20 to 40. These patients had risky sexual behaviors such
41
42 241 as multiple sexual partners and irregular condom use. Among them, 32
43
44 242 cases also suffered from other sexually transmitted diseases. These are all
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 243 risk factors that increase HPV infection [24, 25]. In addition, 34.7% of the
2
3
4 244 patients in this study were recurrences.

5
6 245 Among the 880 patients who underwent HPV testing, the overall HPV test
7
8
9 246 positivity rate was 91.4%, which shows that HPV is the pathogen that
10
11 247 causes CA. There were 8.6% of the patients could not be included in the
12
13
14 248 analysis due to insufficient cellular DNA content. Previous studies have
15
16
17 249 found that 16~26% of the samples will be negative regardless of the type
18
19
20 250 of cell brush sampling [26, 27]. Compared with other studies, the lower
21
22
23 251 negative rate of our study reflects the higher quality of sample collection
24
25
26 252 after unified training. In the analysis of specific HPV types, it was shown
27
28 253 that the most common genotypes in Shandong Province, China were HPV6,
29
30 254 HPV11, HPV16 and HPV42. Compared with other regions in China,
31
32
33 255 HPV42 had a higher prevalence in Shandong province and had become one
34
35
36 256 of the common genotypes of HPV in CA patients. Previous studies have
37
38
39 257 found that the distribution of HPV genotypes varies from region to region.
40
41
42 258 Although the risk of diseases related to nonvaccine HPV genotypes is
43
44
45 259 theoretically still low, the actual situation still needs to be monitored to deal
46
47
48 260 with the disease burden caused by high prevalence of nonvaccine HPV
49
50
51 261 genotypes. Furthermore, the distribution of HPV6, HPV11 and HPV16
52
53
54 262 were consistent with the results of studies in other regions of China [23, 28,
55
56 263 29].

57
58 264 In this study, males were mainly infected with low-risk HPV, while females
59
60
61
62
63
64
65

1 265 were mainly multiple infected with high-risk and low-risk HPV. Most
2
3
4 266 patients, both male and female, were infected with more than one different
5
6 267 HPV genotype. According to our results, HPV6 and 11 (alone or
7
8 268 coinfection with other genotypes) were detected in 87.4% of patients, but
9
10
11 269 most of these patients also had high-risk HPV infection. In this study, 53.5%
12
13
14 270 of patients with CA were infected with high-risk HPV. Among male
15
16
17 271 patients, 49.1% were infected with at least one high-risk type of HPV.
18
19
20 272 Some studies have shown that male penile cancer and anal cancer are
21
22
23 273 associated with high-risk HPV infection [30]. Compared with male patients,
24
25
26 274 female patients had a higher infection rate of high-risk HPV (66.2% vs.
27
28
29 275 49.1%), indicating that women had a higher burden of high-risk HPV
30
31
32 276 infection. Persistent high-risk HPV infection can lead to precancerous
33
34
35 277 lesions and cancers of the cervix, vulva, vagina, and anus in women, so it
36
37
38 278 is very important to prevent the occurrence of these lesions [31]. Some
39
40
41 279 studies find that high HPV vaccination coverage significantly reduced the
42
43
44 280 prevalence of CA, HPV infection and cervical intraepithelial neoplasia
45
46
47 281 grade 2+ (CIN2+) [32, 33]. In addition, when formulating policies to
48
49
50 282 prevent HPV infection in women, it should be considered that men also
51
52
53 283 have a higher infection rate of high-risk HPV. Some studies have found that
54
55
56 284 men HPV multiple infection is very common, and the high-risk HPV
57
58
59 285 infection rate is the same as that of women [34-36]. There is a higher risk
60
61
62 286 of cross-infection between men and women [37, 38]. HPV vaccination to
63
64
65

1 287 men can effectively reduce related HPV infection rates and HPV-related
2
3 288 cancer incidence [39, 40].
4
5
6 289 Nowadays, four prophylactic HPV vaccines are available in China,
7
8 290 including the HPV bivalent vaccine (Cervarix[®]; Cecolin[®]) to protect
9
10 291 against HPV16 and 18; the HPV quadrivalent vaccine (Gardasil[®]) to
11
12 292 protect against HPV 6, 11, 16 and 18; the HPV nonavalent vaccine
13
14 293 (Gardasil[®]9) to protect against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 [41,
15
16 294 42]. At present, there is no HPV vaccination programs implemented in
17
18 295 China, which may be related to the insufficient data of HPV
19
20 296 epidemiological survey. However, the distribution of HPV genotypes
21
22 297 varies from region to region [43]. Although vaccines can provide
23
24 298 protection for people, it is important to study the prevalence and
25
26 299 distribution of HPV genotypes in different regions before implementing
27
28 300 the HPV vaccination plan, because understanding the distribution of HPV
29
30 301 genotypes will help to choose the best vaccine for HPV protection in each
31
32 302 region [44]. In this study, HPV6 and HPV11 were the causes of CA in the
33
34 303 majority of patients (87.4%), and they were included in both the
35
36 304 quadrivalent and nonavalent vaccines. Considering the economic benefits
37
38 305 and the insufficient supply of 9-valent HPV vaccine in China, the 4-valent
39
40 306 HPV vaccine may be more suitable for the prevention of CA in Shandong
41
42 307 Province, China. Furthermore ,HPV42, as one of the genotypes with higher
43
44 308 prevalence in this study, has not been included in any licensed HPV
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 309 vaccines. Previous studies have found that among people vaccinated with
2
3 310 the quadrivalent HPV vaccine, the infection rate of nonvaccine HPV
4
5 311 genotypes is remaining flat or higher [45]. Therefore, it is necessary to
6
7 312 develop a broader spectrum of HPV vaccines to reduce the disease burden
8
9 313 caused by HPV infection [46].
10

11 314 In conclusion, CA cases are mainly infected with low-risk HPV, but there
12
13 315 are more high-risk HPV infections in both males and females, which is a
14
15 316 problem that cannot be ignored in clinical treatment. It is necessary to
16
17 317 monitor the HPV genotype of CA patients, because high-risk HPV
18
19 318 infection is the main risk factor for cancer. For the general public, HPV
20
21 319 typing and HPV vaccination will help to prevent CA or HPV-related cancer
22
23 320 and reduce the risk of disease. Additionally, nonvaccine HPV genotypes
24
25 321 also need to be monitored for their prevalence by regular HPV typing. The
26
27 322 results of our study make a contribution to the epidemiology of HPV in
28
29 323 Chinese CA patients with improving the understanding of existing HPV
30
31 324 genotypes. Furthermore, these will have a positive impact on the
32
33 325 adjustment of CA prevention and treatment strategies, the research and
34
35 326 development of HPV vaccines and the formulation of immunization
36
37 327 programs.
38

39 328

39 329 **Acknowledgments**

40 330 We are grateful to the patients who joined the study. This work has been
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 331 funded by a research grant from Merck Sharpe & Dohme (MISP
2
3 332 IIS#57766). The funders had no role in study design, data collection and
4
5
6 333 analysis, decision to publish, or preparation of the manuscript.
7
8

9 334

10 11 335 **Disclosure of potential conflicts of interest**

12
13
14 336 No potential conflicts of interest were disclosed.
15
16

17 337

18 19 20 338 **Funding**

21
22 339 This work has been funded by a research grant from Merck Sharpe &
23
24
25 340 Dohme (MISP IIS#57766).
26
27

28 341

29 30 31 342 **Ethics and dissemination**

32
33
34 343 Our study was approved by the ethics committee of School of Public
35
36 344 Health, Shandong University, China (protocol n. 20190320). All patients
37
38
39 345 volunteered to participate in this study and signed the informed consent
40
41
42 346 (Minors under the age of 18 had the consent of their guardians).
43
44

45 347


46 47 348 **References**

- 48
49 349 1. Steben M, Garland SM. Genital warts. Best Practice & Research Clinical
50 350 Obstetrics & Gynaecology. 2014;28(7):1063-73.
51 351 2. Dunne EF, Markowitz LE. Genital Human Papillomavirus Infection. Clinical
52 352 Infectious Diseases. 2006;43(5):624-9.
53
54 353 3. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, et al.
55 354 Genital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United
56 355 States. The Journal of Infectious Diseases. 2018;219(5):703-10.
57
58 356 4. Thomas R, Steben M, Greenwald Z, Stutz M, Rodier C, DeAngelis F, et al.

59
60
61
62
63
64
65

Volume 11 | Issue 1 | September 2013

Article Title	Author(s)
Human papillomavirus type 18 and 45 infection in cervical cancer in China	Wang, X., et al.
Immunogenicity and safety of a novel recombinant subunit vaccine for dengue fever in children	Chen, Y., et al.
Effect of a novel adjuvant on the immunogenicity of a subunit vaccine for dengue fever	Chen, Y., et al.
Immunogenicity and safety of a novel recombinant subunit vaccine for dengue fever in children	Chen, Y., et al.
Effect of a novel adjuvant on the immunogenicity of a subunit vaccine for dengue fever	Chen, Y., et al.



Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province, China

Haowen Yuan, Renpeng Li, Jian Lv, Guipeng Yi, Xihong Sun, Na Zhao, Fengjun Zhao, Aiqiang Xu, Zengqiang Kou & Hongling Wen

To cite this article: Haowen Yuan, Renpeng Li, Jian Lv, Guipeng Yi, Xihong Sun, Na Zhao, Fengjun Zhao, Aiqiang Xu, Zengqiang Kou & Hongling Wen (2023): Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province, China, Human Vaccines & Immunotherapeutics, DOI: [10.1080/21645515.2023.2170662](https://doi.org/10.1080/21645515.2023.2170662)

To link to this article: <https://doi.org/10.1080/21645515.2023.2170662>

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

Published online: 15 Mar 2023.

Submit your article to this journal

Article views: 148

View related articles

View Crossmark data

Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province, China

Haowen Yuan^{a*}, Renpeng Li^{b*}, Jian Lv^c, Guipeng Yi^d, Xihong Sun^e, Na Zhao^f, Fengjun Zhao^g, Aiqiang Xu^b, Zengqiang Kou^{b#}, and Hongling Wen^{a#}

^aDepartment of Microbiological Laboratory Technology, School of Public Health, Cheeloo College of Medicine, Shandong University, Key laboratory for the prevention and control of infectious diseases (key labor-atory of China's "13th Five-Year", Shandong University), Jinan, China; ^bShandong Center for Disease Control and Prevention, Shandong Provincial Key Laboratory of Infectious Disease Prevention and Control, Jinan, China; ^cSchool of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Tai'an, China; ^dSchool of Public Health, Weifang Medical University, Weifang, China; ^eDepartment of Infectious Disease Prevention and Control, Jining City Center for Disease Control and Prevention, Jining, China; ^fShandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China; ^gDepartment of Andrology, Shandong Oriental Andrology Hospital, Jinan, China

ABSTRACT

Condyloma acuminatum (CA) is a sexually transmitted disease (STD) caused by human papillomavirus (HPV) infection. It is important to study the prevalence and distribution of HPV genotypes before implementing the HPV vaccination program. Therefore, the aim of this study was to evaluate the epidemiological characteristics of CA cases and the distribution of HPV genotypes in Shandong Province, China. One-to-one questionnaire surveys were conducted on all patients diagnosed with CA in sentinel hospitals from Shandong Province, China. HPV genotypes were determined using the polymerase chain reaction (PCR)-reverse dot blot hybridization method. The study enrolled 1185 patients (870 males and 315 females) and found that CA patients are mainly males and sexually active people between the ages of 20 and 40. Recurrence occurred in 34.7% patients. Among the 880 CA patients who underwent HPV typing, the HPV test positivity rate was 91.4%. In these cases, low-risk (LR) HPV infection was predominant, with an infection rate of 91.3%, while high-risk (HR) HPV genotypes were found in 53.5% patients. The most frequent HPV genotypes encountered were HPV6 (57.8%), HPV11 (37.2%), HPV16 (13.7%), and HPV42 (10.3%). HPV6 and/or HPV11 are the main infections in all patients, and more than half of the patients are coinfecting with HR-HPV. However, unlike other regions, HPV42 has a higher prevalence rate among CA patients in Shandong Province and is a nonvaccine HPV genotype. Therefore, regular HPV typing helps to understand the characteristics of specific genotypes and the choice of the best type for vaccine coverage.

ARTICLE HISTORY

Received 29 September 2022
Revised 9 January 2023
Accepted 15 January 2023

KEYWORDS

Condyloma acuminatum;
human papillomavirus;
epidemiology; HPV
genotypes

Introduction





Condyloma acuminatum (CA), also known as genital warts (GW), is a verrucous hyperplasia of squamous epithelium in the anogenital region caused by human papillomavirus (HPV) infection, and it is one of the most common sexually transmitted diseases (STDs).^{1,2} The CA is the most common benign lesions of the anogenital region, but it can be difficult to treat and easy to recur, which required repeated treatment.³ Studies have shown that approximately 48.5% of CA patients will experience recurrence.⁴ The occurrence of CA reduces the quality of life of patients. Above all, the affected area of CA is private and the treatment process is painful, which brings serious psychological pressure to patients. In addition, the treatment fee is expensive, which brings heavy financial burden to patients and their families.⁵⁻⁷

At present, more than 200 HPV genotypes have been identified and classified as high-risk (HR) or low-risk (LR), based

on oncogenic risk. At least 40 genotypes are associated with infection in the anogenital region.⁸⁻¹⁰ HPV6 and 11 are associated with approximately 90% of CA, whereas 70% of the cervical cancers are caused by HPV16 and 18.¹¹ Patients with CA are often accompanied by HR-HPV infection.¹²⁻¹⁵ Persistent HR-HPV infection is the main pathogenic factor of cervical intraepithelial neoplasia and cervical cancer in women.^{16,17}

There is reliable evidence that HPV vaccination has a good preventive effect against HPV infection in uninfected individuals and subsequent CA and HPV-attributable cancers, thereby greatly reducing the burden of HPV-related diseases in patients.^{18,19} However, HPV vaccine-targeted types are limited, and HPV genotypes vary among different regions and populations.²⁰

At present, HPV infection and epidemiological characteristics of CA patients in China are rare and incomplete. Therefore,

CONTACT Zengqiang Kou  jack-cou@163.com  Shandong Center for Disease Control and Prevention, Shandong Provincial Key Laboratory of Infectious Disease Prevention and Control, Jinan 250014, China; Hongling Wen  wenhongling@sdu.edu.cn  Department of Microbiological Laboratory Technology, School of Public Health, Cheeloo College of Medicine, Shandong University, Key laboratory for the prevention and control of infectious diseases (key laboratory of China's "13th Five-Year", Shandong University), Jinan 250012, China.

*These authors are Co-first authors.

#Zengqiang Kou and Hongling Wen are co-corresponding authors.

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

in this survey, the evaluation of the epidemic characteristics and HPV genotype distribution of CA cases in Shandong Province, China, will contribute to the adjustment of CA prevention and control strategies, the research and development of HPV vaccine and the formulation of immunization plan.

Materials and methods

Study population

Participants were recruited from patients diagnosed according to the Guideline for the Clinical Management of Anogenital Warts in China (2014),²¹ from Shandong Provincial Hospital for Skin Diseases, Shandong Oriental Andrology Hospital, and Jining No.1 People's Hospital from August 2019 to June 2021. None of the recruited patients had ever been vaccinated against HPV. The selection of sentinel hospitals was based on the number of patients diagnosed with CA in the past.

After filling in a questionnaire administered by trained interviewers, each patient underwent sample collection for HPV typing. All patients volunteered to participate in this study and signed the informed consent (Minors under the age of 18 had the consent of their guardians). Our study was approved by the ethics committee of the School of Public Health, Shandong University, China (protocol n. 20190320).

Specimen collection

All patients undergo a clinical examination by a trained clinician at each visit to determine whether there are CA lesions in the cervical, vaginal, vulva, anal, and perianal areas in women or in the external genital, anal, and perianal sites in men. If the CA lesion is found, the sample will be collected from the site by a clinician. Exfoliated cell specimen was collected from the surface of each CA lesion using a sampling brush. The brush was rotated 3–5 full turns in clockwise direction to ensure acquisition of the exfoliated cells. For each patient, each specimen was independently eluted from the sampling brush with normal saline and stored in the refrigerator at -80°C before detecting HPV genotypes.

HPV genotyping

All HPV DNA extraction, amplification and genotype identification were performed with the HPV genotyping panel (polymerase chain reaction (PCR)-reverse dot blot hybridization method; Yaneng Biosciences, Shenzhen, China). The HPV genotyping panel can detect 17 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) and 6 LR-HPV genotypes (6, 11, 42, 43, 81, and 83). Genomic DNA was extracted from specimens following manufacturer's protocols. The PCR cycling conditions were as follows: initial denaturation at 95°C for 5 min, then 40 cycles at 94°C for 30 s, 42°C for 90 s, 72°C for 30 s, and a final extension at 72°C for 5 min. HPV type-specific probes are immobilized on nylon membranes for reverse-blot hybridization on, which can detect 23 types of HPV

genotypes in a single test. Hybridization was performed and visualized by assessing the protocol according to the manufacturer's instructions. The quality and integrity of the extracted DNA is monitored by the β -actin gene assay. The specimens with known HPV genotypes were used as positive controls and enzyme-free water was used as a negative control.

Statistical analysis

Qualitative categorical variables were described as numbers and percentages. Quantitative variables were described using mean and standard deviation or median and interquartile range (P25-P75), depending on the distribution of the variables. *T*-test was used to compare quantitative variables with a normal distribution, and the Mann-Whitney *U*-test was used to compare quantitative variables without a normal distribution. Chi-square test or Fisher's exact test was conducted to test the hypothesis, as appropriate. All hypothesis tests were two-sided, and *P*-value less than or equal to 0.05 was considered statistically significant. All data were analyzed using SPSS software (version 20.0; IBM Corp.).

Result

CA patients' characteristics

A total of 1185 patients (870 males and 315 females) were included in this study. The Shandong Provincial Hospital for Skin Diseases contributed 52.8% of the total participants, whilst 34.4% and 12.8% were from Jining No.1 People's Hospital and Shandong Oriental Andrology Hospital, respectively. The ages ranged from 15 to 88, with a mean of 34.85 years (SD = 13.60 years). The mean age varied slightly between males and females (35.90 vs. 31.94 years; $p < .01$). Among recruited patients, 63.7% cases reported having more than one sexual partner. The vast majority of patients who reported their sexual preferences were heterosexual (89.1%), including 745 (70.4%) heterosexual men (men who have sex with women, MSW) and 312 (29.5%) heterosexual women. There were 101 patients who were homosexual, including 99 males (men who had sex with men, MSM) and 2 females. In addition, 26 males and 1 female were bisexual who had sex with both males and females. Compared with female patients, male patients had more sexual partners ($p < .001$). In this study, 85.7% of the patients (86.8% of males and 85.0% of females) themselves claimed that their sexual partners were not infected with HPV (Table 1).

Of the 1185 patients with genital warts, one or more subsequent genital warts had been detected in 411 patients (33.1% of males and 39.0% of females). (Table 1) In addition, 32 patients reported other STDs (fifteen with syphilis, five with genital herpes, six with HIV/AIDS, four with gonorrhea and two with chlamydia infection).

The majority of patients presented wart lesions at one location (53.5%), 34.3% patients presented warts at two different locations, 8.8% at three, and 3.4% at four or

Table 1. Baseline characteristics of condyloma acuminatum patients, by gender.

Characteristics	Male (n = 870) n (%)	Female (n = 315) n (%)
Age		
<18	18 (2.1)	13 (4.1)
18-24	202 (23.2)	99 (31.4)
25-29	120 (13.8)	38 (12.1)
30-39	228 (26.2)	92 (29.2)
40-49	146 (16.8)	38 (12.1)
50-59	93 (10.7)	28 (8.9)
≥60	63 (7.2)	7 (2.2)
Marital status		
Single	319 (36.7)	124 (39.3)
Married	532 (61.1)	182 (57.8)
Widowed/Separated/Divorced	19 (2.2)	9 (2.9)
Education		
Primary/Middle school	225 (25.9)	94 (29.8)
High school	209 (24.0)	49 (15.6)
University/College	419 (48.2)	167 (53.0)
Postgraduate	17 (1.9)	5 (1.6)
Area of residence at diagnosis		
Rural area	263 (30.2)	96 (30.5)
City	607 (69.8)	219 (69.5)
Age of first sexual intercourse		
<18	76 (8.7)	23 (7.3)
18-21	431 (49.6)	155 (49.2)
≥22	363 (41.7)	137 (43.5)
Type of CA diagnosis		
Recurrent disease	288 (33.1)	123 (39.0)
New diagnosis	582 (66.9)	192 (61.0)
Condom use		
No	108 (12.4)	34 (10.8)
Yes, sometimes/rarely	676 (77.7)	260 (82.5)
Yes, always	86 (9.9)	21 (6.7)
Weekly frequency of sex		
≤1	397 (45.6)	123 (39.0)
= 2	314 (36.1)	118 (37.5)
≥3	159 (18.3)	74 (23.5)
Wash genitalia before sex		
Yes	543 (62.4)	191 (60.6)
No	327 (37.6)	124 (39.4)
Number of sexual partners		
= 1	288 (33.1)	142 (45.1)
≥2	582 (66.9)	173 (54.9)

more different locations. In females, the CA lesions were often located on the urethral orifice/vaginal introitus (62.9% of the cases), labia majora/labia minora (35.9%), and perianal region (26.4%), whereas, for males, the corona sulcus (36.0%), foreskin (26.4%), and perianal region (23.6%) were the most frequent sites.

HPV prevalence

A total of 880 samples were collected from 659 males and 221 females with a clinical diagnosis of CA. Shandong Dermatology Hospital collected 407 samples, while Jining No.1 People's Hospital and Shandong Oriental Anorectal Hospital collected 321 and 152 samples, respectively. The HPV DNA was detected in 804 of the 880 CA cases, with a positive rate of 91.4% (90.6% males and 93.7% females). Seventy-six samples (from 62 males and 14 females) were excluded from further analysis due to PCR inhibition or insufficient DNA.

Among the 804 patients, 734 (91.3%) patients had at least one LR-HPV infection detected, and 430 (53.5%) patients had HR-HPV infection. In addition, there were 374 (46.5%) patients only infected with LR-HPV, 70 (8.7%) patients were

only infected with HR-HPV, and 360 (44.8%) patients were infected with both LR-HPV and HR-HPV. Compared with male patients, female patients had a higher rate of HR-HPV infection ($p < .001$). Moreover, co-infection of LR-HPV and HR-HPV was more common in female patients ($p < .001$). In addition, the prevalence of single HPV genotype infections was 44.2%, while those of multiple HPV genotype coinfections were 55.8%. The total number of HPV genotypes in patients varied from 1 to 12. The frequency of single and multiple infections varied significantly by gender, with single infections being more common among males (47.9% males vs. 33.3% females, $p < .001$) and multiple infections more common among females (52.1% males vs. 66.7% females, $p < .001$). (Table 2)

Distribution of specific HPV genotypes

Overall, all 23 different HPV genotypes were identified in males and females, with a proportion ranging from 1.5% to 57.8% (12/804 to 465/804). The most frequently encountered HPV genotypes were HPV6 (57.8%), HPV11 (37.2%), HPV16 (13.7%), HPV42 (10.3%), and HPV52 (8.8%) by decreasing order of frequency (Figure 1).

Table 2. Distribution of infection types in condyloma acuminatum patients, by gender.

	Males (n = 597) ^a n (%)	Females (n = 207) ^a n (%)	P value
HR-HPV	293(49.1)	137(66.2)	<.001
LR-HPV	543(91.0)	191(92.3)	.563
Only HR-HPV	54 (9.0)	16 (7.7)	.563
Only LR-HPV	304 (50.9)	70 (33.8)	<.001
LR and HR HPV	239 (40.0)	121 (58.5)	<.001
Single infection	286 (47.9)	69 (33.3)	<.001
Multiple infections	311 (52.1)	138 (66.7)	<.001
HPV6 or 11	515 (86.3)	188 (90.8)	.088
HPV16 or 18	109 (18.3)	49 (23.7)	.091
Types of 4-valent vaccines ^b	552 (92.5)	196 (94.7)	.279
Types of 9-valent vaccines ^c	566 (94.8)	200 (96.6)	.290

^aPatients with unqualified HPV results were excluded from the analysis.

^bThe types of 4-valent vaccines conclude HPV 6, 11, 16, or 18.

^cThe types of 9-valent vaccines conclude HPV 6, 11, 16, 18, 31, 33, 45, 52, or 58.




Figure 1. Prevalence of specific human papillomavirus (HPV) infection by decreasing order of frequency. *Patients with unqualified HPV results were excluded from the analysis.

As it was shown, HPV6 was the most common HPV genotype detected in both males (58.1%) and females (57.0%). HPV6/11 (alone or in coinfection with other genotypes) was detected in 87.4% patients, and there was no significant difference between males and females. In addition, there was no significant difference in the distribution of all detective low-risk genotypes between males and females. The most common HR-HPV genotypes were HPV16 (13.7%), HPV52 (8.8%) and HPV51 (8.1%). HPV16/18 (alone or in coinfection with other genotypes) were observed in 19.7% patients. In the HR-HPV genotypes, the frequency of HPV45, HPV56, and HPV58 were significantly higher in women than in men ($p < .05$). Among the patients coinfecting with LR-HPV and HR-HPV, the most infection mode is HPV6 + HPV16 (5.6%). Different frequencies of other HPV genotypes in different genders are shown in Table 3.

Discussion

As we all know, CA is one of the most common sexually transmitted diseases (STDs) caused by HPV infection, and most sexually active persons are usually exposed to HPV during their lifetime.²² In this study based on surveys in sentinel

hospitals, we reported the prevalent characteristics of CA and distribution of HPV genotypes in patients with CA in Shandong Province, China. In our study, a total of 1185 CA patients were recruited. The recruited patients were mainly males. This may be due to differences in the anatomical structure of males and females. Compared with males, females need to undergo a professional gynecological examination in the hospital to find out whether they have CA. The average age of CA patients recruited in this study was 34.85 years. Compared with men, women were younger. These results are consistent with a previous Chinese multi-center study of genital warts conducted in 2013 including 1,005 cases from 18 hospitals in seven geographical regions of China.²³ In this study, most patients were in the sexually active stage aged 20 to 40. These patients had risky sexual behaviors such as multiple sexual partners and irregular condom use. Among them, 32 cases also suffered from other sexually transmitted diseases. These are all risk factors that increase HPV infection.^{24,25} In addition, 34.7% of the patients in this study had recurrences.

Among the 880 patients who underwent HPV testing, the overall HPV test positivity rate was 91.4%, which shows that HPV is the pathogen that causes CA. There were 8.6% of the patients that could not be included in the analysis due to

Table 3. Prevalence of specific human papillomavirus (HPV) genotypes in condyloma acuminatum patients, by decreasing order of frequency.

HPV genotypes	Males (n = 597) ^a n (%)	Females (n = 207) ^a n (%)	P value
LR genotypes			
HPV6	347 (58.1)	118 (57.0)	.779
HPV11	214 (35.8)	85 (41.4)	.181
HPV42	64 (10.7)	19 (9.2)	.530
HPV43	37 (6.2)	8 (3.9)	.208
HPV81	23 (3.9)	12 (5.8)	.237
HPV83	10 (1.7)	3 (1.4)	.824
HR genotypes			
HPV16	77 (12.9)	33 (15.9)	.272
HPV52	51 (8.5)	20 (9.7)	.625
HPV51	43 (7.2)	22 (10.6)	.119
HPV18	43 (7.2)	20 (9.7)	.257
HPV53	44 (7.4)	18 (8.7)	.538
HPV56	36 (6.0)	24 (11.6)	.009
HPV59	44 (7.4)	15 (7.2)	.953
HPV58	34 (5.7)	21 (10.1)	.029
HPV66	36 (6.0)	17 (8.2)	.276
HPV68	24 (4.0)	14 (6.8)	.109
HPV33	20 (3.4)	13 (6.3)	.067
HPV73	23 (3.9)	3 (1.4)	.092
HPV39	17 (2.8)	7 (3.4)	.697
HPV31	16 (2.7)	5 (2.4)	.837
HPV82	12 (2.0)	5 (2.4)	.727
HPV35	8 (1.3)	6 (2.9)	.140
HPV45	5 (0.8)	7 (3.4)	.009

^aPatients with unqualified HPV results were excluded from the analysis.

insufficient cellular DNA content. Previous studies have found that 16 ~ 26% of the samples will be negative regardless of the type of cell brush sampling.^{26,27} Compared with other studies, the lower negative rate of our study reflects the higher quality of sample collection after unified training. In the analysis of specific HPV types, it was shown that the most common genotypes in Shandong Province, China, were HPV6, HPV11, HPV16, and HPV42. Compared with other regions in China, HPV42 had a higher prevalence in Shandong province and had become one of the most common genotypes of HPV in CA patients. Previous studies have found that the distribution of HPV genotypes varies from region to region. Although the risk of diseases related to nonvaccine HPV genotypes is theoretically still low, the actual situation still needs to be monitored to deal with the disease burden caused by high prevalence of nonvaccine HPV genotypes. Furthermore, the distribution of HPV6, HPV11, and HPV16 were consistent with the results of studies in other regions of China.^{23,28,29}

In this study, males were mainly infected with LR-HPV, while females were mainly multiple infected with high-risk and LR-HPV. Most patients, both male and female, were infected with more than one different HPV genotype. According to our results, HPV6 and 11 (alone or coinfection with other genotypes) were detected in 87.4% of the patients, but most of these patients also had HR-HPV infection. In this study, 53.5% of the patients with CA were infected with HR-HPV. Among male patients, 49.1% were infected with at least one HR-type of HPV. Some studies have shown that male penile cancer and anal cancer are associated with high-risk HPV infection.³⁰ Compared with male patients, female patients had a higher infection rate of HR-HPV (66.2% vs. 49.1%), indicating that women had a higher burden of HR-HPV infection. Persistent HR-HPV infection can lead to precancerous lesions and

cancers of the cervix, vulva, vagina, and anus in women, so it is very important to prevent the occurrence of these lesions.³¹ Some studies have found that high HPV vaccination coverage significantly reduced the prevalence of CA, HPV infection, and cervical intraepithelial neoplasia grade 2+ (CIN2+).^{32,33} In addition, when formulating policies to prevent HPV infection in women, it should be considered that men also have a higher infection rate of HR-HPV. Some studies have found that male HPV multiple infection is very common, and the HR-HPV infection rate is the same as that of women.³⁴⁻³⁶ There is a higher risk of cross-infection between men and women.^{37,38} HPV vaccination in men can effectively reduce related HPV infection rates and HPV-related cancer incidence.^{39,40}

Nowadays, four prophylactic HPV vaccines are available in China, including the HPV bivalent vaccine (Cervarix[®]; Cecolin[®]) to protect against HPV16 and 18; the HPV quadrivalent vaccine (Gardasil[®]) to protect against HPV6, 11, 16, and 18; the HPV nonavalent vaccine (Gardasil[®]9) to protect against HPV6, 11, 16, 18, 31, 33, 45, 52, and 58.^{41,42} At present, there are no HPV vaccination programs implemented in China, which may be related to the insufficient data of HPV epidemiological survey. However, the distribution of HPV genotypes varies from region to region.⁴³ Although vaccines can provide protection for people, it is important to study the prevalence and distribution of HPV genotypes in different regions before implementing the HPV vaccination plan, because understanding the distribution of HPV genotypes will help to choose the best vaccine for HPV protection in each region.⁴⁴ In this study, HPV6 and HPV11 were the causes of CA in the majority of patients (87.4%), and they were included in both the quadrivalent and nonavalent vaccines. Considering the economic benefits and the insufficient supply of 9-valent HPV vaccine in China, the 4-valent HPV vaccine may be more suitable for the prevention of CA in Shandong

Province, China. Furthermore, HPV42, as one of the genotypes with higher prevalence in this study, has not been included in any licensed HPV vaccines. Previous studies have found that among people vaccinated with the quadrivalent HPV vaccine, the infection rate of nonvaccine HPV genotypes remains flat or higher.⁴⁵ Therefore, it is necessary to develop a broader spectrum of HPV vaccines to reduce the disease burden caused by HPV infection.⁴⁶

In conclusion, CA cases are mainly infected with LR-HPV, but there are more HR-HPV infections in both males and females, which is a problem that cannot be ignored in clinical treatment. It is necessary to monitor the HPV genotype of CA patients, because HR-HPV infection is the main risk factor for cancer. For the general public, HPV typing and HPV vaccination will help to prevent CA or HPV-related cancer and reduce the risk of disease. Additionally, nonvaccine HPV genotypes also need to be monitored for their prevalence by regular HPV typing. The results of our study make a contribution to the epidemiology of HPV in Chinese CA patients by improving the understanding of existing HPV genotypes. Furthermore, this will have a positive impact on the adjustment of CA prevention and treatment strategies, the research and development of HPV vaccines and the formulation of immunization programs.

Acknowledgments

We are grateful to the patients who joined the study. This work has been funded by a research grant from Merck Sharpe & Dohme (MISP IIS#57766). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work has been funded by a research grant from Merck Sharpe & Dohme [MISP IIS#57766].

Ethics and dissemination

Our study was approved by the ethics committee of the School of Public Health, Shandong University, China (protocol n. 20190320). All patients volunteered to participate in this study and signed the informed consent (Minors under the age of 18 had the consent of their guardians).

References

1. Steben M, Garland SM. Genital warts. *Best Pract Res Clin Obstet Gynaecol.* 2014;28(7):1063–73. doi:10.1016/j.bpobgyn.2014.07.002.
2. Dunne EF, Markowitz LE. Genital human papillomavirus infection. *Clin Infect Dis.* 2006;43(5):624–29. doi:10.1086/505982.
3. Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, Cintra RC, Lazcano-Ponce E, Villa LL. Genital wart recurrence among men residing in Brazil, Mexico, and the United States. *J Infect Dis.* 2018;219(5):703–10. doi:10.1093/infdis/jiy533.
4. Thomas R, Steben M, Greenwald Z, Stutz M, Rodier C, DeAngelis F, Rampakakis, E. Recurrence of human papillomavirus external genital wart infection among high-risk adults in Montreal, Canada. *Sex Transm Dis.* 2017;44(11):700–06. doi:10.1097/OLQ.0000000000000666.
5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. *Vaccine.* 2012;30:F12–23. doi:10.1016/j.vaccine.2012.07.055.
6. Wang S-M, Shi J-F, Kang D-J, Song P, Qiao Y-L. Impact of human papillomavirus-related lesions on quality of life: a multicenter hospital-based study of women in Mainland China. *Int J Gynecol Cancer.* 2011;21(1):182–88. doi:10.1097/IGC.0b013e3181ffbed8.
7. McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden of human papillomavirus infection in the Netherlands, 1989–2014: the gap between females and males is diminishing. *Cancer Causes Control.* 2017;28(3):203–14. doi:10.1007/s10552-017-0870-6.
8. Kocjan BJ, Sterbenc A, Hosnjak L, Chouhy D, Bolatti E, Giri AA, Poljak M. Genome announcement: complete genome sequence of a novel Mupapillomavirus, HPV204. *Acta Dermatovenerol Alp Panon Adriat.* 2015;24(2):21–23. doi:10.15570/actaapa.2015.7.
9. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers E-M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology.* 2010;401(1):70–79. doi:10.1016/j.virol.2010.02.002.
10. Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, Baussano I. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. *Lancet Public Health.* 2021;6(7):e510–21. doi:10.1016/S2468-2667(21)00046-3.
11. Cubie HA. Diseases associated with human papillomavirus infection. *Virology.* 2013;445(1):21–34. doi:10.1016/j.virol.2013.06.007.
12. Al-Awadhi R, Al-Mutairi N, Albatineh AN, Chehadeh W. Association of HPV genotypes with external anogenital warts: a cross sectional study. *BMC Infect Dis.* 2019;19(1):375. doi:10.1186/s12879-019-4005-4.
13. Ma L, Lu S, Jiang Y, Li M, Cong X, Cao Y. Distribution of human papillomavirus genotypes (2014–2016) in women with genital warts at a sexually transmitted disease clinic in Beijing, China. *Future Virol.* 2018;13(2):111–17. doi:10.2217/fvl-2017-0097.
14. Mastutik G, Rahniayu A, Murtiastutik D, Arista A, Setyaningrum T, Missaoui N, Putra ST. Distribution genotype high risk (HR) and low risk (LR) human papillomavirus (HPV) at condyloma acuminata. *Biomol Health Sci J.* 2021;4(1):10–14. doi:10.20473/bhsj.v4i1.26250.
15. Mastutik G, Rahniayu A, Arista A, Murtiastutik D, Kurniasari N, Setyaningrum T, Rahaju A, Sulistyani E. P16ink4a expression in condyloma acuminata lesions associated with high-risk human papillomavirus infection[J]. *Asian Pac J Cancer Prev.* 2021;22(10):3219–25. doi:10.31557/APJCP.2021.22.10.3219.
16. de Sanjose S, Quint WGV, Aleman L, Geraets DT, Klaustermeier JE, Lloveras B, de Sanjose S, Tous S, Felix A, Bravo LE, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol.* 2010;11(11):1048–56. doi:10.1016/S1470-2045(10)70230-8.
17. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. *JAMA.* 2001;286(24):3106–14. doi:10.1001/jama.286.24.3106.
18. Hall MT, Simms KT, Lew J-B, Smith MA, Brotherton JML, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in Australia: a modelling study. *Lancet Public Health.* 2019;4(1):e19–27. doi:10.1016/S2468-2667(18)30183-X.
19. Hariri S, Schuler MS, Naleway AL, Daley MF, Weinmann S, Crane B, Newcomer SR, Tolsma D, Markowitz LE. Human

- Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States. *Am J Epidemiol.* 2017;187(2):298–305. doi:10.1093/aje/kwx253.
20. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical Human Papillomavirus Prevalence in 5 Continents: meta-Analysis of 1 Million Women with Normal Cytological Findings. *J Infect Dis.* 2010;202(12):1789–99. doi:10.1086/657321.
 21. Chinese Society of Dermatology and Venereology. China Dermatologist Association, Chinese Association of Rehabilitation Dermatology and Venereology. Guideline for the Clinical Management of Anogenital Warts in China (2014) [J]. *Chin J Dermatol.* 2014;47(08):598–99.
 22. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: a Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. *Clin Infect Dis.* 2015;61(suppl_8):S849–55. doi:10.1093/cid/civ813.
 23. Chang L, Ci P, Shi J, Zhai K, Feng X, Colombara D, Wang W, Qiao Y, Chen W, Wu Y. Distribution of genital wart human papillomavirus genotypes in China: a multi-center study. *J Med Virol.* 2013;85(10):1765–74. doi:10.1002/jmv.23646.
 24. Mueller SM, Menzi S, Kind AB, Blaich A, Bayer M, Navarini A, Itin P, Brandt O. Sexually transmitted coinfections in patients with anogenital warts – a retrospective analysis of 196 patients. *JDDG.* 2020;18(4):325–32. doi:10.1111/ddg.14060.
 25. Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR. Consistent Condom Use is Associated with Lower Prevalence of Human Papillomavirus Infection in Men. *J Infect Dis.* 2010;202(3):445–51. doi:10.1086/653708.
 26. Aubin F, Prétet J-L, Jacquard A-C, Saunier M, Carcopino X, Jaroud F, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, et al. Human Papillomavirus Genotype Distribution in External Acuminata Condylomata: a Large French National Study (EDiTH IV). *Clin Infect Dis.* 2008;47(5):610–15. doi:10.1086/590560.
 27. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. *Lancet Infect Dis.* 2006;6(1):21–31. doi:10.1016/S1473-3099(05)70323-6.
 28. Luo Z-Y, Chen Q, Yang H, Lin M, Chen C-Y, Yang C, Yang L-Y. The Prevalence and Genotype of Human Papillomavirus from patients with Genital Warts in Eastern Guangdong Province. *Asian Pac J Cancer Prev.* 2015;16(14):5675–79. doi:10.7314/APJCP.2015.16.14.5675.
 29. Zhu C, Wang Y, Mao W, Zhang H, Ma J. Prevalence and distribution of HPV types in genital warts in Xi'an, China: a prospective study. *BMJ Open.* 2019;9(5):e023897. doi:10.1136/bmjopen-2018-023897.
 30. Sudenga SL, Ingles DJ, Pierce Campbell CM, Lin H-Y, Fulp WJ, Messina JL, Stoler MH, Abrahamsen M, Villa LL, Lazcano-Ponce E, et al. Genital Human Papillomavirus Infection Progression to External Genital Lesions: the HIM Study. *Eur Urol.* 2016;69(1):166–73. doi:10.1016/j.eururo.2015.05.032.
 31. Chaturvedi AK. Beyond Cervical Cancer: burden of Other HPV-Related Cancers Among Men and Women. *J Adolesc Health.* 2010;46(4, Supplement):S20–6. doi:10.1016/j.jadohealth.2010.01.016.
 32. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. *Lancet.* 2019;394(10197):497–509. doi:10.1016/S0140-6736(19)30298-3.
 33. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. *Br Med J.* 2010 Jul 20;341:c3493.
 34. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, L-F X, Stern M, Lee S-K, O'Reilly S, Hawes S, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. *J Infect Dis.* 2007;196(8):1128–36. doi:10.1086/521192.
 35. Ingles DJ, Pierce Campbell CM, Messina JA, Stoler MH, Lin H-Y, Fulp WJ, Abrahamsen M, Sirak BA, O'Keefe MT, Papenfuss M, et al. Human papillomavirus virus (HPV) genotype- and age-specific analyses of external genital lesions among men in the HPV infection in men (HIM) study. *J Infect Dis.* 2014;211(7):1060–67. doi:10.1093/infdis/jiu587.
 36. Chan PKS, Luk ACS, Luk TNM, Lee K-F, Cheung JLK, K-M H, Lo K-K. Distribution of human papillomavirus types in anogenital warts of men. *J Clin Virol.* 2009;44(2):111–14. doi:10.1016/j.jcv.2008.11.001.
 37. Nyitray AG, Menezes L, Lu B, Lin H-Y, Smith D, Abrahamsen M, Papenfuss M, Gage C, Giuliano AR. Genital human papillomavirus (HPV) concordance in heterosexual couples. *J Infect Dis.* 2012;206(2):202–11. doi:10.1093/infdis/jis327.
 38. Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, de Sanjosé S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. *N Engl J Med.* 2002;346(15):1105–12. doi:10.1056/NEJMoa011688.
 39. Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Garland SM, Cornall AM, Atchison S, Hocking JS, Bradshaw CS, et al. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. *Lancet Infect Dis.* 2021;21(10):1448–57. doi:10.1016/S1473-3099(20)30687-3.
 40. Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, Fairley CK. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. *Sex Transm Infect.* 2015;91(3):214–19. doi:10.1136/sextrans-2014-051813.
 41. Cheng L, Wang Y, Du J. Human papillomavirus vaccines: an updated review. *Vaccines.* 2020;8(3):391. doi:10.3390/vaccines8030391.
 42. Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, Chow EPF, Xu X, Zhang L, Zhuang G. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. *Lancet Glob Health.* 2020;8(10):e1335–44. doi:10.1016/S2214-109X(20)30277-1.
 43. Zhu B, Liu Y, Zuo T, Cui X, Li M, Zhang J, Yu H, Piao H. The prevalence, trends, and geographical distribution of human papillomavirus infection in China: the pooled analysis of 1.7 million women. *Cancer Med.* 2019;8(11):5373–85. doi:10.1002/cam4.2017.
 44. Mastutik G, Alia R, Rahniayu A, Seio Rahaju A, Kurniasari N, Putra ST. Genotyping of human papillomavirus in cervical precancerous lesion and squamous cell carcinoma at Dr. Soetomo hospital, Surabaya, Indonesia[J]. *Afr J Infect Dis.* 2018;12(1S):7–12. doi:10.21010/ajid.v12i1S.2.
 45. Schlecht NF, Diaz A, Nucci-Sack A, Shyhallo K, Shankar V, Guillot M, Hollman D, Strickler HD, Burk RD. Incidence and types of human papillomavirus infections in adolescent girls and young women immunized with the human papillomavirus vaccine. *JAMA Netw Open.* 2021;4(8):e2121893. doi:10.1001/jama-networkopen.2021.21893.
 46. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. *Epidemiol Infect.* 2016;144(3):449–68. doi:10.1017/S0950268815002198.